References

Joseph F. Goldberg; Stephen M. Stahl

doi:10.1017/9781108553216.025

References

Published online by Cambridge University Press: 19 October 2021

Joseph F. Goldberg and

Stephen M. Stahl

Foreword by

Alan F. Schatzberg

Show author details

Joseph F. Goldberg: Affiliation:
Icahn School of Medicine at Mount Sinai, New York
Stephen M. Stahl: Affiliation:
University of California, San Diego

Book contents

Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Chapter
Information: Practical Psychopharmacology
Translating Findings From Evidence-Based Trials into Real-World Clinical Practice
, pp. 508 - 567

DOI: https://doi.org/10.1017/9781108553216.025 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Adamson, SJ, Sellman, JD, Foulds, JA, et al. A randomized trial of combined citalopram and naltrexone for nonabstinent outpatients with co-occurring alcohol dependence and major depression. J Clin Psychopharmacol 2015; 35: 143–149Google Scholar

Adan-Manes, J, Novalbos, J, López-Rodríguez, R, et al. Lithium and venlafaxine interaction: a case of serotonin syndrome. J Clin Pharm Ther 2006; 31: 397–400Google Scholar

Adler, LA, Dirks, B, Deas, PF, et al. Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2013; 74: 694–702Google Scholar

Afshar, M, Knapp, CM, Sarid-Segal, O, et al. The efficacy of mirtazapine in the treatment of cocaine dependence with comorbid depression. Am J Drug Alcohol Abuse 2012; 38: 181–186Google Scholar

Agabio, R, Trogu, E, Pani, PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev 2018; 4: CD008581Google Scholar

Agarwal, LJ, Berger, CE, Gill, L. Naltrexone for severe self-harm: a case report. Am J Psychiatry 2011; 168: 437–438Google Scholar

Agid, O, Siu, CO, Potkin, SG, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970–2010. Am J Psychiatry 2013; 170: 1335–1344Google Scholar

Aguglia, A, Mineo, L, Rodolico, A, et al. Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study. Int Clin Psychopharmacol 2018; 33: 121–130Google Scholar

Ahmed, AO, Richardson, J, Buckner, A, et al. Do cognitive deficits predict negative emotionality and aggression in schizophrenia? Psychiatry Res 2018a; 259: 350–357Google Scholar

Ahmed, R, Kotapati, VP, Khan, AM, et al. Adding psychotherapy to the naltrexone treatment of alcohol use disorder: a meta-analytic review. Cureus 2018b; 10: e3107Google Scholar

Aiken, CB, Orr, C. Rechallenge with lamotrigine after a rash. Psychiatry (Edgmont) 2010; 7: 27–32Google Scholar

Airagnes, G, Lemogne, C, Renuy, A, et al. Prevalence of prescribed benzodiazepine long-term use in the French general population according to sociodemographic and clinical factors: findings from the CONSTANCS cohort. BMC Public Health 2019; 19: 566CrossRef Google Scholar PubMed

Albers, LJ, Ozdemir, V, Marder, SR. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose adjusted drug interaction strategy. J Clin Psychopharmacol 2005; 25: 170–174CrossRef Google Scholar PubMed

Albertini, E, Ernst, CL, Tamaroff, RS. Psychopharmacological decision making in bipolar disorder during pregnancy and lactation: a case-by-case approach to using current evidence. Focus 2019; 17: 249–258Google Scholar

Albott, CS, Lim, KO, Forbes, MK, et al. Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. J Clin Psychiatry 2018; 79: 17m11684CrossRef Google Scholar PubMed

Alexopoulos, GS, Canuso, CM, Gharabawi, GM, et al. Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry 2008; 16: 21–30Google Scholar

Alexopoulos, GS, Katz, IR, Reynolds, CF 3rd, et al. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med 2001; Spec No Pharmacotherapy: 1–86Google Scholar

Allan, ER, Alpert, M, Sison, CE, et al. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J Clin Psychiatry 1996; 57: 455–459Google Scholar

Allen, MH, Hirschfeld, RM, Wozniak, PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163: 272–275Google Scholar

Allgulander, C, Mangano, R, Zhang, J, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004; 19: 387–396Google Scholar

Alpert, M, Allan, ER, Citrome, L, et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990; 26: 367–371Google Scholar

Alphs, L, Davis, JM. Noncatecholaminergic treatments of tardive dyskinesia. J Clin Psychopharmachol 1982; 2: 380–385Google Scholar

Altemus, M, Neeb, CC, Davis, A, et al. Phenotypic differences between pregnancy-onset and postpartum-onset major depressive disorder. J Clin Psychiatry 2012; 73: e1485–e1491Google Scholar

Altshuler, LL, Bauer, M, Frye, MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response?: a review and meta-analysis of the literature. Am J Psychiatry 2001; 158: 1617–1622Google Scholar

Altshuler, LL, Post, RM, Hellemann, G, et al. Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry 2009; 70: 450–457Google Scholar

Altshuler, L, Suppes, T, Black, D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160: 1252–1262Google Scholar

Altshuler, LL, Suppes, T, Black, DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry 2006; 163: 313–315Google Scholar

Alvarez, E, Perez, V, Dragheim, M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 2012; 15: 589–600Google Scholar

American Psychiatric Association. Practice Guideline for the Treatment of Major Depressive Disorder, 3rd Edn. Arlington, VA: American Psychiatric Association; 2010Google Scholar

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edn. Arlington, VA: American Psychiatric Association; 2013Google Scholar

American Society of Hospital Pharmacists. ASHP statement on pharmaceutical care. Am J Hosp Pharm. 1993; 50: 1720–1723Google Scholar

Amerio, A, Ossola, P, Scagnelli, F, et al. Safety and efficacy of lithium in children and adolescents: a systematic review in bipolar illness. Eur Psychiatry 2018; 54: 85–97Google Scholar

Amerio, A, Stubbs, B, Odone, A, et al. The prevalence and predictors of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review and meta-analysis. J Affect Disord 2015; 186: 99–109Google Scholar

Amieva, H, LeGoff, M, Millet, X, et al. Prodromal Alzheimer’s disease: successive emergence of the clinical symptoms. Ann Neurol 2008; 64: 492–498Google Scholar

Amital, D, Vishne, T, Roitman, S, et al. Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder. J Clin Psychiatry 2006; 67: 836–837CrossRef Google Scholar PubMed

Amsterdam, JD, Berwish, NJ. High dose tranylcypromine therapy for refractory depression. Pharmacopsychiatry 1989; 22: 21–25Google Scholar

Amsterdam, JD, Fawcett, J, Quitkin, FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997; 154: 963–969Google Scholar

Amsterdam, JD, Li, Y, Soeller, I, et al. A randomized, double-blind, placebo-controlled trial of oral Matricaria recutita (chamomile) extract therapy for generalized anxiety disorder. J Clin Psychopharmacol 2009; 29: 378–382Google Scholar

Anand, A, Charney, DS, Oren, DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57: 170–176Google Scholar

Anderson, M, Björkhem-Bergman, L, Beck, O. Possible mechanism for inhibition of morphine formation from 6-acetylmorphine after intake of street heroin. Forensic Sci Int 2015; 252: 150–156Google Scholar

Andrade, C. Nonsteroidal anti-inflammatory drugs and 5-HT3 serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia. J Clin Psychiatry 2014; 75: e707–e709Google Scholar

Andrade, C. Antidepressant exposure during pregnancy and risk of autism in the offspring: 1: meta-review of meta-analyses. J Clin Psychiatry 2017; 78: e1047–e1051Google Scholar

Andrade, C, Kisely, S, Monteiro, I, et al. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Psychiatry Res 2015; 60: 14–21CrossRef Google Scholar PubMed

Andrade, C, Sandarsh, S, Chetan, KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71: 1565–1575Google Scholar

Andreason, NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39: 784–788Google Scholar

Andreason, NC, Liu, D, Ziebell, S, et al. Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 2013; 170: 609–615CrossRef Google Scholar

Andreason, NC, Pressler, M, Nopoulos, P, et al. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry 2010; 67: 255–262Google Scholar

Andrezina, R, Josiassen, RC, Marcus, RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison of intramuscular haloperidol. Psychopharmacology (Berl) 2006; 188: 281–292Google Scholar

Anglin, RES, Samaan, Z, Walter, SD, et al. Vitamin D deficiency and depression in adults: systematic review and meta-analysis. Br J Psychiatry 2013; 202: 100–107Google Scholar

Anton, RF, Moak, DH, Latham, PK. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 1996; 53: 225–231. Erratum in: Arch Gen Psychiatry 1996; 53: 576Google Scholar

Anton, RF, Myrick, H, Wright, TM, et al. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 2011; 168: 709–717Google Scholar

Anton, RF, O’Malley, SS, Ciraulo, DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. A randomized controlled trial. J Am Med Assoc 2006; 295: 2003–2017Google Scholar

Anttila, S, Viikki, M, Huuhka, K, et al. TPH2 polymorphisms may modify clinical picture in treatment-resistant depression. Neurosci Lett 2009; 464: 43–46Google Scholar

Appelberg, BG, Syvälahti, EK, Koskinen, TE, et al. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Clin Psychiatry 2001; 62: 448–452Google Scholar

Appelhof, BC, Fliers, E, Wekking, EM, et al. Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind, randomized, controlled clinical trial. J Clin Endocrinol Metab 2005; 90: 2666–2674Google Scholar

Arato, M, O’Connor, R, Meltzer, HY, et al. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17: 207–215Google Scholar

Argolo, FC, Cavalcanti-Ribeiro, P, Netto, LR, et al. Prevention of posttraumatic stress disorder with propranolol: a meta-analytic review. J Psychosom Res 2015; 79: 89–93Google Scholar

Argyropoulou, P, Patakas, D, Koukou, A, et al. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993; 60: 214–220Google Scholar

Arnold, LE. Methylphenidate vs. amphetamine: comparative review. J Attention Disord 2000; 4: 200–211Google Scholar

Arnold, LM, Mutasim, DF, Dwight, MM, et al. An open clinical trial of fluvoxamine treatment of psychogenic excoriation. J Clin Psychopharmacol 1999; 19: 15–18Google Scholar

Arnow, BA, Blasey, C, Williams, LM, et al. Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial. Am J Psychiatry 2015; 172: 743–750Google Scholar

Arns, M, Bruder, G, Hegerl, U, et al. EEG alpha asymmetry as a gender-specific predictor of outcome to acute treatment with different antidepressant medications in the randomized iSPOT-D study. Clin Neurophysiol 2016; 17: 509–519Google Scholar

Arntz, A, Van den Hoorn, M, Cornelis, J. Reliability and validity of the borderline personality disorder severity index. J Pers Disord 2003; 17: 45–59Google Scholar

Aronson, R, Offman, HJ, Joffe, RT, et al. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53: 842–848CrossRef Google Scholar PubMed

Askari, N, Moin, M, Sanati, M, et al. Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2012; 26: 883–892Google Scholar

Astill Wright, L, Sijbrandij, M, Sinnerton, R, et al. Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis. Transl Psychiatry 2019; 9: 334Google Scholar

AstraZeneca. A multi-center, double-blind, randomized-withdrawal, parallel-group, placebo-controlled Phase III study of the efficacy and safety of quetiapine fumarate extended release (Seroquel XR^™) as monotherapy in the maintenance treatment of patients with major depressive disorder following an open-label stabilization period (AMETHYST study). www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/8579609 ClinicalTrials.gov ID NCT00278941. Study code: D1448C00005. 2008Google Scholar

Astrup, A, Caterson, I, Zelissen, P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004; 12: 1658–1669Google Scholar

Avgerinos, KI, Spyrou, N, Bougioukas, KI, et al. Effects of creatine supplementation on cognitive function of healthy individuals: a systematic review of randomized controlled trials. Exp Gerontol 2018; 108: 166–173Google Scholar

Awortwe, C, Makiwane, M, Reuter, H, et l. Critical evaluation of causality assessment of herb-drug interactions in patients. Br J Clin Pharmacol 2018; 84: 679–693Google Scholar

Azuma, K, Takaesu, Y, Soeda, H, et al. Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute Med Surg 2018; 5: 362–368Google Scholar

Baandrup, L, Ebdrup, BH, Rasmussen, JØ, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev 2018; 3: CD011481Google Scholar

Babor, TF, Hofmann, M, DelBoca, FK, et al. Types of alcoholics, I: evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry 1992; 49: 599–608Google Scholar

Bacaltchuk, J, Hay, P, Mari, JJ. Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review. Aust N Z J Psychiatry 2000; 34: 310–317Google Scholar

Back, SE, McCauley, JL, Korte, KJ, et al. A double-blind, randomized, controlled pilot study of N-acetylcysteine in veterans with posttraumatic stress disorder and substance use disorders. J Clin Psychiatry 2016; 77: e1439–e1446Google Scholar

Bagby, RM, Ryder, AG, Cristi, C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 2002; 27: 250–257Google Scholar

Bahji, A, Forsyth, A, Groll, D, et al. Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2020; 96: 109735Google Scholar

Baillon, SF, Narayana, U, Luxenberg, JS, et al. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2018; 10: CD003945Google Scholar

Bak, M, Weltens, I, Bervoets, C, et al. The pharmacological management of agitated and aggressive behaviour: a systematic review and meta-analysis. Eur Psychiatry 2019; 57: 78–100Google Scholar

Baker, RW, Kinon, BJ, Maguire, GA, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003; 23: 342–348Google Scholar

BALANCE Investigators and Collaborators; Geddes, JR, Goodwin, GM, Rendell, J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385–395Google Scholar

Baldaçara, L, Cogo-Moreira, H, Parreira, BL, et al. Efficacy of topiramate in the treatment of crack cocaine dependence: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2016; 77: 398–406Google Scholar

Baldessarini, RJ, Vázques, G, Tondo, L. Treatment of cyclothymic disorder: commentary. Psychother Psychosom 2011; 80: 131–135Google Scholar

Baldwin, DS, Loft, H, Dragheim, M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 2012; 22: 482–491Google Scholar

Bali, V, Chatterjee, S, Carnahan, RM, et al. Risk of dementia among elderly nursing home patients using paroxetine and other selective serotonin reuptake inhibitors. Psychiatr Serv 2015; 66: 1333–1340Google Scholar

Ballenger, JC, Davidson, JR, Lecrubier, Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 1998; 59(Suppl 8): 47–54Google Scholar

Bandelow, B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 1995; 2: 73–81Google Scholar

Baniasadi, M, Hosseini, G, Bordbar, MRF, et al. Effect of pregabalin augmentation in treatment of patients with combat-related chronic posttraumatic stress disorder: a randomized controlled trial. J Psychiatr Pract 2014; 20: 419–427Google Scholar

Banzi, R, Cusi, C, Randazzo, C, et al. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults. Cochrane Database Syst Rev 2015; 4: CD002919Google Scholar

Barbee, JG, Thompson, TR, Jamhour, NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry 2011; 72: 1405–1412Google Scholar

Bareggi, SR, Bianchi, L, Cavallaro, R, et al. Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs 2004; 18: 329–335Google Scholar

Barker, MJ, Greenwood, KM, Jackson, M, et al. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs 2004; 18: 37–48CrossRef Google Scholar PubMed

Barnett, R, Maruff, P, Vance, A, et al. Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory. Psychol Med 2001; 31: 1107–1115Google Scholar

Barnett, SD, Kramer, ML, Casat, CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16: 365–368Google Scholar

Barrons, R, Roberts, N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther 2010; 35: 153–167Google Scholar

Barsky, AJ, Saintfort, R, Rogers, MP, et al. Nonspecific medication side effects and the nocebo phenomenon. J Am Med Assoc 2002; 287: 622–627Google Scholar

Batail, JM, Langrée, B, Robert, G, et al. Use of very-high dose olanzapine in treatment-resistant schizophrenia. Schizophr Res 2014; 159: 411–414Google Scholar

Batelaan, NM, Bosman, RC, Muntingh, A, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. Br Med J 2017; 358: j3927Google Scholar

Bauer, M, Dell’Osso, L, Kasper, S, et al. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder. J Affect Disord 2013; 151: 209–219Google Scholar

Bauer, MS, Whybrow, PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47: 435–440Google Scholar

Baune, BT, Brignone, M, Larsen, KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol 2018; 21: 97–107Google Scholar

Bazire, SR. Sudden death associated with switching monoamine oxidase inhibitors. Drug Intell Clin Pharm 1986; 20: 954–956Google Scholar

Beasley, CM Jr, Tollefson, G, Tran, P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111–123Google Scholar

Beck, AT, Epstein, N, Brown, G, et al. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893–897Google Scholar

Begemann, MJ, Dekker, CF, van Lunenburg, M, et al. Estrogen augmentation in schizophrenia: a quantitative review of current evidence. Schizophr Res 2012; 141: 179–184Google Scholar

Beinat, C, Banister, SD, Herrera, M, et al. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs 2015; 29: 529–542Google Scholar

Bellatuono, C, Tofani, S, Di Sciascio, G, et al. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. Gen Hosp Psychiatry 2013; 35: 3–8Google Scholar

Bellino, S, Paradiso, E, Bogetto, F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2005; 66: 1111–1115Google Scholar

Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2006; 67: 1042–1046Google Scholar

Bellino, S, Paradiso, E, Bogetto, F. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder. Psychiatry Res 2008; 161: 206–212Google Scholar

Bellino, S, Bozzatello, P, Rinaldi, C, et al. Paliperidone ER in the treatment of borderline personality disorder: a pilot study of efficacy and tolerability. Depress Res Treat 2011; 2011: 680194Google Scholar

Bellino, S, Bozzatello, P, Rocca, G, et al. Efficacy of omega-3 fatty acids in the treatment of borderline personality disorder: a study of the association with valproic acid. J Psychopharmacol 2014; 28: 125–132Google Scholar

Bellino, S, Paradiso, E, Bozzatello, P, et al. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study. J Psychopharmacol 2010; 24: 333–339Google Scholar

Benazzi, F. Characteristics of bipolar II patients with interpersonal rejection sensitivity. Psychiatr Clin Neurosci 2001; 54: 499–501Google Scholar

Bergamaschi, MM, Queiroz, RH, Chagas, MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011; 36: 1219–1226CrossRef Google Scholar PubMed

Bergero-Miguel, T, García-Encinas, MA, Villena-Jimena, A, et al. Gender dysphoria and social anxiety: an exploratory study in Spain. J Sex Med 2016; 13: 1270–1278Google Scholar

Beri, A, Boydell, J. Clozapine in borderline personality disorder: a review of the evidence. Ann Clin Psychiatry 2014; 26: 139–144Google Scholar

Berk, M, Dean, OM, Cotton, SM, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2014; 75: 628–636Google Scholar

Berlant, J. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004; 4: 24Google Scholar

Berlant, J, van Kammen, DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002; 63: 15–20Google Scholar

Berlin, HA, Koran, LM, Jenike, MA, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2011; 72: 716–721Google Scholar

Berman, M, Marcus, RN, Swanink, R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 843–853Google Scholar

Berman, RM, Fava, M, Thase, ME, et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009; 14: 197–206Google Scholar

Bersudsky, Y. Phenytoin: an anti-bipolar anticonvulsant? Int J Neuropsychopharmacol 2006; 9: 479–484Google Scholar

Berwaerts, J, Lane, R, Nuamah, IF, et al. Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. J Affect Disord 2011; 129: 252–260Google Scholar

Berwaerts, J, Melkote, R, Nuamah, I, et al. A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012b; 138: 247–258Google Scholar

Berwaerts, J, Xu, H, Nuamah, I, et al. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord 2012a; 136: e51–e60Google Scholar

Beucke, JC, Sepulcre, J, Talukdar, T, et al. Abnormally high degree connectivity of the orbitofrontal cortex in obsessive-compulsive disorder. JAMA Psychiatry 2013; 70: 619–629Google Scholar

Bhatara, VS, Magnus, RD, Paul, KL, et al. Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998; 32: 432–436Google Scholar

Biederman, J, Faraone, SV, Keenan, K, et al. Evidence of familial association between attention deficit disorder and major affective disorders. Arch Gen Psychiatry 1991a; 48: 633–642Google Scholar

Biederman, J, Faraone, SV, Keenan, K, et al. Familial association between attention deficit disorder and anxiety disorders. Am J Psychiatry 1991b; 148: 251–256Google Scholar

Biederman, J, Fried, R, Tarko, L, et al. Memantine in the treatment of executive function deficits in adults with ADHD. J Atten Disord 2017; 21: 343–352Google Scholar

Biederman, J, Joshi, G, Mick, E, et al. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther 2010; 16: 91–102Google Scholar

Biederman, J, Krishnan, S, Zhang, Y, et al. Efficacy and safety of lisdexamfetamine (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase 3, randomized, multicenter, double-blind, parallel-group study. Clin Ther 2007; 29: 450–463Google Scholar

Biederman, J, Lindsten, A, Sluth, LB, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: a randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol 2019; 33: 511–521Google Scholar

Biederman, J, Petty, CR, Wilens, TE, et al. Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 2008a; 165: 107–115Google Scholar

Biederman, J, Seidman, LJ, Petty, CR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2008b; 69: 1150–1156Google Scholar

Biel, MG, Peselow, E, Mulcare, L, et al. Continuation versus discontinuation of lithium in recurrent bipolar illness: a naturalistic study. Bipolar Disord 2007; 9: 435–442Google Scholar

Bighelli, I, Castellazzi, M, Cipriani, A, et al. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev 2018; 4: CD010676Google Scholar

Bilder, RM, Goldman, RS, Volavka, J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159: 1018–1028Google Scholar

Binder, RL, Levy, R. Extrapyramidal reactions in Asians. Am J Psychiatry 1981; 138: 1243–1244Google Scholar

Birkeland, SF. Psychopharmacological treatment and course in paranoid personality disorder: a case series. Int Clin Psychopharmacol 2013; 28: 283–285Google Scholar

Birks, JS, Harvey, RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2018; (6): CD001190Google Scholar

Birmingham, CL, Goldner, EM, Bakan, R, et al. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord 1994; 15: 231–235Google Scholar

Bisaga, A, Aharonovich, E, Garawi, F, et al. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend 2006; 81: 267–274Google Scholar

Bishara, D, Olofinjana, O, Sparshatt, A, et al: Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 2013; 33: 329–335Google Scholar

Bishop, JR, Moline, J, Ellingrod, VL, et al. Serotonin 2A-1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006; 31: 2281–2288Google Scholar

Bisol, LW, Lara, DR. Low-dose quetiapine for patients with dysregulation of hyperthymic and cyclothymic temperaments. J Psychopharmacol 2001; 24: 421–424Google Scholar

Bivard, A, Lillicrap, T, Krishnamurthy, V, et al. MIDAS (Modafinil in Debilitating Fatigue After Stroke): a randomized, double-blind, placebo-controlled, cross-over trial. Stroke 2017; 48: 1293–1298Google Scholar

Bixby, AL, VandenBerg, A, Bostwick, JR. Clinical management of bleeding risk with antidepressants. Ann Pharmacother 2019; 53: 186–194Google Scholar

Black, DW, Gabel, J, Hansen, J, et al. A double-blind comparison of fluvoxamine versus placebo in the treatment of compulsive buying disorder. Ann Clin Psychiatry 2000; 12: 205–211Google Scholar

Black, N, Stockings, E, Campbell, G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 2019; 6: 995–1010Google Scholar

Blackford, JU, Buckholtz, JW, Avery, SN, et al. A unique role for the human amygdala in novelty detection. Neuroimage 2010; 50: 1188–1193Google Scholar

Blanchard, EB, Jones-Alexander, J, Buckley, TC, et al. Psychometric properties of the PTSD checklist (PCL). Behav Res Ther 1996; 34: 699–673Google Scholar

Blessing, EM, Steenkamp, MM, Manzanares, J, et al. Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 2015; 12: 825–836Google Scholar

Blier, P, Bergeron, R, de Montigny, C. Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997; 16: 333–338Google Scholar

Blier, P, Ward, HE, Tremblay, P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281–288Google Scholar

Bloch, M, Schmidt, PJ, Danaceau, MA, et al. Dehydroandrosterone treatment of mid-life dysthymia. Biol Psychiatry 1999; 45: 1533–1541Google Scholar

Bloch, MH, Landeros-Weisenberger, A, Dombrowski, P, et al. Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry 2007; 62: 839–846Google Scholar

Bloch, MR, Elliott, M, Thompson, H, et al. Fluoxetine in pathological skin-picking: open-label and double-blind results. Psychosomatics 2001; 42: 314–319Google Scholar

Blodgett, JC, Del Re, AC, Maisel, NC, et al. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res 2014; 38: 1481–1488Google Scholar

Blom, TJ, Mingione, CJ, Guerdjikova, AI, et al. Placebo response in binge eating disorder: a pooled analysis of 10 clinical trials from one research group. Eur Eat Disord Rev 2014; 22: 140–146Google Scholar

Bocchetta, A, Ardau, R, Fanni, T, et al. Renal function during long-term lithium treatment: a cross-sectional and longitudinal study. BMC Med 2015; 13: 12Google Scholar

Boeker, T. Ziprasidone and migraine headache. Am J Psychiatry 2002; 159: 1435–1436Google Scholar

Bogenschutz, MP, Nurnberg, GH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104–109Google Scholar

Boggs, DL, Kelly, DL, Feldman, S, et al. Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res 2008; 101: 347–348Google Scholar

Bohus, MJ, Landwehrmeyer, GB, Stiglmayr, CE, et al. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J Clin Psychiatry 1999; 60: 598–603Google Scholar

Bonari, L, Pinto, N, Ahn, E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49: 726–735Google Scholar

Bondolfi, G, Chautems, C, Rochat, B, et al. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology (Berl) 1996; 128: 421–425Google Scholar

Bondolfi, G, Lissner, C, Kosel, M, et al. Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropsychopharmacol 2000; 3: 55–60Google Scholar

Bonn-Miller, MO, Loflin, MJE, Thomas, BF, et al. Labeling accuracy of cannabidiol extracts sold online. J Am Med Assoc 2017; 218: 1708–1709Google Scholar

Boonstra, E, de Kleijn, R, Colzato, LS, et al. Neurotransmitters as food supplements: the effects of GABA on brain and behavior. Front Psychol 2015; 6: 1520Google Scholar

Borison, RL, Arvanitis, LA, Miller, BG. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group. J Clin Psychopharmacol 1996; 16: 158–169Google Scholar

Borras, L, Huguelet, P, Eytan, A. Delusional “pseudotranssexualism” in schizophrenia. Psychiatry 2007; 70: 175–179Google Scholar

Bortnick, B, El-Khalili, N, Banov, M, et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 2011; 128: 83–94Google Scholar

Bose, A, Li, D, Gandhi, C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 2008; 16: 14–20Google Scholar

Bottlender, R, Rudolf, D, Strauß, A, et al. Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord 2001; 63: 79–83Google Scholar

Boulenger, J-P, Loft, H, Florea, I. A randomized clinical study of LuAA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 2012; 26: 1408–1416Google Scholar

Boulenger, J-P, Loft, H, Olsen, CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol 2014; 29: 138–149Google Scholar

Bourgeois, JA. The management of performance anxiety with beta adrenergic-blocking agents. Jefferson J Psychiatry 1991; 9: 13–28Google Scholar

Bourgeois, BF, D’Souza, J. Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience. Epilepsy Behav 2005; 7: 375–382Google Scholar

Bowden, CL, Calabrese, JR, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400Google Scholar

Bowden, CL, Janicak, PG, Orsulak, P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153: 765–770Google Scholar

Bowden, CL, Keck, PE Jr., McElroy, SL, et al. A randomized, placebo-controlled 12 month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57: 481–489Google Scholar

Bowden, CL, Singh, R, Weisler, P, et al. Lamotrigine vs. lamotrigine plus divalproex in randomized, placebo-controlled maintenance treatment for bipolar depression. Acta Psychiatr Scand 2012; 126: 342–350Google Scholar

Bowden, CL, Vieta, E, Ice, KS, et al. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130–137Google Scholar

Bowtell, M, Eaton, S, Thien, K, et al. Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis. Schizophr Res 2018; 195: 231–236Google Scholar

Bozzatello, P, Rocca, P, Uscinska, M, et al. Efficacy and tolerability of asenapine compared with olanzapine in borderline personality disorder: an open-label randomized controlled trial. CNS Drugs 2017; 31: 809–819Google Scholar

Brady, K, Pearlstein, T, Asnis, G, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. J Am Med Assoc 2000; 283: 1837–1844Google Scholar

Braun, P, Greenberg, S, Dasberg, H, et al. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51: 236–238Google Scholar

Brawman-Mintzer, O, Knapp, RG, Nietert, PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66: 1321–1325Google Scholar

Breier, A, Buchanan, RW, Kirkpatrick, B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20–60Google Scholar

Breilmann, J, Girlanda, F, Guaiana, G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database Syst Rev 2019; (3): CD010677Google Scholar

Breitbart, W, Rosenfeld, B, Kaim, M, et al. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001; 161: 411–420Google Scholar

Brekhman, II, Dardymov, IV. New substances of plant origin which increase nonspecific resistance. Ann Rev Pharmacol 1969; 9: 419–430Google Scholar

Bremner, JD, Shearer, K, McCaffery, P. Retinoic acid and affective disorders: the evidence for an association. J Clin Psychiatry 2012; 73: 37–50Google Scholar

Briggs-Gowan, MJ, Carter, S, Bosson-Heenan, J, et al. Are infant-toddler social-emotional and behavioral problems transient? J Am Acad Child Adolesc Psychiatry 2006; 45: 849–858Google Scholar

Britnell, SR, Jackson, AD, Brown, JN., et al. Aripiprazole for post-traumatic stress disorder: a systematic review. Clin Neuropharmacol 2017; 40: 273–278Google Scholar

Bro, SP, Kjaersgard, MI, Parner, ET, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol 2015; 7: 139–147Google Scholar

Brown, WA. Placebo as a treatment for depression. Neuropsychopharmacology 1994; 10: 265–269Google Scholar

Brown, ES, Gabrielson, B. A randomized double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord 2012; 143: 257–260Google Scholar

Brown, ES, Gorman, AR, Hynan, LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol 2007; 27: 498–502Google Scholar

Brown, ES, Todd, JP, Hu, T, et al. A randomized, double-blind, placebo-controlled trial of citicoline for cocaine dependence in bipolar I disorder. Am J Psychiatry 2015; 172: 1014–1021Google Scholar

Bruder, GE, Sedoruk, JP, Stewart, JW, et al. Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. Biol Psychiatry 2008; 63: 1171–1177Google Scholar

Brunet, A, Saumier, D, Liu, A, et al. Reduction of PTSD symptoms with pre-reactivation propranolol therapy: randomized controlled trial. Am J Psychiatry 2018; 175: 427–433Google Scholar

Brunner, E, Tohen, M, Osuntokun, O, et al. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. Neuropsychopharmacology 2014; 39: 2549–2559Google Scholar

Bruno, A, Micò, U, Pandolfo, G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol 2012; 26: 1456–1462Google Scholar

Buchanan, RW, Breier, A, Kirkpatrick, B, et al. Positive and negative symptoms response to clozapine with and without the deficit syndrome. Am J Psychiatry 1998; 155: 751–760Google Scholar

Bugarski-Kirola, D, Iwata, N, Sameliak, S, et al. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry 2016; 3: 1115–1128Google Scholar

Buitelaar, JK, Sobanski, E, Stieglitz, RD, et al. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate. J Clin Psychiatry 2012; 73: 1097–1102Google Scholar

Burdick, KE, Endick, CJ, Goldberg, JF. Assessing cognitive deficits in bipolar disorder: are self-reports valid? Psychiatry Res 2005; 136: 43–50Google Scholar

Burdick, KE, Braga, RJ, Nnadi, CU, et al. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry 2012; 73: 103–112Google Scholar

Burdick, KE, Russo, M, Frangou, S, et al. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. Psychol Med 2014; 44: 3083–3096Google Scholar

Bürkner, PC, Williams, DR, Simmons, TC, et al. Intranasal oxytocin may improve high-level social cognition in schizophrenia, but not social cognition or neurocognition in general: a multilevel Bayesian meta-analysis. Schizophr Bull 2017; 43: 1291–1303Google Scholar

Butterfield, MI, Becker, ME, Connor, KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 2001; 16: 197–203Google Scholar

Bystritsky, A, Kerwin, L, Feusner, JD, et al. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder. Psychopharmacol Bull 2008; 41: 46–51Google Scholar

Cain, JW. Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a “therapeutic window”? J Clin Psychiatry 1992; 53: 272–277Google Scholar

Cakir, S, Kulakisizoglu, IB. The efficacy of mirtazapine in agitated patients with Alzheimer’s disease: a 12-week open-label pilot study. Neuropsychiatr Dis Treat 2008; 4: 963–966Google Scholar

Calabrese, JR, Bowden, CL, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013–1024Google Scholar

Calabrese, JR, Bowden, CL, Sachs, GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88Google Scholar

Calabrese, JR, Keck, PE Jr, Starace, A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2015; 76: 284–292Google Scholar

Calabrese, JR, Pikalov, A, Streicher, C, et al. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017a; 27: 865–876Google Scholar

Calabrese, JR, Sanchez, R, Jin, N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry 2017b; 78: 324–331Google Scholar

Calabrese, JR, Shelton, MD, Rapport, DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152–2161Google Scholar

Calabrese, JR, Suppes, T, Bowden, CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder: Lamictal 614 Study Group. J Clin Psychiatry 2000; 61: 841–850Google Scholar

Campbell, M, Adams, PB, Small, AM, et al. Lithium in hospitalized aggressive children with conduct disorder: a double-blind and placebo-controlled study. J Am Acad Child Adolesc Psychiatry 1995; 34: 445–453Google Scholar

Campbell, M, Small, AM, Green, WH, et al. Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Arch Gen Psychiatry 1984; 41: 650–656Google Scholar

Canuso, CM, Singh, JB, Fedgchin, M, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2018; 175: 620–630Google Scholar

Carbon, H, Hsieh, CH, Kane, JM, et al. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry 2017; 78: e264–e278Google Scholar

Cardenas, D. Let not thy food be confused with thy medicine: the Hippocratic misquotation. E-SPEN 2013; 8: e260–e262Google Scholar

Careri, JM, Draine, AE, Hanover, R, et al. A 12-week double-blind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder. Prim Care Companion CNS Disord 2015; 17: 10.4088/PCC.15m01831Google Scholar

Carey, P, Suliman, S, Ganesan, K, et al. Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study. Hum Psychopharmacol 2012; 27: 386–391Google Scholar

Carhart-Harris, RL, Bolstridge, M, Dy, CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018; 235: 399–408Google Scholar

Carman, J, Peuskens, S, Vangeneugden, A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 207–213Google Scholar

Caroff, SN, Mann, SC. Neuroleptic malignant syndrome. Med Clin North Amer 1993; 77: 185–202Google Scholar

Carpenter, KM, Hasin, DS. Reliability and discriminant validity of the Type I/II and Type A/B alcoholic subtype classifications in untreated problem drinkers: a test of the Apollonian–Dionysian hypothesis. Drug Alcohol Depend 2001; 63: 51–67Google Scholar

Casamassima, F, Huang, J, Fava, M, et al. Phenotypic effects of bipolar liability gene among individuals with major depressive disorder. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 303–309Google Scholar

Casey, DE, Daniel, DG, Tamminga, C, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 2009; 34: 1330–1338Google Scholar

Casey, DE, Daniel, DG, Wassef, AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003; 28: 182–192Google Scholar

Castells, X, Blanco-Silvente, L, Cunill, R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018; 8: CD007813Google Scholar

Castells, X, Cunill, R, Pérez-Mañá, C, et al. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev 2016; 9: CD007380Google Scholar

Castro, VM, Roberson, AM, McCoy, TH, et al. Stratifying risk for renal insufficiency among lithium-treated patients: an electronic health record study. Neuropsychopharmacology 2016; 41: 1138–1143Google Scholar

Catalá-López, F, Hutton, B, Núñez-Beltrán, A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One 2017; 12: e0180355Google Scholar

Caye, A, Rocha, TB, Anselmi, L, et al. Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood: evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry 2016; 73: 705–712Google Scholar

Center for Behavioral Health Statistics and Quality (CBHSQ). Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. HHS Publication No. SMA 15–4927, NSDUH Series H-50. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2015Google Scholar

Chakrabarti, A, Bagnall, A, Chue, P, et al. Loxapine for schizophrenia. Cochrane Database Syst Rev 2007; (4): CD001943Google Scholar

Chambers, CD, Hernandez-Diaz, S, Van Marter, LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New Engl J Med 2006; 354: 579–587Google Scholar

Chan, GC, Hinds, TR, Impey, S, et al. Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. J Neurosci 1998; 18: 5322–5332Google Scholar

Chang, K, Saxena, K, Howe, M. An open-label study of lamotrigine adjunct or monotherapy for the treatment of adolescents with bipolar depression. J Am Acad Child Adolesc Psychiatry 2006; 45: 298–304Google Scholar

Chang, HY, Tseng, PT, Stubbs, B, et al. The efficacy and tolerability of paliperidone in mania of bipolar disorder: a preliminary meta-analysis. Exp Clin Psychopharmacol 2017; 25: 422–433Google Scholar

Chang, SS, Liu, CM, Lin, SH, et al. Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading. Schizophr Bull 2009; 35: 213–221Google Scholar

Charney, DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry 2004; 161: 195–216Google Scholar

Charney, DA, Heath, LM, Zikos, E, et al. Poorer drinking outcomes with citalopram treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2015; 39: 1756–1765Google Scholar

Chaudhry, IB, Neelam, K, Duddu, V, et al. Ethnicity and Psychopharmacology. J Psychopharmachol 2008; 22: 673–680Google Scholar

Chekroud, AM, Gueorguieva, R, Krumholz, HM, et al. Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. JAMA Psychiatry 2017; 74: 370–378Google Scholar

Chen, JJ, Hua, H, Massihi, L, et al. Systematic literature review of quetiapine for the treatment of psychosis in patients with parkinsonism. J Psychiatry Clin Neurosci 2019a; 31: 188–195Google Scholar

Chen, JX, Su, YA, Bian, QT, et al. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015; 58: 130–140Google Scholar

Chen, MH, Lin, WC, Wu, HJ, et al. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). J Affect Disord 2019b; 251: 162–169Google Scholar

Chen, TR, Huang, HC, Hsu, JH, et al. Pharmacological and psychological interventions for generalized anxiety disorder in adults: a network meta-analysis. J Psychiatr Res 2019c; 118: 73–83Google Scholar

Chen, YF, Wang, SJ, Khin, NA, et al. Trial design issues and treatment effect modeling in multi-regional schizophrenia trials. Pharm Stat 2010; 9: 217–229Google Scholar

Chengappa, KNR, Brar, JS, Gannon, JM, Schlicht, PJ. Adjunctive use of a standardized extract of Withania somnifera (ashwaganda) to treat symptom exacerbation in schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2018; 79: 17m11826Google Scholar

Chengappa, KN, Bowie, CR, Schlicht, PJ, et al. Randomized placebo-controlled adjunctive study of an extract of Withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry 2013; 74: 1076–1083Google Scholar

Chessick, CA, Allen, MH, Thase, M, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; (3) :CD006115Google Scholar

Chiappini, S, Schifano, F. A decade of gabapentinoid misuse: an analysis of the European Medicines Agency’s “Suspected Adverse Drug Reactions” database. CNS Drugs 2016; 30: 647–654Google Scholar

Chick, J, Aschauer, H, Hornik, K, et al. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 2004; 74: 61–70Google Scholar

Cho, M, Lee, TY, Kwak, YB, et al. Adjunctive use of anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Aust N Z J Psychiatry 2019; 53: 742–759Google Scholar

Chollet, F, Tardy, J, Albucher, JF. Fluoxetine for motor recovery after stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011; 10: 123–130Google Scholar

Choy, Y, Peselow, ED, Case, BG, et al. Three-year medication prophylaxis in panic disorder: to continue or discontinue? A naturalistic study. Compr Psychiatry 2007; 48: 419–425Google Scholar

Christensen, J, Grønborg, TK, Sørensen, MJ. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. J Am Med Assoc 2013; 309: 1696–1703Google Scholar

Christenson, GA, MacKenzie, TB, Mitchell, JE, et al. A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania. Am J Psychiatry 1991; 148: 1566–1571Google Scholar

Chung, YC, Lee, CR, Park, TW, et al. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial. World J Biol Psychiatry 2009; 10: 156–162Google Scholar

Cipriani, A, Furukawa, TA, Salanti, G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–1366Google Scholar

Citrome, L. The ABCs of dopamine receptor partial agonists – aripiprazole, brexpiprazole, and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015; 69: 1211–1220Google Scholar

Citrome, L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol 2017a; 37: 138–147Google Scholar

Citrome, L, Meng, X, Hochfeld, M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Research 2011; 131(1–3): 75–81Google Scholar

Citrome, L, Durgam, S, Lu, K, et al. The effect of cariprazine on hostility associated with schizophrenia: post hoc analyses from 3 randomized controlled trials. J Clin Psychiatry 2016a; 77: 109–115Google Scholar

Citrome, L, Ota, A, Nagamizu, K, et al. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. Int Clin Psychopharmacol 2016b; 31: 192–201Google Scholar

Citrome, L, Landbloom, R, Chang, CT, et al. Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder. Neuropsychiatr Dis Res 2017b; 13: 2955–2963Google Scholar

Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52: 1510–1514Google Scholar

Ciudad, A, Alvarez, E, Roca, M, et al. Early response and remission as predictors of a good outcome of a major depressive episode at 12-month follow-up: a prospective, longitudinal, observational study. J Clin Psychiatry 2012; 73: 185–191Google Scholar

Claes, L, Bouman, WP, Witcomb, G, et al. Non-suicidal self-injury in trans people: associations with psychological symptoms, victimization, interpersonal functioning, and perceived social support. J Sex Med 2015; 12: 168–179Google Scholar

Clark, CT, Klein, AM, Perel, JM, et al. Lamotrigine dosing for pregnant patients with bipolar disorder. Am J Psychiatry 2013; 170: 1240–1247Google Scholar

Clark, RD, Canive, JM, Calais, LA, et al. Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 1999; 12: 395–401Google Scholar

Clayton, AH, Stewart, RS, Fayyad, R, et al. Sex differences in clinical presentation and response in panic disorder: pooled data from sertraline treatment studies. Arch Womens Ment Health 2006; 9: 151–157Google Scholar

Clemons, WE, Makela, E, Young, J. Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. Sleep Med 2004; 5: 509–511Google Scholar

Cloninger, CR. The Temperament and Character Inventory (TCI): A Guide to its Development and Use. St. Louis, MO: Washington University; Center for Psychobiology of Personality; 1994Google Scholar

Cloninger, CR, Przybeck, TR, Svrakic, DM. The Tridimensional Personality Questionnaire: US normative data. Psychol Rep 1991; 69: 1047–1057Google Scholar

Cloninger, CR, Zohar, AH, Hirschmann, S, et al. The psychological costs and benefits of being highly persistent: personality profiles distinguish mood disorders from anxiety disorders. J Affect Disord 2012; 136: 758–766Google Scholar

Clyde, PW, Harari, AE, Getka, EJ, et al. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. J Am Med Assoc 2003; 290: 2952–2958Google Scholar

Coccaro, EF, Kavoussi, RJ. Fluoxetine and impulsive aggressive behavior in personality disordered subjects. Arch Gen Psychiatry 1997; 54: 1081–1088Google Scholar

Coccaro, EF, Lee, RJ, Kavoussi, JR. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009; 70: 653–662Google Scholar

Coccaro, EF, Adan, F, Allen, D, et al. Plasma-serum differences in the assessment of tricyclic antidepressant blood levels. Int Clin Psychopharmacol 1987; 2: 217–224Google Scholar

Cohen, JM, Hernández-Díaz, S, Bateman, BT, et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol 2017; 130: 1192–1201Google Scholar

Cohen, JM, Huybrechts, KF, Patorno, E, et al. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. J Clin Psychiatry 2019; 80: 18m12572Google Scholar

Cohen, LG, Chesly, S, Eugenio, S, et al. Erythromycin-induced clozapine toxic reaction. Arch Intern Med 1996; 156: 675–677Google Scholar

Cohen, LS, Soares, CN, Poitras, JR, et al. Short-term use of estradiol for depression in perimenopausal and postmenopausal women: a preliminary report. Am J Psychiatry 2003; 160: 1519–1522Google Scholar

Cohen, LS, Viguera, AC, McInerney, KA, et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Am J Psychiatry 2016; 173: 263–270Google Scholar

Cohen, NL, Ross, EC, Bagby, RM, et al. The 5-factor model of personality and antidepressant medication compliance. Can J Psychiatry 2004; 49: 106–113Google Scholar

Cole, JD, Kazarian, SS. The Level of Expressed Emotion Scale: a new measure of expressed emotion. J Clin Psychol 1988; 44: 392–397Google Scholar

Comer, JS, Olfson, M, Mojtabai, R. National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. J Am Acad Child Adolesc Psychiatry 2010; 49: 1001–1010Google Scholar

Compton, WM, Han, B, Blanco, C, et al. Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. Am J Psychiatry 2018; 175: 741–755Google Scholar

Conley, RR, Kelly, DL, Richardson, CM, et al. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 2003; 23: 668–671Google Scholar

Connor, DF, Fletcher, KE, Swanson, JM, et al. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1551–1559Google Scholar

Connor, KM, Davidson, JRT, Churchill, LE, et al. Psychometric properties of the Social Phobia Inventory. Br J Psychiatry 2000; 176: 379–386Google Scholar

Connor, KM, Davidson, JR, Weisler, RH, et al. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology 2006; 184: 21–25Google Scholar

Connor, KM, Hidalgo, RB, Crockett, B, et al. Predictors of treatment response in patients with posttraumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 337–345Google Scholar

Conus, P, Cotton, SM, Francey, SM, et al. Predictors of favourable outcome in young people with a first episode psychosis without antipsychotic medication. Schizophr Res 2017; 185: 130–136Google Scholar

Cook, IA, Hunter, AM, Gilmer, WS, et al. Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD) trial. J Clin Psychiatry 2013; 74: 51–56Google Scholar

Cools, R, Robbins, TW. Chemistry of the adaptive mind. Philos Trans A Math Phys Eng Sci 2004; 362: 2871–2888Google Scholar

Cooper, TB, Bergner, PE, Simpson, GM. The 24-hour serum lithium level as a prognosticator of dosage requirements. Am J Psychiatry 1973; 130: 601–603Google Scholar

Cooper-Karaz, R, Apter, JT, Cohen, R, et al. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64: 679–688Google Scholar

Corá-Locatelli, G, Greenberg, BD, Martin, J, et al. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry 1998; 59: 480–481Google Scholar

Cordás, TA, Tavares, H, Calderoni, DM, et al. Oxcarbazepine for self-mutilating bulimic patients. Int J Neuropsychopharmacol 2006; 9: 769–771Google Scholar

Cornelius, JR, Salloum, IM, Ehler, JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997; 54: 700–705Google Scholar

Cornelius, JR, Salloum, IM, Thase, ME, et al. Fluoxetine versus placebo in depressed alcoholic cocaine abusers. Psychopharmacol Bull 1998; 34: 117–121Google Scholar

Cornelius, JR, Soloff, PH, George, A, et al. Haloperidol vs. phenelzine in continuation therapy of borderline disorder. Psychopharmacol Bull 1993; 29: 333–337Google Scholar

Correll, CU, Kane, JM. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. J Child Adolesc Psychopharmacol 2007; 17: 647–656Google Scholar

Correll, CU, Davis, RE, Weingart, M, et al. Efficacy and safety of lumateperone for treatment of schizophrenia: a randomized trial. JAMA Psychiatry 2020; 77: 349–358Google Scholar

Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414–425Google Scholar

Correll, CU, Rubio, JM, Kane, JM. What is the risk-benefit ratio of long-term antipsychotic treatment in patients with schizophrenia? World Psychiatry 2018; 17: 149–160Google Scholar

Correll, CU, Manu, P, Olshanskiy, V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. J Am Med Assoc 2009; 302: 1765–1773Google Scholar

Correll, CU, Rubio, JM, Inczedy-Farkas, G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017; 74: 675–684Google Scholar

Correll, CU, Skuban, A, Hobart, M, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: review of three randomized, double-blind, placebo-controlled studies. Schizophr Res 2016; 174: 82–92Google Scholar

Cortese, S, Adamo, N, Del Giovane, C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018; 5: 727–738Google Scholar

Corya, SA, Williamson, D, Sanger, TM, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 2006; 23: 364–372Google Scholar

Coryell, W, Winokur, G, Solomon, D, et al. Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychol Med 1997; 27: 281–289Google Scholar

Costi, S, Soleimani, L, Glasgow, A, et al. Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. Neuropsychopharmacol 2019; 44: 1812–1819Google Scholar

Coupland, CAC, Hill, T, Dening, T, et al. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med 2019; 179: 1084–1093Google Scholar

Cowdry, RW, Gardner, DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45: 111–119Google Scholar

Crawford, MJ, Sanatinia, R, Barrett, B, et al. The clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder: a randomized placebo-controlled trial. Am J Psychiatry 2018; 175: 756–764Google Scholar

Crippa, JA, Derenusson, GN, Ferrari, TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol 2011; 25: 121–130Google Scholar

Cristancho, P, Lenze, EJ, Dixon, D, et al. Executive function predicts antidepressant treatment noncompletion in late-life depression. J Clin Psychiatry 2018; 79: 16m11371Google Scholar

Cross-Disorder Group of the Psychiatric Genomics Consortium. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet 2013; 45: 984–994Google Scholar

Crossley, NA, Constante, M. Efficacy of atypical v typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry 2010; 196: 434–439Google Scholar

Crossley, NA, Marques, TR, Taylor, H, et al. Connectomic correlates of response to treatment in first-episode psychosis. Brain 2017; 140: 487–496Google Scholar

Cummings, JL, Lyketsos, CG, Peskind, ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. J Am Med Assoc 2015; 314: 1242–1254Google Scholar

Cutler, AJ, Montgomery, SA, Feifel, D, et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry 2009; 70: 526–539Google Scholar

Czerwensky, F, Leucht, S, Steimer, W. MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain? Int J Neuropsychopharmacol 2013; 16: 2103–2109Google Scholar

Czobor, P, Volavka, J, Meibach, RC. Effect of risperidone on hostility in schizophrenia. J Clin Psychopharmacol 1995; 15: 243–249Google Scholar

D’Abreu, A, Friedman, JH. Tardive dyskinesia-like syndrome due to drugs that do not block dopamine receptors: rare or non-existent. Literature review. Tremor Other Hyperkinet Mov (NY) 2018; 8: 570Google Scholar

Dackis, CA, Kampman, KM, Lynch, KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacol 2005; 30: 205–211Google Scholar

Dackis, CA, Kampman, KM, Lynch, KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abuse Treat 2012; 43: 303–312Google Scholar

Dager, SR, Khan, A, Cowley, DS, et al. Characteristics of placebo response during long-term treatment of panic disorder. Psychopharmacol Bull 1990; 26: 273–278.Google Scholar

Daly, C, Griffin, E, Ashcroft, DM, et al. Intentional drug overdose involving pregabalin and gabapentin: findings from the National Self-Harm Registry Ireland, 2007–2015. Clin Drug Investig 2018a; 38: 373–380Google Scholar

Daly, J, Singh, JB, Fedgchin, M, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2018b; 75: 139–148Google Scholar

Daly, J, Trivedi, MH, Janik, A, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention of patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry 2019; 76: 893–903Google Scholar

Daniel, DG, Zimbroff, DL, Potkin, SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491–505Google Scholar

Dannlowski, U, Baune, BT, Böckemann, I, et al. Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Hum Psychopharmacol 2008; 23: 587–593Google Scholar

Daray, FM, Thommi, SB, Ghaemi, SN. The pharmacogenetics of antidepressant-induced mania: a systemic review and meta-analysis. Bipolar Disord 2010; 12: 702–706Google Scholar

Darbinyan, V, Aslanyan, G, Amroyan, E, et al. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry 2007; 61: 343–348Google Scholar

Davanzano, R, Dal Bo, S, Bua, J, et al. Antiepileptic drug and breastfeeding. Ital J Pediatr 2013; 39: 50Google Scholar

Davidson, J, Baldwin, D, Stein, DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006; 63: 1158–1165Google Scholar

Davidson, J, Pearlstein, T, Londborg, P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001a; 158: 1974–1981Google Scholar

Davidson, J, Stein, DJ, Rothbaum, BO, et al. Resilience as a predictor of treatment response in patients with posttraumatic stress disorder treated with venlafaxine extended release or placebo. J Psychopharmacol 2012; 26: 778–783Google Scholar

Davidson, JR, Book, SW, Colket, JT, et al. Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med 1997a; 27: 153–160Google Scholar

Davidson, JR, Malik, ML, Sutherland, SN. Response characteristics to antidepressants and placebo in post-traumatic stress disorder. Int Clin Psychopharmacol 1997b; 12: 291–296Google Scholar

Davidson, JR, Potts, N, Richichi, E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13: 423–428Google Scholar

Davidson, JR, Potts, NL, Richichi, EA, et al. The Brief Social Phobia Scale. J Clin Psychiatry 1991; (52 Suppl): 48S–51SGoogle Scholar

Davidson, JR, Rothbaum, BO, van der Kolk, BA et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001b; 58: 485–492Google Scholar

Davidson, M, Emsley, R, Kramer, M, et al. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007; 93: 117–130Google Scholar

Davis, JM. Dose equivalence of the antipsychotic drugs. J Psychiatr Res 1974; 11: 65–69Google Scholar

Davis, LL, Barotlucci, A, Petty, F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85: 259–266Google Scholar

Davis, LL, Davidson, JR, Ward, LC, et al. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008a; 28: 84–88Google Scholar

Davis, LL, Ota, A, Perry, P, et al. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study. Brain Behav 2016; 6: e00520Google Scholar

Davis, LL, Ward, C, Rasmussen, C, et al. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008b; 41: 8–18Google Scholar

Davison, JM, Dunlop, W. Renal hemodynamics and tubular function in normal human pregnancy. Kidney Int 1980; 18: 152–161Google Scholar

de Bejczy, A, Söderpalm, B. The effects of mirtazapine versus placebo on alcohol consumption in male high consumers of alcohol: a randomized, controlled trial. J Clin Psychopharmacol 2015; 35: 43–50Google Scholar

Debonnel, G, Saint-André, E, Hébert, C, et al. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol 2007; 10: 51–61Google Scholar

De Hert, M, Sermon, J, Geerts, P, et al. The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics. CNS Drugs 2015; 29: 637–658Google Scholar

DeKosky, ST, Williamson, JD, Fitzpatrick, AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. J Am Med Assoc 2008; 300: 2253–2262Google Scholar

de la Fuente, JM, Lotstra, F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994; 4: 479–486Google Scholar

de Leon, J, Wynn, G, Sandson, NB. The pharmacokinetics of risperidone versus paliperidone. Psychosomatics 2010; 51: 80–88Google Scholar

de Lucena, D, Fernandes, BS, Berk, M, et al. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009; 70: 1416–1423Google Scholar

DeMartinis, A, Schweizer, E, Rickels, K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry 1996; 57: 245–248Google Scholar

Deng, L, Sun, X, Qiu, S, et al. Interventions for management of post-stroke depression: a Bayesian network meta-analysis of 23 randomized controlled trials. Sci Rep 2017; 7: 16466Google Scholar

Dennis, CL, Ross, LE, Herxheimer, A. Oestrogens and progestins for preventing and treating postpartum depression. Cochrane Database Syst Rev 2008;(4):CD001690Google Scholar

de Oliveira, IR, de Sena, EP, Pereira, EL, et al. Haloperidol blood levels and clinical outcome: a meta-analysis of studies relevant to testing the therapeutic window hypothesis. J Clin Pharm Ther 1996; 21: 229–236Google Scholar

DePetris, AE, Cook, BL. Differences in diffusion of FDA antidepressant risk warnings across racial-ethnic groups. Psychiatr Serv 2013; 64: 466–471Google Scholar

De Picker, L, Van Den Eede, F, Dumont, G, et al. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics 2014; 55: 536–537Google Scholar

Depping, AM, Komossa, K, Kissling, W, Leucht, S. Second generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010; (12): CD008120Google Scholar

de Silva, VA, Suraweera, C, Ratnatuga, SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry 2016; 16: 341Google Scholar

de Vries, C, van Bergen, A, Regeer, EJ, et al. The effectiveness of restarted lithium treatment after discontinuation: reviewing the evidence for discontinuation-induced refractoriness. Bipolar Disord 2013; 15: 645–649Google Scholar

Devulapalli, KK, Nasrallah, HA. An analysis of the high psychotropic off-label use in psychiatric disorders. The majority of psychiatric diagnoses have no approved drug. Asian J Psychiatry 2009; 2: 29–36Google Scholar

DeYoung, CG, Hirsh, JB, Shane, MS, et al. Testing predictions from personality neuroscience: brain structure and the big five. Psychol Sci 2010; 21: 820–828Google Scholar

Di Florio, A, Forty, L, Gordon-Smith, K, et al. Perinatal episodes across the mood disorder spectrum. JAMA Psychiatry 2013; 70: 168–175Google Scholar

DiMascio, A, Bernardo, DL, Greenblatt, DJ, et al. A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry 1976; 33: 599–602Google Scholar

Dinz, JB, Shavitt, RG, Fossaluza, V, et al. A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol 2011; 31: 763–768Google Scholar

Docherty, JP, Sack, DA, Roffman, M, et al. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J Psychiatr Pract 2005; 11: 302–314Google Scholar

Dodd, S, Dean, OM, Berk, M. A review of the theoretical and biological understanding of the nocebo and placebo phenomena. Clin Ther 2017; 39: 469–476Google Scholar

Dodd, S, Berk, M, Kelin, K, et al. Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder. J Affect Disord 2013; 150: 344–349Google Scholar

Dodd, S, Schacht, A, Kelin, K, et al. Nocebo effects in the treatment of major depression: results from an individual study participant-level meta-analysis of the placebo arm of duloxetine clinical trials. J Clin Psychiatry 2015; 76: 702–711Google Scholar

Dodd, S, Walker, AJ, Brnabic, JM, et al. Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder. Bipolar Disord 2019; 21: 142–150Google Scholar

Dold, M, Aigner, M, Lanzenberger, R, Kasper, S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neurpharmacol 2015a; 18: pyv047Google Scholar

Dold, M, Bartova, L, Rupprecht, R, et al. Dose escalation of antidepressants in unipolar depression: a meta-analysis of double-blind, randomized controlled trials. Psychother Psychosom 2017; 86: 283–291Google Scholar

Dold, M, Fugger, G, Aigner, M, et al. Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Res 2015b; 166: 187–193Google Scholar

Dold, M, Li, C, Tardy, M, et al. Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2012; (11): CD006391Google Scholar

Domes, G, Ower, N, von Dawans, B, et al. Effects of intranasal oxytocin administration on empathy and approach motivation in women with borderline personality disorder: a randomized controlled trial. Transl Psychiatry 2019; 9: 328Google Scholar

Doody, RS, Ferris, SH, Salloway, S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology 2009; 72: 1555–1561Google Scholar

Dorph-Petersen, KA, Pierri, JN, Perel, JM, et al. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacol 2005; 30: 1649–1661Google Scholar

Downing, AM, Kinon, BJ, Millen, BA, et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry 2014; 14: 351Google Scholar

Drevets, WC, Zarate, CA Jr., Furey, ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry 2013; 73: 1156–1163Google Scholar

Duffy, A, Heffer, N, Goodday, SM, et al. Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: a systematic review: a report from the ISBD-IGSLi joint task force on lithium treatment. Bipolar Disord 2018; 20: 583–593Google Scholar

Duggal, HS, Mendhekar, DN. High-dose aripiprazole in treatment-resistant schizophrenia. J Clin Psychiatry 2006; 67: 674–675Google Scholar

Duinkerke, SJ, Botter, PA, Jansen, AA, et al. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br J Psychiatry 1993; 163: 451–455Google Scholar

Dumon, JP, Catteau, J, Lanvin, F, et al. Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1992; 149: 647–650Google Scholar

Dumville, JC, Miles, JN, Porthouse, J, et al. Can vitamin D supplementation prevent winter-time blues? A randomised trial among older women. J Nutr Health Aging 2006; 10: 151–153Google Scholar

Duncan, EJ, Szilagyi, S, Schwartz, MP, et al. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res 2004; 71: 239–248Google Scholar

Dunkley, EJ, Isbister, GK, Sibbritt, D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003; 96: 635–642Google Scholar

Dunlop, BW, Kelley, ME, Aponte-Rivera, V, et al. Effects of patient preferences on outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study. Am J Psychiatry 2017; 174: 546–556Google Scholar

Dunner, DL, Fieve, RR. Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229–233Google Scholar

Dunner, DL, Amsterdam, JD, Shelton, RC, et al. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. J Clin Psychiatry 2007; 68: 1071–1077Google Scholar

Dupuis, B, Catteau, J, Dumon, JP, et al. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 802–805Google Scholar

Durgam, S, Earley, W, Guo, H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry 2016a; 77: 371–378Google Scholar

Durgam, S, Earley, W, Li, R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res 2016b; 176: 264–271Google Scholar

Durgam, S, Gommoll, C, Forero, G, et al. Efficacy and safety of vilazodone in patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, flexible-dose trial. J Clin Psychiatry 2016c; 77: 1687–1694Google Scholar

Durgam, S, Satlin, A, Vanover, K, et al. Lumateperone (ITI-007) in the treatment of bipolar depression: results from a randomized clinical trial. Poster presented at the Annual Meeting of the American College of Neuropsychopharmacology, Orlando, Florida, December 8–11, 2019Google Scholar

Durgam, S, Starace, A, Li, D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2015; 17: 63–75Google Scholar

Earley, W, Burgess, MV, Rekeda, L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry 2019a; 176: 439–448Google Scholar

Earley, WR, Burgess, MV, Khan, B, et al. Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord 2020; 22: 372–384Google Scholar

Earley, W, Guo, H, Daniel, D, et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data. Schizophr Res 2019b; 204; 282–288Google Scholar

Earley, WR, Guo, H, Németh, G, et al. Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull 2018; 48: 62–80Google Scholar

Egbe, A, Uppu, S, Lee, S, et al. Congenital malformations in the newborn population: a population study and analysis of the effect of sex and prematurity. Pediatr Neonatol 2015; 56: 25–30Google Scholar

Eison, AS, Mullins, UL. Regulation of central 5HT2A receptors: a review of in vivo studies. Behav Brain Res 1996; 73: 177–181Google Scholar

Ekeberg, O, Kjeldsen, SE, Greenwood, DT, et al. Effects of selective beta-adrenoceptor blockade on anxiety associated with flight phobia. J Psychopharmacol 1990; 4: 35–41Google Scholar

el-Ganzouri, AR, Ivankovich, AD, Braverman, B, et al. Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anesth Analg 1985; 64: 592–596Google Scholar

Elkashef, A, Kahn, R, Yu, E, et al. Topiramate for the treatment of methamphetamine addiction: a multi-center placebo-controlled trial. Addiction 2012; 107: 1297–1306Google Scholar

El-Khalili, N, Joyce, M, Atkinson, S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13: 917–932Google Scholar

El-Mallakh, RS, Vöhringer, PA, Ostacher, MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial. J Affect Disord 2015; 184: 318–321Google Scholar

Emamzadehfard, S, Kamaloo, A, Paydary, K, et al. Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci 2016; 70: 332–341Google Scholar

Erland, LAE, Saxena, PK. Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. J Clin Sleep Med 2017; 13: 275–281Google Scholar

Ernst, CL, Goldberg, JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63(Suppl 4): 42–55Google Scholar

Etkin, A, Patenaude, B, Song, YJ, et al. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology 2015; 40: 1332–1342Google Scholar

Etminan, M, Sodhi, M, Procyshyn, RM, et al. Risk of hair loss with different antidepressants: a comparative retrospective cohort study. Int Clin Psychopharmacol 2018; 33: 44–48Google Scholar

Faedda, GL, Tondo, L, Baldessarini, RJ, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50: 448–455Google Scholar

Fallon, BA. Pharmacotherapy of somatoform disorders. J Psychosom Res 2004; 56: 455–460Google Scholar

Fang, H, Zhen, YF, Liu, XY, et al. Association of the BDNF Val66Met polymorphism with BMI in chronic schizophrenic patients and healthy controls. Int Clin Psychopharmacol 2016; 31: 353–357Google Scholar

Faridhossinie, F, Sadeghi, R, Farid, L, et al. Celecoxib: a new augmentation strategy for depressive mood episodes: a systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014; 29: 216–223Google Scholar

Farnia, V, Gharebaghi, H, Alikhani, M, et al. Efficacy and tolerability of adjunctive gabapentin and memantine in obsessive compulsive disorder: double-blind, randomized, placebo-controlled trial. J Psychiatr Res 2018; 104: 137–143Google Scholar

Farren, CK, Scimeca, M, Wu, R, et al. Double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug Alcohol Depend 2009; 99: 317–321Google Scholar

Fava, M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61(Suppl 11): 37–41Google Scholar

Fava, M, Rosenbaum, JF. Anger attacks in depression. Depress Anxiety 1998; 8(Suppl 1): 59–63Google Scholar

Fava, GA, Benasi, G, Lucente, M, et al. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom 2018a; 87: 195–203Google Scholar

Fava, GA, Gatti, A, Belaise, C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72–81Google Scholar

Fava, M, Durgam, S, Earley, W, et al. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 2018b; 33: 312–321Google Scholar

Fava, M, Evins, AE, Dorer, DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 2003; 72: 115–127Google Scholar

Fava, M, Ménard, F, Davidsen, CK, et al. Adjunctive brexpiprazole in patients with major depressive disorder and irritability: an exploratory study. J Clin Psychiatry 2016; 77: 1695–1701Google Scholar

Fava, M, Mischoulon, D, Iosifescu, D, et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012; 81: 87–97Google Scholar

Fava, M, Nierenberg, AA, Quitkin, FM, et al. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull 1997; 33: 101–103Google Scholar

Fava, M, Rappe, SM, Pava, JA, et al. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995; 56: 52–55Google Scholar

Fava, M, Rush, AJ, Alpert, JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165: 342–351Google Scholar

Fawcett, J, Barkin, RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety. J Clin Psychiatry 1998; 59: 123–127Google Scholar

Fawcett, J, Marcus, RN, Anton, SF, et al. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry 1995; 56 (Suppl 6): 37–42Google Scholar

Fawcett, J, Rush, AJ, Vukelich, J, et al. Clinical experience with high-dose pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar disorder. Am J Psychiatry 2016; 173: 107–111Google Scholar

Feder, A, Parides, MK, Murrough, JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2014; 71: 681–688Google Scholar

Fedgchin, M, Trivedi, M, Daly, EJ, et al. Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). Int J Neuropsychopharmacol 2019; 22: 616–630Google Scholar

Fein, S, Paz, V, Rao, N, et al. The combination of lithium carbonate and an MAOI in refractory depressions. Am J Psychiatry 1988; 145: 249–250Google Scholar

Feinberg, SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry 2004; 65: 1520–1524Google Scholar

Feltner, DE, Crockatt, JG, Dubovsky, SJ, et al. A randomized, double blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–249Google Scholar

Feltner, DE, Liu-Dumaw, M, Schweizer, E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol 2011; 26: 213–220Google Scholar

Ferreria-Garcia, R, da Rocha Freire, RC, Appolinário, JC, et al. Tranylcypromine plus amitriptyline for electroconvulsive therapy-resistant depression: a long-term study. J Clin Psychopharmacol 2018; 38: 502–504Google Scholar

Ferrando, SJ. Psychopharmacologic treatment of patients with HIV/AIDS. Curr Psychiatry Rep 2009; 11: 235–242Google Scholar

Ferrnadon, SJ, Freyberg, Z. Treatment of depression in HIV positive individuals: a critical review. Int Rev Psychiatry 2008; 20: 61–71Google Scholar

Fesler, FA. Valproate in combat-related post-traumatic stress disorder. J Clin Psychiatry 1991; 52: 361–364Google Scholar

Fiedorowicz, JG, Endicott, J, Leon, AC, et al. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 2011; 168: 40–48Google Scholar

Figueroa, Y, Rosenberg, DR, Birmaher, B, et al. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 1998; 8: 61–67Google Scholar

Findling, RL, Ginsberg, LD. The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode. Neuropsychiatr Dis Treat 2014; 10: 1589–1597Google Scholar

Findling, RL, Chang, K, Robb, A, et al. Adjunctive maintenance lamotrigine for pediatric bipolar I disorder: a placebo-controlled, randomized withdrawal study. J Am Acad Child Adolesc Psychiatry 2015; 54: 1020–1031Google Scholar

Florio, V, Porcelli, S, Saria, A, et al. Escitalopram plasma levels and antidepressant response. Eur Neuropsychopharmacol 2017; 27: 940–944Google Scholar

Focosi, D, Azzarà, A, Kast, RE, et al. Lithium and hematology: established and proposed uses. J Leukoc Biol 2009; 85: 20–28Google Scholar

Foglia, JP, Pollock, BG, Kirschner, MA, et al. Plasma levels of citalopram enantiomers and metabolites in elderly patients. Psychopharmacol Bull 1997; 33: 109–112Google Scholar

Ford, AC, Lacy, BE, Harris, LA, et al. Antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol 2019; 114: 21–39Google Scholar

Forester, BP, Harper, DG, Georgakas, J, et al. Antidepressant effects with open label treatment with coenzyme Q10 in geriatric bipolar depression. J Clin Psychopharmacol 2015; 35: 338–340Google Scholar

Förg, A, Hein, J, Volkmar, K, et al. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol 2012; 47: 149–155Google Scholar

Fornaro, M, Anastasia, A, Novello, S, et al. Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis. Bipolar Disord 2018; 20: 195–227Google Scholar

Förster, K, Jörgens, S, Air, TM, et al. The relationship between social cognition and executive function in major depressive disorder in high-functioning adolescents and young adults. Psychiatr Res 2018; 263: 139–146Google Scholar

Fournier, JC, DeRubeis, RJ, Hollon, SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. J Am Med Assoc 2010; 303: 47–53Google Scholar

Franchini, L, Serretti, A, Gasperini, M, et al. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32: 244–259Google Scholar

Frank, C. Pharmacologic treatment of depression in the elderly. Can Fam Physician 2014; 60: 121–126Google Scholar

Frank, J. Managing hypertension using combination therapy. Am Fam Physician 2008; 77: 1279–1286Google Scholar

Frank, E, Prien, RF, Jarrett, RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48: 851–855Google Scholar

Frankenburg, FR, Zanarini, MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63: 442–446Google Scholar

Freeman, D, Dunn, G, Murray, RM, et al. How cannabis causes paranoia: using the intravenous administration of ∆9-tetrahydrocannabinol (THC) to identify key cognitive mechanisms leading to paranoia. Schizophr Bull 2015; 41: 391–399Google Scholar

Freeman, EW, Rickels, K, Arredondo, R, et al. Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. J Clin Psychopharmacol 1999; 19: 3–8Google Scholar

Freudenreich, O, Goff, DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002; 106: 323–330Google Scholar

Frieder, A, Fersh, M, Hainline, R, et al. Pharmacotherapy of postpartum depression: current approaches and novel drug development. CNS Drugs 2019; 33: 265–282Google Scholar

Friedman, RA, Mitchell, J, Kocsis, JH. Retreatment for relapse following desipramine discontinuation in dysthymia. Am J Psychiatry 1995; 152: 926–928Google Scholar

Friedman, MJ, Marmar, CR, Baker, DG, et al. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 2007; 68: 711–720Google Scholar

Frye, MA, Helleman, G, McElroy, SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry 2009; 166: 164–172Google Scholar

Frye, MA, Ketter, TA, Kimbrell, TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607–614Google Scholar

Fujii, H, Goel, A, Bernard, N, et al. Pregnancy outcomes following gabapentin use: results of a prospective comparative cohort study. Neurology 2013; 80: 1565–1570Google Scholar

Furieri, FA, Nakamura-Palacios, EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007; 68: 1691–1700Google Scholar

Furmark, T, Appel, L, Henningssohn, S, et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci 2008; 28: 13066–13074Google Scholar

Furu, K, Kieler, H, Haglund, B, et al. Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design. Br Med J 2015; 350: h1798Google Scholar

Furukawa, TA, Cipriani, A, Atkinson, LZ, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled trials. Lancet 2016; 3: 1059–1066Google Scholar

Furukawa, TA, Cipriani, A, Leucht, S, et al. Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. Evid Based Ment Health 2018a; 21: 1–3Google Scholar

Furukawa, TA, Levine, SZ, Tanaka, S, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015; 72: 14–21Google Scholar

Furukawa, TA, Maruo, K, Noma, H, et al. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand 2018b; 137: 450–458Google Scholar

Fusar-Poli, P, Cappucciati, M, Rutigiano, G, et al. Diagnostic stability of ICD/DSM first episode psychosis diagnoses: meta-analysis. Schizophr Bull 2016; 42: 1395–1406Google Scholar

Fusar-Poli, P, Papanasatiou, E, Stahl, D, et al. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull 2015; 41: 892–899Google Scholar

Gadde, KM, Kopping, MF, Wagner, HT 2nd, et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012; 172: 1557–1564Google Scholar

Gallagher, P, Young, AH. Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications. Neuropsychiatr Dis Treat 2006; 2: 33–42Google Scholar

Galling, B, Roldán, A, Hagi, K, et al. Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry 2017; 16: 77–89Google Scholar

Galling, B, Vernon, JA, Pagsberg, AK, et al. Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. Acta Psychiatr Scand 2018; 137: 187–205Google Scholar

Gambi, F, De Berardis, D, Campanella, D, et al. Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 2005; 19: 483–487Google Scholar

Garakani, A, Martinez, JM, Marcus, S, et al. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol 2008; 23: 269–275Google Scholar

Garcia-Garcia, AL, Newman-Tancredi, A, Leonardo, ED. 5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. Psychopharmacol (Berl) 2014; 231: 623–636Google Scholar

Gardini, S, Cloninger, CR, Venneri, A. Individual differences in personality traits reflect structural variance in specific brain regions. Brain Res Bull 2009; 79: 265–270Google Scholar

Gardner, DL, Cowdry, RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143: 519–522Google Scholar

Gardner, DM, Shulman, KI, Walker, SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996; 57: 99–104Google Scholar

Garlow, SJ, Dunlop, BW, Ninan, PT, et al. The combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder. J Psychiatr Res 2012; 46: 1406–1413Google Scholar

Gatti, F, Bellini, L, Gasperini, M, et al. Fluvoxamine alone in the treatment of delusional depression. Am J Psychiatry 1996; 153: 414–416Google Scholar

Gaul, C, Diener, H-C, Danesch, U, et al. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 2015; 16: 516Google Scholar

Geddes, JR, Calabrese, JR, Goodwin, GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4–9Google Scholar

Geddes, JR, Burgess, S, Hawton, K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161: 217–222Google Scholar

Geddes, JR, Gardiner, A, Rendell, J, et al. Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 x 2 factorial randomised trial. Lancet Psychiatry 2016; 3: 31–39Google Scholar

Geers, AL, Helfer, SG, Kosbab, K, et al. Reconsidering the role of personality in placebo effects: dispositional optimism, situational expectations, and the placebo response. J Psychosom Res 2005; 58: 121–127Google Scholar

Gelaye, B, Rondon, M, Araya, R, et al. Epidemiology of maternal depression, risk factors, and child outcomes in low-income and middle-income countries. Lancet Psychiatry 2016; 3: 973–982Google Scholar

Gelenberg, AJ, Kane, JM, Keller, MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489–1493Google Scholar

Generoso, MB, Trevizol, AP, Kasper, S, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol 2017; 32: 49–55Google Scholar

Gengo, F, Timko, J, D’Antonio, J, et al. Prediction of dosage of lithium carbonate: use of a standard predictive model. J Clin Psychiatry 1980; 41: 319–320Google Scholar

Gentile, JP, Dillon, KS, Gillig, PM. Psychotherapy and pharmacotherapy for patients with dissociative identity disorder. Innov Clin Neurosci 2013; 10: 22–29Google Scholar

Genuis, SJ, Schwalfenberg, G, Siy A-K, J, et al. Toxic element contamination of natural health products and pharmaceutical preparations. PLoS One 2012; 7: e49676Google Scholar

George, KC, Kebejian, L, Ruth, LJ, et al. Meta-analysis of the efficacy and safety of prazosin versus placebo for the treatment of nightmares and sleep disturbances in adults with posttraumatic stress disorder. J Trauma Dissociation 2016; 17: 494–510Google Scholar

Georgotas, A, McCue, RE, Hapworth, W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986; 21: 1155–1166Google Scholar

Gerner, R, Estabrook, W, Steur, J, et al. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. J Clin Psychiatry 1980; 41: 216–220Google Scholar

Gex-Fabry, M, Gervasoni, N, Eap, CB, et al. Time course of response to paroxetine: influence of plasma level. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 892–900Google Scholar

Ghaemi, SN, Gilmer, WS, Goldberg, JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007; 68: 1840–1844Google Scholar

Ghaemi, SN, Ostacher, MM, El-Mallakh, RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry 2010; 71: 372–380Google Scholar

Ghajar, A, Gholamian, F, Tabatabei-Motlagh, M, et al. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Hum Psychopharmacol 2018a; 33: e2662Google Scholar

Ghajar, A, Khoaie-Ardakani, MR, Shahmoradi, Z, et al. L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial. Psychiatry Res 2018b; 262: 94–101Google Scholar

Ghanizadeh, A, Nikseresht, MS, Sahraian, A. The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. Schizophr Res 2013; 147: 110–115Google Scholar

Ghio, L, Gotelli, S, Marcenaro, M, et al. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. J Affect Disord 2014; 152–154: 45–51Google Scholar

Giacobbe, P, Rakita, U, Lam, R, et al. Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: a meta-analysis of randomized controlled trials. J Affect Disord 2018; 226: 294–300Google Scholar

Gibson, AP, Bettinger, TL, Patel, NC, et al. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother 2006; 40: 1134–1142Google Scholar

Gilaberte, I, Montejo, AL, de la Gandara, J, et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol 2001; 21: 417–424Google Scholar

Gilbert, DG, Rabinovich, NE, McDaniel, JT. Nicotine patch for cannabis withdrawal symptom relief: a randomized controlled trial. Psychopharmacol (Berl) 2020; 237: 1507–1519Google Scholar

Gildengers, AG, Chung, K-H, Huang, S-H, et al. Neuroprogressive effects of lifetime illness duration in older adults with bipolar disorder. Bipolar Disord 2014; 16: 617–623Google Scholar

Gilles, M, Deuschle, M, Kellner, S, et al. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 2005; 38: 118–121Google Scholar

Gilmor, ML, Owens, MJ, Nemeroff, CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry 2002; 159: 1701–1710Google Scholar

Ginde, AA, Liu, MC, Camargo, CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch Intern Med 2009; 169: 626–632Google Scholar

Ginsberg, LD. Carbamazepine extended-release capsules: a retrospective review of its use in children and adolescents. Ann Clin Psychiatry 2006; 18(Suppl 1): 3–7Google Scholar

Glantz, MD, Anthony, JC, Berglund, PA, et al. Mental disorders as risk factors for later substance dependence: estimates of optimal prevention and treatment benefits. Psychol Med 2009; 39: 1365–1377Google Scholar

Glassman, AH, O’Connor, CM, Califf, RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. J Am Med Assoc 2002; 288: 701–709Google Scholar

Gleeson, M. Dosing and efficacy of glutamine supplementation in human exercise and sport training. J Nutr 2008; 138: 2045S–2049SGoogle Scholar

Goedhard, LE, Stolker, JJ, Heerdink, ER, et al. Pharmacotherapy for the treatment of aggressive behavior in general adult psychiatry: a systematic review. J Clin Psychiatry 2006; 67: 1013–1024Google Scholar

Goff, DC, Cather, C, Gottlieb, JD, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106: 320–327Google Scholar

Goff, DC, Keefe, R, Citrome, L, et al. Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials. J Clin Psychopharmacol 2007; 27: 582–589Google Scholar

Goff, DC, McEvoy, JP, Citrome, L, et al. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol 2013; 33: 485–490Google Scholar

Goldberg, JF. Complex combination pharmacotherapy for bipolar disorder: knowing when less is more or more is better. Focus 2019; 17: 218–231Google Scholar

Goldberg, JF, Ernst, CL. Managing the Side Effects of Psychotropic Medications, 2nd Edn. Washington, DC: American Psychiatric Association Publishing; 2019Google Scholar

Goldberg, JF, Whiteside, JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry 2002; 63: 791–795Google Scholar

Goldberg, JF, Bowden, CL, Calabrese, JR, et al. Six-month prospective life charting of mood symptoms with lamotrigine versus placebo in rapid cycling bipolar disorder. Biol Psychiatry 2008; 63: 125–130Google Scholar

Goldberg, JF, Calabrese, JR, Saville, BR, et al. Mood stabilization and destabilization during acute and continuation phase treatment for bipolar I disorder with lamotrigine or placebo. J Clin Psychiatry 2009; 70: 1273–1280Google Scholar

Goldberg, JF, Freeman, MP, Balon, R, et al. The American Society of Clinical Psychopharmacology survey of psychopharmacologists’ practice patterns for the treatment of mood disorders. Depress Anxiety 2015; 32: 605–613Google Scholar

Goldberg, SC, Schulz, SC, Schulz, PM, et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43: 680–686Google Scholar

Golden, JC, Goethe, JW, Wooley, SB. Complex psychotropic polypharmacy in bipolar disorder across varying mood polarities: a prospective cohort study of 2712 patients. J Affect Disord 2017; 221: 6–10Google Scholar

Goldlewska, BR, Olajossy-Hilkesberger, L, Ciwoniuk, M, et al. Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene. Pharmacogenomics J 2009; 9: 234–241Google Scholar

Goldstein, TR, Frye, MA, Denicoff, KD, et al. Antidepressant discontinuation-related mania: critical prospective observation and theoretical implications in bipolar disorder. J Clin Psychiatry 1999; 60: 563–567Google Scholar

Gómez, JM, Teixidó Perramón, C. Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings. J Clin Psychiatry 2000; 61; 285–289Google Scholar

Gomez, AF, Barthel, AL, Hofmann, SG. Comparing the efficacy of benzodiazepines and serotonergic antidepressants for adults with generalized anxiety disorder: a meta-analytic review. Expert Opin Pharmacother 2018; 19: 883–894Google Scholar

Gonul, AS, Akdeniz, F, Donat, O, et al. Selective serotonin reuptake inhibitors combined with venlafaxine in depressed patients who had partial response to venlafaxine: four cases. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 889–891Google Scholar

Gonzalez, G, Feingold, A, Oliveto, A, et al. Comorbid major depressive disorder as a prognostic factor in cocaine-abusing buprenorphine-maintained patients treated with desipramine and contingency management. Am J Drug Alcohol Abuse 2003; 29: 497–514Google Scholar

Good, KP, Kiss, I, Buiteman, C, et al. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005; 8: 457–472Google Scholar

Goodnick, PJ. Blood levels and acute response to bupropion. Am J Psychiatry 1992; 149: 399–400Google Scholar

Goodnick, PJ, Puig, A, DeVane, CL, Freund, BV. Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 1999; 60: 446–468Google Scholar

Goodwin, FK, Fireman, B, Simon, GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. J Am Med Assoc 2003; 290: 1467–1473Google Scholar

Gorwood, P, Demyttenare, K, Vaiva, G, et al. An increase in joy after two weeks is more specific of later antidepressant response than a decrease in sadness. J Affect Disord 2015; 185: 97–103Google Scholar

Gorwood, P, Weiller, E, Lemming, O, et al. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatr 2007; 15: 581–593Google Scholar

Goss, AJ, Kaser, M, Costafreda, SG, et al. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2013; 74: 1101–1107Google Scholar

Gowing, L, Ali, R, White, JM, Mbewe, D. Buprenorphine for managing opioid withdrawal. Cochrane Database Sys Rev 2017; (2): CD002025Google Scholar

Grace, AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neurosci 1991; 41: 1–24Google Scholar

Grant, JE, Kim, SW, Odlaug, BL. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry 2009; 65: 600–606Google Scholar

Grant, JE, Odlaug, BL, Kim, SW. Lamotrigine treatment of pathologic skin picking: an open-label study. J Clin Psychiatry 2007; 68: 1384–1391Google Scholar

Grant, JE, Odlaug, BL, Kim, SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009a; 66: 756–763Google Scholar

Grant, JE, Odlaug, BL, Chamberlain, SR, et al. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. J Clin Psychopharmacol 2010; 30: 396–403Google Scholar

Grant, JE, Chamberlain, SR, Redden, SA, et al. N-Acetylcysteine in the treatment of excoriation disorder: a randomized clinical trial. JAMA Psychiatry 2016; 73: 490–496Google Scholar

Grant, JE, Odlaug, BL, Chamberlain, SR, et al. Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacol (Berl) 2011; 218: 493–502Google Scholar

Grant, JE, Odlaug, BL, Schreiber, LR, et al. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J Clin Psychopharmacol 2014; 34: 134–138Google Scholar

Gray, KM, Carpenter, MJ, Baker, NL, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry 2012; 169: 805–812Google Scholar

Gray, KM, Sonne, SC, McClure, EA, et al. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend 2017; 177: 249–257Google Scholar

Greden, JF, Parikh, SV, Rothschild, AJ, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized controlled study, J Psychiatr Res 2019; 111: 59–67Google Scholar

Greendyke, RM, Kanter, DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry 1986; 47: 423–426Google Scholar

Greist, JH, Liu-Dumaw, M, Schweizer, E, et al. Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder: results of a double-blind, placebo-controlled 26-week study. Int Clin Psychopharmacol 2011; 26: 243–251Google Scholar

Grieve, SM, Korgaonkur, MS, Gordon, E, et al. Prediction of nonremission to antidepressant therapy using diffusion tensor imaging. Clin Psychiatry 2016; 77: e436–e443Google Scholar

Grigoriadis, S, Graves, L, Peer, M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. J Clin Psychiatry 2019; 80: 18r12412Google Scholar

Grof, P, Duffy, A, Cavazzoni, P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002; 63: 942–947Google Scholar

Grossman, E, Messerli, FH, Grodzicki, T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? J Am Med Assoc 1996; 276: 1328–1331Google Scholar

Grunze, H, Kotlik, E, Costa, R, et al. Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicenter, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. J Affect Disord 2015; 174: 70–82Google Scholar

Guaiana, G, Barbui, C, Cipriani, A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev 2010; (12): CD006815Google Scholar

Guina, J, Rossetter, SR, DeRhodes, BJ, et al. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatr Pract 2015; 21: 281–303Google Scholar

Guitivano, J, Sullivan, PF, Stuebe, AM, et al. Adverse life events, psychiatric history, and biological predictors of postpartum depression in an ethnically diverse sample of postpartum women. Psychol Med 2018; 48: 1190–1200Google Scholar

Gunasekara, NS, Spencer, CM. Quetiapine: a review of its use in schizophrenia. CNS Drugs 1998; 9: 325–340Google Scholar

Gunn, RL, Finn, PR. Impulsivity partially mediates the association between reduced working memory capacity and alcohol problems. Alcohol 2013; 47: 3–8Google Scholar

Gvirts, HZ, Lewis, YD, Dvora, S, et al. The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. Int Clin Psychopharmacol 2018; 33: 233–237Google Scholar

Gyurak, A, Patenaude, B, Korgaonkar, MS, et al. Frontoparietal activation during response inhibition predicts remission to antidepressants in patients with major depression. Biol Psychiatry 2016; 79: 274–281Google Scholar

Hackam, DG, Mrobrada, M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012; 79: 1862–1865Google Scholar

Haddy, TB, Rana, SR, Castro, O. Benign ethnic neutropenia: what is the normal absolute neutrophil count? J Lab Clin Med 1999; 133: 15–22Google Scholar

Hadley, SJ, Mandel, FS, Schweizer, E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012; 26: 461–470Google Scholar

Hagos, FT, Daood, MJ, Ocque, JA, et al. Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasms and brain exposure of N-acetylcysteine. Xenobiotica 2017; 47: 346–353Google Scholar

Haji, EO, Tadić, A, Wagner, S, et al. Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychopharmacol 2011; 31: 281–286Google Scholar

Halikas, JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995; 10(Suppl 2): S125–S133Google Scholar

Hall, K, Lembo, AJ, Kirsch, I, et al. Catechol-o-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS ONE 2012; 7: e48135Google Scholar

Hall, KT, Loscalzo, J, Kaptchuk, TJ. Genetics and the placebo effect. Trends Mol Med 2015; 2: 285–294Google Scholar

Hambrecht, M, Lammertink, M, Klosterktter, J, et al. Subjective and objective neuropsychological abnormalities in a psychosis prodrome clinic. Br J Psychiatry Suppl 2002; 43: S30–S37Google Scholar

Hamilton, MW. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 10–16Google Scholar

Hamner, MB, Brodrick, PS, Labatte, LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13: 141–146Google Scholar

Hamner, MB, Hernandez-Tejada, MA, Zuschlag, ZD, et al. Ziprasidone augmentation of SSRI antidepressants in posttraumatic stress disorder: a randomized, placebo-controlled pilot study of augmentation therapy. J Clin Psychopharmacol 2019; 39: 153–157Google Scholar

Han, B, Compton, WM, Blanco, C, et al. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Ann Int Med 2017; 167: 293–301Google Scholar

Han, C, Pae, C-U, Wang, S-M, et al. The potential role of atypical antipsychotics for the treatment of posttraumatic stress disorder. J Psychiatr Res 2014; 56: 72–81Google Scholar

Hanania, NA, Singh, S, El-Wali, R, et al. The safety and effects of the beta blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 2008; 21: 134–141Google Scholar

Haney, M, Rubin, E, Foltin, RW. Aripiprazole maintenance increases smoked cocaine self-administration in humans. Psychopharmacol (Berl) 2011; 216: 379–387Google Scholar

Hanling, SR, Hickey, A, Lesnik, I, et al. Stellate ganglion block for the treatment of posttraumatic stress disorder: a randomized, double-blind, controlled trial. Reg Anesth Pain Med 2016; 41: 494–500Google Scholar

Hansen, LB, Larsen, NE, Vestergard, P. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacol (Berl) 1981; 74: 306–309Google Scholar

Haroon, E, Daguanno, AW, Woolwine, BJ, et al. Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology 2018; 95: 43–49Google Scholar

Harris, DS, Wolkowitz, OM, Reus, VI. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients. World J Biol Psychiatry 2001; 2: 99–102Google Scholar

Harrow, M, Jobe, TH. Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull 2013; 39: 962–965Google Scholar

Harrow, M, Jobe, TH. Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period? World Psychiatry 2018; 17: 162–163Google Scholar

Härtter, S, Wetzel, H, Hammes, E, et al. Serum concentrations of fluvoxamine and clinical effects: a prospective open clinical trial. Pharmacopsychiatry 1998; 31: 199–200Google Scholar

Hartwell, EE, Feinn, R, Morris, PE, et al. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction 2020; 115: 1426–1437Google Scholar

Harvey, RC, James, AC, Shields, GE. A systematic review and network meta-analysis to assess the relative efficacy of antipsychotics for the treatment of positive and negative symptoms in early-onset schizophrenia. CNS Drugs 2016; 30: 27–39Google Scholar

Hata, T, Kanazawa, T, Hamada, T, et al. What can predict and prevent the long-term use of benzodiazepines? J Psychiatr Res 2018; 97: 94–100Google Scholar

Hawkins, RA. The blood-brain barrier and glutamate. Am J Clin Nutr 2009; 90: 867S–874SGoogle Scholar

Hayasaka, Y, Purgato, M, Magni, LR, et al. Dose equivalents of antidepressant: evidence-based recommendations from randomized controlled trials. J Affect Disord 2015; 180: 179–184Google Scholar

Hedayati, SS, Gregg, LP, Carmody, T, et al. Effect of sertraline on depressive symptoms in patients with chronic kidney disease without dialysis dependence: the CAST randomized clinical trial. J Am Med Assoc 2017; 318: 1876–1890Google Scholar

Hegerl, U, Mergl, R, Sanders, C, et al. A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study). Eur Neuropsychopharmacol 2018; 28: 185–194Google Scholar

Heidari, M, Zarei, M, Hosseini, SM, et al. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder. Int Clin Psychopharmacol 2014; 29: 344–350Google Scholar

Heinälä, P, Alho, H, Kiianmaa, K, et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 2001; 21: 287–292Google Scholar

Hieronymous, F, Nilsson, S, Eriksson, E. A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Transl Psychiatry 2016; 6: e34Google Scholar

Helfer, B, Samara, MT, Huhn, M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry 2016; 173: 876–886CrossRef Google Scholar PubMed

Hendricks, J, Greenway, FL, Westman, EC, et al. Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity 2011; 19: 2351–2360Google Scholar

Henigsberg, N, Mahableshwarkar, A, Jacobsen, P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 2012; 73: 953–959Google Scholar

Henry, C, Mitropoulou, V, New, AS, et al. Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences. J Psychiatr Res 2001; 35: 307–312Google Scholar

Henssler, J, Kurschus, M, Franklin, J, et al. Trajectories of acute antidepressant efficacy: how long to wait for response? J Clin Psychiatry 2018; 79: 17r11470Google Scholar

Heresco-Levy, U, Javitt, D, Ermilov, M, et al. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 1996; 169: 610–617Google Scholar

Heresco-Levy, U, Vass, A, Bloch, B, et al. Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2009; 12: 1275–1282CrossRef Google Scholar PubMed

Herman, J. Trauma and Recovery: the Aftermath of Violence from Domestic Abuse to Political Terror. New York, NY: Basic Books; 1988Google Scholar

Heringa, SM, Begemann, MJH, Goverde, AJ, et al. Sex hormones and oxytocin augmentation strategies in schizophrenia: a quantitative review. Schizophr Res 2015; 168: 603–613Google Scholar

Herring, WJ, Connor, KM, Snyder, E, et al. Suvorexant in elderly patients with insomnia: pooled analyses of data from phase III randomized controlled clinical trials. Am J Geriatr Psychiatry 2017; 25: 791–802Google Scholar

Hertzberg, MA, Butterfield, MI, Feldman, ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 45: 1226–1229Google Scholar

Hesdorffer, DC, Berg, AT, Kanner, AM. An update on antiepileptic drugs and suicide: are there definitive answers yet? Epilepsy Curr 2010; 10: 137–145Google Scholar

Hewett, K, Chrzanowski, W, Jokinen, R, et al. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder. J Psychopharmacol 2010; 24: 521–529Google Scholar

Heylens, G, Elaut, E, Kreukels, BP, et al. Psychiatric characteristics in transsexual individuals: multicenter study in four European countries. Br J Psychiatry 2014; 204: 151–156Google Scholar

Hidaka, T, Fujii, K, Funahashi, I, et al. Safety assessment of coenzyme Q10 (CoQ10). Biofactors 2008; 32: 199–208Google Scholar

Hidalgo, RB, Tupler, LA, Davidson, JR. An effect-size analysis of pharmacological treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21: 864–872Google Scholar

Hidese, S, Ota, M, Wakbayashi, C, et al. Effects of chronic l-theanine administration in patients with major depressive disorder: an open-label study. Acta Neuropsychiatr 2017; 29: 72–79Google Scholar

Hieber, R, Dellenbaugh, T, Nelson, LA. Role of mirtazapine in the treatment of antipsychotic-induced akathisia. Ann Pharmacother 2008; 42: 841–846CrossRef Google Scholar PubMed

Hiemke, C, Bergemann, N, Clement, HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9–62Google Scholar

Hiemke, C, Peled, A, Jabarin, M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 2002; 22: 502–506Google Scholar

Hill, AB. The environment and disease: association or causation? Proc Royal Soc Med 1965; 58: 295–300Google Scholar

Hill, KP, Palastro, MD, Gruber, SA, et al. Nabilone pharmacotherapy for cannabis dependence: a randomized, controlled pilot study. Am J Addict 2017; 26: 795–801Google Scholar

Hinz, M, Stein, A, Uncini, T. Relative nutritional deficiencies are associated with centrally acting monoamines. Int J Gen Med 2012; 5: 413–430Google Scholar

Hirsch, LJ, Weintraub, D, Du, Y, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63: 1022–1026CrossRef Google Scholar PubMed

Hirschmann, S, Dannon, P, Iancu, I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000; 20: 556–559Google Scholar

Hirschfeld, RM, Russell, JM, Delgado, PL, et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 1998; 59: 669–675Google Scholar

Hirschfeld, RM, Weisler, RH, Raines, SR, et al. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 355–362Google Scholar

Ho, BC, Andreasen, NC, Dawson, JD, et al. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am J Psychiatry 2007; 164: 1890–1899Google Scholar

Ho, BC, Andreasen, NC, Ziebell, S, et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68: 128–137Google Scholar

Hoes, MJ, Zeijpveld, JH. Mirtazapine as a treatment for serotonin syndrome. Pharmacopsychiatry 1996; 29: 81Google Scholar

Hoffer, A. Schizophrenia: an evolutionary defence against severe stress. J Orthomolec Med 1994; 9: 205–221Google Scholar

Hollander, E, Allen, A, Lopez, RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62: 199–203CrossRef Google Scholar PubMed

Hollander, E, Koran, LM, Goodman, WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003a; 64: 640–647Google Scholar

Hollander, E, Swann, AC, Coccaro, EF, et al. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162: 621–624Google Scholar

Hollander, E, Tracey, KA, Swann, AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003b; 28: 1186–1197Google Scholar

Holmes, TH, Rahe, RH. The social readjustment rating scale. J Psychosom Res 1967; 11: 213–218Google Scholar

Holmquist, GL. Opioid metabolism and effects of cytochrome P450. Pain Med 2009; 10 (Suppl 1): S20–S29Google Scholar

Holst, J, Bäckström, T, Hammarbäck, S, et al. Progestogen addition during oestrogen replacement therapy – effects on vasomotor symptoms and mood. Maturitas 1989; 11: 13–20Google Scholar

Hooley, JM, Parker, HA. Measuring expressed emotion: an evaluation of the shortcuts. J Fam Psychol 2006; 20: 386–396.Google Scholar

Horing, B, Weimer, K, Muth, ER, et al. Prediction of placebo responses: a systematic review of the literature. Front Psychol 2014; 5: 1079Google Scholar

Horvath, AO, Symonds, BD. Relation between working alliance and outcome in psychotherapy: a meta-analysis. J Counsel Psychol 1991; 38: 139–149CrossRef Google Scholar

Horvitz-Lennon, M, Mattke, S, Predmore, Z. The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry 2017; 174: 421–426Google Scholar

Howes, OD, Kambeitz, J, Kim, E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012; 69: 776–786Google Scholar

Hrøbjartsson, A, Gøtzsche, PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594–1602Google Scholar

Hsu, W-Y, Lane, H-Y, Li, C-H. Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer’s disease, and Parkinson’s disease. Front Psychiatry 2018; 9: 91Google Scholar

Huang, CL, Hwang, TJ, Chen, YH, et al. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: an open-label, randomized controlled trial. J Formos Med Assoc 2015; 114: 438–445Google Scholar

Huband, N, Ferriter, M, Nathan, R, et al. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst Rev 2010; (2): CD003499Google Scholar

Hudson, JI, Hiripi, E, Pope, HG Jr., et al. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 61: 348–358Google Scholar

Huerta-Ramos, E, Iniesta, R, Ochoa, S, et al. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 2014; 24: 223–231Google Scholar

Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 2019; 394: 939–951Google Scholar

Hurd, YL, Spriggs, S, Alishayev, J, et al. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry 2019; 176: 911–922Google Scholar

Hymowitz, P, Frances, A, Jacobsberg, LB, et al. Neuroleptic treatment of schizotypal personality disorders. Compr Psychiatry 1986; 27: 267–271Google Scholar

Imaz, ML, Torra, M, Soy, D, et al. Clinical lactation studies of lithium: a systematic review. Front Pharmacol 2019; 10: 1005Google Scholar

Indave, BI, Minozzi, S, Paolo Pani, P, et al. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2016; (3): CD006306Google Scholar

Insel, TR, Hamilton, JA, Guttmacher, LB, et al. D-amphetamine in obsessive-compulsive disorder. Psychopharmacol (Berl) 1983; 80: 231–235Google Scholar

Ionescu, DF, Bentley, KH, Eikermann, M, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial. J Affect Disord 2019; 243: 516–524Google Scholar

Ionescu, DF, Fava, M, Kim, DJ, et al. A placebo-controlled crossover study of iloperidone augmentation for residual anger and irritability in major depressive disorder. Ther Adv Psychopharmacol 2016a; 6: 4–12Google Scholar

Ionescu, DF, Swee, MB, Pavone, KJ, et al. Rapid and sustained reductions in current suicidal ideation following repeated doses of intravenous ketamine: secondary analysis of an open-label study. J Clin Psychiatry 2016b; 77: e719–e725Google Scholar

Ipser, JC, Wilson, D, Akindipe, TO, et al. Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev 2015; 1: CD007505Google Scholar

ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349–360Google Scholar

Isojärvi, JI, Laatikainen, TJ, Pakarinen, AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993; 329: 1383–1388Google Scholar

Jacobs-Pilipski, MJ, Wilfley, DE, Crow, SJ, et al. Placebo response in binge eating disorder. Int J Eat Disord 2007; 40: 204–211Google Scholar

Jacobsen, FM. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study. J Clin Psychiatry 1990; 51: 298–302Google Scholar

Jacobson, PL, Mahableshwarkar, AR, Serenko, M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. J Clin Psychiatry 2015; 76: 575–582Google Scholar

Jafferany, M, Osuagwu, FC. Use of topiramate in skin-picking disorder: a pilot study. Prim Care Companion CNS Disord 2017; 19(1)Google Scholar

Jahangard, L, Akbarian, S, Haghighi, M, et al. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed: results from a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res 2017; 251: 182–191Google Scholar

Jain, FA, Hunter, AM, Brooks III, JO, et al. Predictive socioeconomic and clinical profiles of antidepressant response and remission. Depress Anxiety 2013; 30: 624–630Google Scholar

Jakobsen, KD, Skyum, E, Hashemi, N, et al. Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review. J Psychopharmacol 2017; 31: 397–405Google Scholar

Jakubczyk, A, Wrzosek, M, Łukaszkiewicz, J, et al. The CC genotype in HTR2A T102C polymorphism is associated with behavioral impulsivity in alcohol-dependent patients. J Psychiatr Res 2012; 46: 44–49Google Scholar

Jakubovski, E, Varigonda, AL, Freemantle, N, et al. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 2016; 173: 174–183Google Scholar

Jana, U, Sur, TK, Maity, LN, et al. A clinical study on the management of generalized anxiety disorder with Centella asiatica. Nepal Med Coll J 2010; 12: 8–11Google Scholar

Janowsky, DS, Davis, JM, el-Yousef, MK, et al. A cholinergic-adrenergic hypothesis of mania and depression. Lancet 1972; 300: 632–635Google Scholar

Jarivavilas, A, Thavichachart, N, Kongsakon, R, et al. Effects of paliperidone extended release on hostility among Thai patients with schizophrenia. Neuropsychiatr Dis Treat 2017; 13: 141–146Google Scholar

Jasinski, D, Krishnan, S. Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol 2009b; 23: 419–427Google Scholar

Jasinski, DR, Krishnan, S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol 2009a; 23: 410–418Google Scholar

Javitt, DC, Zylberman, I, Zukin, SR, et al. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994; 151: 1234–1236Google Scholar

Jentink, J, Loane, MA, Dolk, H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362: 2185–2193Google Scholar

Jiang, H, Ling, Z, Zhang, Y, et al. Altered microbiota composition in patients with major depressive disorder. Brain Behav Immun 2015; 48: 186–194Google Scholar

Jin, W, Zheng, H, Shan, B, et al. Changes of serum trace elements level in patients with alopecia areata: a meta-analysis. J Derm 2017; 44: 588–591CrossRef Google Scholar PubMed

Joffe, RT, Swinson, RP, Levitt, AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11: 237–241Google Scholar

Joffe, H, Cohen, LS, Suppes, T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006; 59: 1078–1086Google Scholar

Joffe, H, Petrillo, LF, Viguera, AC, et al. Treatment of premenstrual worsening of depression with adjunctive oral contraceptive pills: a preliminary report. J Clin Psychiatry 2007; 68: 1954–1962Google Scholar

Johnson, BA, Ait-Daoud, N, Bowden, CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361: 1677–1685Google Scholar

Johnson, BA, Ait-Daoud, N, Wang, XQ, et al. Topiramate for the treatment of cocaine addiction: a randomized clinical trial. JAMA Psychiatry 2013; 70: 1338–1346Google Scholar

Johnson, BA, Roache, JD, Javors, MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. Arch Gen Psychiatry 2000; 284: 23–30Google Scholar

Johnson, BA, Rosenthal, N, Capece, JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. J Am Med Assoc 2007; 298: 1641–1651Google Scholar

Jonas, DE, Amick, HR, Feltner, C, et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. J Am Med Assoc 2014; 311: 1889–1900CrossRef Google Scholar PubMed

Jones, JM, Aldrich, J, Gillham, R, et al. Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: systematic review and meta-analysis. Br J Psychiatry 2011; 198: 93–98Google Scholar

Joos, L, Goudriaan, A, Schmaal, L, et al. Effect of modafinil on cognitive functions in alcohol dependent patients: a randomized, placebo-controlled trial. J Psychopharmacol 2013; 27: 998–1006Google Scholar

Jorge, RE, Acion, L, Moser, D, et al. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry 2010; 67: 187–196Google Scholar

Ju, SY, Lee, YJ, Jeong, SN. Serum 25-hydroxyvitamin D levels and the risk of depression: a systematic review and meta-analysis. J Nutr Health Aging 2013; 17: 447–455Google Scholar

Kabul, S, Altorre, C, Motejano, LB, et al. Real-world dosing patterns of atomoxetine in adults with attention-deficit/hyperactivity disorder. CNS Neurosci Ther 2015; 21: 936–942Google Scholar

Kagawa, S, Mihara, K, Nakamura, A, et al. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder. Ther Drug Monit 2014; 36: 730–733Google Scholar

Kahn, RS, van Rossum, IW, Leucht, S, et al. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 2018; 5: 797–807Google Scholar

Kalivas, J, Kalivas, L, Gilman, D, et al. Sertraline in the treatment of neurotic excoriations and related disorders. Arch Dermatol 1996; 132: 589–590Google Scholar

Kamarck, TW, Haskett, RF, Muldoon, M, et al. Citalopram intervention for hostility: results of a randomized clinical trial. J Consult Clin Psychol 2009; 77: 174–188Google Scholar

Kamendulis, LM, Brzezinski, MR, Pindel, EV, et al. Metabolism of cocaine and heroin is catalyzed by the same human liver carboxylesterases. J Pharmacol Exp Ther 1996; 279: 713–717Google Scholar

Kamijima, K, Higuchi, T, Ishigooka, J, et al. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study). J Affect Disord 2013; 151: 899–905Google Scholar

Kampman, KM, Pettinati, HM, Lynch, KG, et al. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 2013; 133: 94–99Google Scholar

Kampman, KM, Pettinati, H, Lynch, KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Abuse 2004; 75: 233–240Google Scholar

Kan, CC, Hilberink, SR, Breteler, MH. Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach. Compr Psychiatry 2004; 45: 88–94Google Scholar

Kane, JM, Assunção-Talbott, S, Eudicone, JM, et al. The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: a pooled analysis of data from the pivotal trials. Schizophr Res 2008; 105: 208–215Google Scholar

Kane, JM, Canas, F, Kramer, M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007; 90: 147–161Google Scholar

Kane, JM, Cohen, M, Zhao, J, et al. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with an acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010; 30: 106–115Google Scholar

Kane, JM, Marder, SR, Schooler, NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001; 58: 965–972Google Scholar

Kaneriya, SH, Robbins-Welty, GA, Smaqula, SF, et al. Predictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-GRey randomized clinical trial. JAMA Psychiatry 2016; 73: 329–336Google Scholar

Kanes, S, Colquhoun, H, Gunduz-Bruce, H, et al. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 2017; 390: 480–489Google Scholar

Kapciski, F, Lima, MS, Souza, JS, Schmitt, R. Antidepressants for generalized anxiety disorder. Cochrane Database Syst Rev 2003; (2): CD003592Google Scholar

Kapur, S, Seeman, P. Does fast dissociation from the dopamine D₂ receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001; 158: 360–369Google Scholar

Kapur, S, Remington, G, Jones, C, et al. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 1996; 153: 948–950Google Scholar

Kapur, S, Zipursky, R, Remington, G, et al. PET evidence that loxapine is an equipotent blocker of 5-HT₂ and D₂ receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 1997a; 154: 1525–1529Google Scholar

Kapur, S, Zipursky, R, Roy, P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacol (Berl) 1997b; 131: 148–152Google Scholar

Kardashev, A, Ratner, Y, Ritsner, MS. Add-on pregnenolone with L-theanine to antipsychotic therapy relieves negative and anxiety symptoms of schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Clin Schizophr Relat Psychoses Spring 2018; 12: 31–41Google Scholar

Karpouzian-Rogers, T, Stocks, J, Meltzer, HY, et al. The effect of high vs. low dose lurasidone on eye movement biomarkers of prefrontal abilities in treatment-resistant schizophrenia. Schizophr Res 2020; 215: 314–321Google Scholar

Kashani, L, Shams, N, Moazen-Zadeh, E, et al. Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: a randomized double-blind placebo-controlled clinical trial. J Psychiatr Res 2017; 94: 70–77Google Scholar

Kasper, S, Dold, M. Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry 2015; 14: 304–306Google Scholar

Kasper, S, de Swart, H, Friis-Andersen, H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005; 13: 884–891Google Scholar

Kasper, S, Barnas, C, Heiden, A, et al. Pramipexole as adjunct to haloperidol in schizophrenia: safety and efficacy. Eur Neuropsychopharmacol 1997; 7: 65–70Google Scholar

Katila, H, Mezhebovsky, I, Mulroy, A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry 2013; 21: 769–784Google Scholar

Kato, H, Fukatsu, N, Noguchi, T, et al. Lamotrigine improves aggression in patients with temporal lobe epilepsy. Epilepsy Behav 2011; 21: 173–176Google Scholar

Katona, C, Hansen, T, Olsen, CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 2012; 27: 215–223Google Scholar

Katz, IR, Jeste, DV, Mintzer, JE, et al. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with demetia: a randomized, double-blind trial. J Clin Psychiatry 1999; 60: 107–115Google Scholar

Katzelnick, DJ, Kobak, KA, Greist, JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152: 1368–1371Google Scholar

Kavoussi, RJ, Coccaro, EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998; 59: 676–680Google Scholar

Kavoussi, RJ, Liu, J, Coccaro, EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994; 55: 137–141Google Scholar

Kawada, K, Ohta, T, Tanaka, K, et al. Addition of suvorexant to ramelteon therapy for improved sleep quality with reduced delirium risk in acute stroke patients. Stroke Cerebrovasc Dis 2019; 28: 142–148Google Scholar

Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–276Google Scholar

Kayser, A, Robinson, DS, Nies, A, et al. Response to phenelzine among depressed patients with features of hysteroid dysphoria. Am J Psychiatry 1985; 142: 486–488Google Scholar

Kazemi, A, Noorbala, AA, Azam, K, et al. Effect of probiotic and prebiotic vs. placebo on psychological outcomes in patients with major depressive disorder: a randomized clinical trial. Clin Nutr 2019; 38: 522–528Google Scholar

Keck, P Jr., Buffenstein, A, Ferguson, J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacol (Berl) 1998; 140: 173–184Google Scholar

Keck, PE Jr., Bowden, CL, Meinhold, JM, et al. Relationship between serum valproate and lithium levels and efficacy and tolerability in bipolar maintenance therapy. Intl J Psychiatry Clin Pract 2005; 9: 271–277Google Scholar

Keck, PE Jr., Calabrese, JR, McIntyre, RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007; 68: 1480–1491Google Scholar

Keck, PE Jr., McElroy, SL, Tugrul, KC, et al. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993; 54: 305–308Google Scholar

Keck, PE Jr., Strakowski, SM, Hawkins, JM, et al. A pilot study of rapid lithium administration in the treatment of acute mania. Bipolar Disord 2001; 3: 68–72Google Scholar

Keck, PE Jr., Versiani, M, Potkin, S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741–748Google Scholar

Keefe, RS, Bilder, RM, Davis, SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64: 633–647Google Scholar

Keefe, RSE, Seidman, LJ, Christensen, BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004; 161: 985–995Google Scholar

Keitner, GI, Garlow, SJ, Ryan, CE, et al. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 2009; 43: 205–214Google Scholar

Kelleher, JP, Centorrino, F, Huxley, NA, et al. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol 2012; 22: 415–418Google Scholar

Kelley, JM, Kaptchuk, TJ, Cusin, C, et al. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother Psychosom 2012; 81: 312–314Google Scholar

Kellner, CH, Knapp, RG, Petrides, G, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). Arch Gen Psychiatry 2006; 63: 1337–1344Google Scholar

Kelly, LE, Poon, S, Madadi, P, et al. Neonatal benzodiazepines exposure during breastfeeding. J Pediatr 2012; 161: 448–451Google Scholar

Kemp, DE, Ganocy, SJ, Brecher, M, et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord 2011; 130: 171–179Google Scholar

Kemp, DE, Gao, K, Fein, EB, et al. Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder. Bipolar Disord 2012; 14: 780–789Google Scholar

Kendell, RE, Cooper, JE, Gourlay, AJ. Diagnostic criteria of American and British psychiatrists. Arch Gen Psychiatry 1971; 25: 123–130Google Scholar

Kennedy, SH, Lam, RW, McIntyre, RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016: Clinical Guidelines for the Management of Adults with Major Depressive Disorder Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61: 540–560Google Scholar

Kennel, KA, Drake, MT, Hurley, DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc 2010; 85: 752–758Google Scholar

Keshavan, M, Shad, M, Soloff, P, et al. Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res 2004; 71: 97–101Google Scholar

Kessler, DS, MacNeill, SJ, Tallon, D, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). Br Med J 2018; 363: k4218Google Scholar

Kessler, RC, Adler, LA, Barkley, R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the National Comorbidity Survey Replication. Biol Psychiatry 2005a; 57: 1442–1451Google Scholar

Kessler, RC, Adler, L, Barkley, R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006; 163: 716–723Google Scholar

Kessler, RC, Birnbaum, H, Demler, O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry 2005b; 58: 668–676Google Scholar

Kessler, RC, Chiu, WT, Demler, O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005c; 62: 617–627Google Scholar

Ketter, TA, Post, RM, Theodore, WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53 (5 Suppl 2): S53–S67Google Scholar

Ketter, TA, Post, RM, Parekh, PI, et al. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J Clin Psychiatry 1995; 56: 471–475Google Scholar PubMed

Keuthen, N, Jameson, M, Loh, R, et al. Open-label escitalopram treatment for pathological skin picking. Int Clin Psychopharmacol 2007; 22: 268–274Google Scholar

Khan, A, Redding, N, Brown, WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res 2008; 42: 791–796Google Scholar

Khan, A, Brodhead, AE, Schwartz, KA, et al. Sex differences in antidepressant response in recent antidepressant clinical trials. J Clin Psychopharmacol 2005; 25: 318–324Google Scholar

Khan, A, Fahl Mar, K, Faucett, J, et al. Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987–2013. World Psychiatry 2017; 16: 181–192Google Scholar

Khan, A, Ginsberg, LD, Asnis, GM, et al. Effect of lamotrigine on cognitive complaints in patients with bipolar I disorder. J Clin Psychiatry 2004; 65: 1483–1490Google Scholar

Khan, SJ, Fersh, ME, Ernst, C, et al. Bipolar disorder in pregnancy and postpartum: principles of management. Curr Psychiatry Rep 2016; 18: 13Google Scholar

Khera, R, Murad, MH, Chandar, AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. J Am Med Assoc 2016; 315: 2424–2434Google Scholar

Kim, HJ, Kim, JE, Cho, G, et al. Associations between anterior cingulate cortex glutamate and gamma-aminobutyric acid concentrations and the harm avoidance temperament. Neurosci Lett 2009; 464: 103–107Google Scholar

Kim, JE, Yoon, SJ, Kim, J, et al. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Int J Clin Pract 2011; 65: 323329Google Scholar

Kim, SW, Dodd, S, Berk, L, et al. Impact of cannabis use on long-term remission in bipolar I and schizoaffective disorder. Psychiatry Investig 2015; 12: 349–355Google Scholar

Kim, S-W, Kang, H-J, Jhon, M, et al. Statins and inflammation: new therapeutic opportunities in psychiatry. Front Psychiatry 2019; 10: 103Google Scholar

Kimmel, M, Hess, E, Roy, PS, et al. Family history, not lack of medication use, is associated with the development of postpartum depression in a high-risk sample. Arch Womens Ment Health 2015; 18: 113–121Google Scholar

Kimura, M, Tateno, A, Robinson, RG. Treatment of poststroke generalized anxiety disorder comorbid with poststroke depression: merged analysis of nortriptyline trials. Am J Geriatr Psychiatry 2003; 11: 320–327Google Scholar

King, DJ, Link, CGG, Kowalcyk, B. A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia. Psychopharmacology 1998; 137: 139–146Google Scholar

Kinon, BJ, Millen, BA, Zhang, L, et al. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biol Psychiatry 2015; 78: 754–762Google Scholar

Kinon, BJ, Volavka, J, Stauffer, V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008; 28: 392–400Google Scholar

Kinon, BJ, Zhang, L, Millen, BA, et al. A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011; 31: 349–355Google Scholar

Kinrys, G, Pollack, MH, Simon, NM, et al. Valproic acid for the treatment of social anxiety disorder. Int Clin Psychopharmacol 2003; 18: 169–172Google Scholar

Kinrys, G, Wygant, LE, Pardo, TB, et al. Levetiracetam for treatment refractory posttraumatic stress disorder. J Clin Psychiatry 2006; 67: 211–214Google Scholar

Kirsch, I, Deacon, BJ, Huedo-Medina, TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: e45Google Scholar

Kishi, T, Iwata, N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol 2014; 17: 343–354Google Scholar

Kishi, T, Mukai, T, Matsuda, Y, et al. Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. Neuromolecular Med 2014; 16: 61–69Google Scholar

Kishi, T, Sevy, S, Chekuri, R, et al. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J Clin Psychiatry 2013; 74: e642–e654Google Scholar

Kittipeerachon, M, Chaichan, W. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: pragmatic double-blind randomized trial. Schizophr Res 2016; 176: 231–238Google Scholar

Kleinstäuber, M, Witthöft, M, Steffanowski, A, et al. Pharmacological interventions for somatoform disorders in adults. Cochrane Database Syst Rev 2014; (11): CD010628Google Scholar

Klinge, C, Shuttleworth, C, Muglia, P, et al. Methylphenidate enhances implicit learning in healthy adults. J Psychopharmacol 2018; 32: 70–80Google Scholar

Knegtering, R, Baselmans, P, Castelein, S, et al. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005; 162: 1010–1012Google Scholar

Knight, R, Khondoker, M, Magill, N, et al. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dementia Geriatr Cogn Disord 2018; 45: 131–151Google Scholar

Ko, DT, Herbert, PR, Coffey, CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. J Am Med Assoc 2002; 288: 351–357Google Scholar

Ko, YH, Lew, YM, Jung, SW, et al. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2008; 28: 375–383Google Scholar

Koblan, KS, Hopkins, SC, Sarma, K, et al. Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology 2015; 40: 2745–2752Google Scholar

Koblan, KS, Kent, J, Hopkins, SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med 2020; 382: 1497–1606Google Scholar

Kocsis, JH, Thase, ME, Trivedi, MH, et al. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. J Clin Psychiatry 2007; 68: 1014–1023Google Scholar

Koenig, AM, Butters, MA, Begley, A, et al. Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning. J Clin Psychiatry 2014; 75: e100–e107Google Scholar

Koenigsberg, HW, Reynolds, D, Goodman, M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003; 64: 628–634Google Scholar

Koethe, D, Juelicher, A, Nolden, BM, et al. Oxcarbazepine – efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomized, placebo-controlled multicenter pilot study. Alcohol Clin Exp Res 2007; 31: 1188–1194Google Scholar

Köhler, O, Benros, ME, Nordentoft, M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry 2014; 71: 1381–1391Google Scholar

Koob, GF, Volkow, ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 2016; 3: 760–773Google Scholar

Koran, LM, Aboujaoude, E, Gamel, NN. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2009; 70: 1530–1535Google Scholar

Koran, LM, Aboujaoude, EN, Gamel, NN. Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry 2007; 68: 422–427Google Scholar

Koran, LM, Cain, JW, Dominguez, RA, et al. Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? Am J Psychiatry 1996; 153: 1450–1454Google Scholar

Koran, LM, Chuong, HW, Bullock, KD, et al. Citalopram for compulsive shopping disorder: an open-label study followed by double-blind discontinuation. J Clin Psychiatry 2003; 64: 793–798Google Scholar

Koran, LM, Gamel, NN, Choung, HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005; 66: 515–520Google Scholar

Koran, LM, Gelenberg, AJ, Kornstein, SG, et al. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001; 65: 27–36Google Scholar

Korgaonkar, MS, Williams, LM, Song, YJ, et al. Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder. Br J Psychiatry 2014; 205: 321–328Google Scholar

Kornstein, SG, Bose, A, Li, D, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2006; 67: 1767–1775Google Scholar

Kornstein, SG, Schatzberg, AF, Thase, ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000; 157: 1445–1452Google Scholar

Kosten, T, Oliveto, A, Feingold, A, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 2003; 70: 315–325Google Scholar

Kosten, TR, Fontana, A, Sernyak, MJ, et al. Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse. J Nerv Ment Dis 2000; 188: 454–459Google Scholar

Kotov, R, Gamez, W, Schmidt, F, et al. Linking “big” personality traits to anxiety, depressive, and substance use disorders: a meta-analysis. Psychol Bull 2010; 136: 768–821Google Scholar

Kowalczyk, WJ, Phillips, KA, Jobes, ML, et al. Clonidine maintenance prolongs opioid abstinence and decouples stress from craving in daily life: a randomized controlled trial with ecological momentary assessment. Am J Psychiatry 2015; 172: 760–767Google Scholar

Kowatch, RA, Suppes, T, Carmody, TJ, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 713–720Google Scholar

Koychev, I, McMullen, K, Lees, J, et al. A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study. Eur Neuropsychopharmacol 2012; 22: 469–481Google Scholar

Kozel, FA, Trivedi, MH, Wisniewski, SR, et al. Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatry 2008; 16: 58–64Google Scholar

Kraemer, HC. Messages for clinicians: moderators and mediators of treatment outcome in randomized clinical trials. Am J Psychiatry 2016; 173: 672–679Google Scholar

Kranz, GS, Wadsak, W, Kayfmann, U, et al. High-dose testosterone treatment increases serotonin transporter binding in transgender people. Biol Psychiatry 2015; 78: 525–533Google Scholar

Kranzler, HR, Armeli, S, Tennen, H, et al. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter linked promoter region genotype. J Clin Psychopharmacol 2011; 31: 22–30Google Scholar

Kranzler, HR, Burleson, JA, Korner, P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. Am J Psychiatry 1995; 152: 391–397Google Scholar

Kranzler, HR, Covault, J, Feinn, R, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry 2014; 171: 445–452Google Scholar

Kraus, RP. Pindolol augmentation of tranylcypromine in psychotic depression. J Clin Psychopharmacol 1997; 17: 225–226Google Scholar

Kraus, SW, Etuk, R, Potenza, MN. Current pharmacotherapy for gambling disorder: a systematic review. Expert Opin Pharmacother 2020; 21: 287–296Google Scholar

Krause, M, Huhn, M, Schneider Thoma, J, et al. Antipsychotic drugs for elderly patients with schizophrenia: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2018a; 28: 1360–1370Google Scholar

Krause, M, Zhu, Y, Huhn, M, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry 2018b; 268: 625–639Google Scholar

Krebs, TS, Johansen, PØ. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012; 26: 994–1002Google Scholar

Kreinin, A, Bawakny, N, Ritsner, MS. Adjunctive pregnenolone ameliorates the cognitive deficits in recent-onset schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. Clin Schizophr Relat Psychoses 2017; 10: 201–210Google Scholar

Kremer, I, Vass, A, Gorlik, I, et al. Placebo-controlled trial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. Biol Psychiatry 2004; 56: 441–446Google Scholar

Krivoy, A, Balicer, RD, Feldman, B, et al. The impact of age and gender on adherence to antidepressants: a 4-year population-based cohort study. Psychopharmacol (Berl) 2015; 232: 3385–3390Google Scholar

Krivoy, A, Onn, R, Vilner, Y, et al. Vitamin D supplementation in chronic schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. EBioMedicine 2017; 26: 138–145Google Scholar

Krymchantowski, AV, Jevoux, C, Moreira, PF. An open pilot study assessing the benefits of quetiapine for the prevention of migraine refractory to the combination of atenolol, nortriptyline, and flunarizine. Pain Med 2010; 11: 48–52Google Scholar

Krystal, JH, Rosenheck, RA, Cramer, JA, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. J Am Med Assoc 2011; 306: 493–502Google Scholar

Kulkarni, J, Gavrilidis, E, Gwini, S, et al. Effect of adjunctive raloxifene therapy on severity of refractory schizophrenia in women. A randomized clinical trial. JAMA Psychiatry 2016; 73: 947–954Google Scholar

Kulkarni, J, Thomas, N, Hudaib, AB, et al. Effect of the glutamate NMDA receptor antagonist memantine as adjunctive treatment in borderline personality disorder: an exploratory, randomised, double-blind, placebo-controlled trial. CNS Drugs 2018; 32: 179–187Google Scholar

Kupfer, DJ, Frank, E, Perel, JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769–773Google Scholar

Kuruvilla, K, Shaji, KS. How reliable is 24 hour serum lithium level after a test dose of lithium in predicting optimal lithium dose? Indian J Psychiatry 1989; 31: 70–72Google Scholar

Kushner, SF, Khan, A, Lane, R, et al. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disord 2006; 8: 15–27Google Scholar

Laib, AK, Brünen, S, Pfeifer, P, et al. Serum concentrations of hydroxybupropion for dose optimization of depressed patients with bupropion. Ther Drug Monit 2014; 36: 473–479Google Scholar

Laird, KT, Lavretsky, H, St Cyr, N, et al. Resilience predicts remission in antidepressant treatment of geriatric depression. Int J Geriatr Psychiatry 2018; 33: 1596–1603Google Scholar

Lakhan, SE, Vieira, KF. Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review. Nutr J 2010; 9: 42.Google Scholar

Lal, R, Sukbuntherng, J, Luo, W, et al. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther 2009; 31: 1776–1786Google Scholar

Lane, HY, Chang, YC, Liu, YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 2005; 62: 1196–1204Google Scholar

Lane, HY, Huang, CL, Wu, PL, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol Psychiatry 2006; 60: 645–649CrossRef Google Scholar PubMed

Lane, HY, Lin, CH, Green, MF, et al. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor. JAMA Psychiatry 2013; 70: 1267–1275Google Scholar

LaPorta, LA. Relief from migraine headache with aripiprazole treatment. Headache 2007; 47: 922–926Google Scholar

Laporte, S, Chapelle, C, Caillet, P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res 2017; 118: 19–32Google Scholar

Larsen, JR, Vedtofte, L, Jacobsen, MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry 2017; 74: 719–728Google Scholar

Larsson, H, Rydén, E, Boman, M, et al. Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry 2013; 203: 103–106Google Scholar

Lasser, RA, Dirks, B, Nasrallah, H, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology 2013; 38: 2140–2149Google Scholar

Lavretsky, H, Park, S, Siddarth, P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006; 14: 181–185Google Scholar

Lavretsky, H, Reinlieb, M, St Cyr, N, et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015; 172: 561–569Google Scholar

Lawn, W, Freeman, TP, Pope, RA, et al. Acute and chronic effects of cannabinoids on effort-related decision-making and reward learning: an evaluation of the cannabis “amotivational’” hypotheses. Psychopharmacol (Berl) 2016; 233: 3537–3552Google Scholar

Lazarus, LW, Moberg, PJ, Langsley, PR, et al. Methylphenidate and nortriptyline in the treatment of poststroke depression: a retrospective comparison. Arch Phys Med Rehabil 1994; 75: 403–406Google Scholar

Lazarus, LW, Winemiller, DR, Lingam, VR, et al. Efficacy and side effects of methylphenidate for poststroke depression. J Clin Psychiatry 1992; 53: 447–449Google Scholar

Leach, MJ, Page, AT. Herbal medicine for insomnia: a systematic review and meta-analysis. Sleep Med Rev 2015; 24: 1–12Google Scholar

Lecrubier, Y, Judge, R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 153–160Google Scholar

Lee, DJ, Schnitzlein, CW, Wolf, JP, et al. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systematic review and meta-analyses to determine first-line treatments. Depress Anxiety 2016; 33: 792–806Google Scholar

Lee, EE, Della Selva, MP, Liu, A, et al. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 2015; 37: 178–184Google Scholar

Lee, SY, Wang, TY, Chen, SL, et al. Add-on memantine treatment for bipolar II disorder comorbid with alcohol dependence: a 12-week follow-up study. Alcohol Clin Exp Res 2018; 42: 1044–1050Google Scholar

Lehman, AF, Lieberman, JA, Dixon, LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2014; 161 (2 Suppl): 1–56Google Scholar

Leiberich, P, Nickel, MK, Tritt, K, et al. Lamotrigine treatment of aggression in female borderline patients, part II: an 18-month follow-up. J Psychopharmacol 2008; 22: 805–808Google Scholar

Leibowitz, M, Klein, DF. Interrelationship of hysteroid dysphoria and borderline personality disorder. Psych Clin N Amer 1981; 4: 67–87Google Scholar

Lejoyeux, M, Weinstein, A. Compulsive buying. Am J Drug Alcohol Abuse 2010; 36: 248–253Google Scholar

Lenhard, W, Lenhard, A. Calculation of Effect Sizes. Psychometrica 2016; DOI: 10.13140/RG.2.2.17823.92329. www.psychometrica.de/effect_size.html (accessed August 2020)Google Scholar

Lenze, EJ, Mulsant, BH, Blumberger, DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 2404–2412Google Scholar

Leonard, HL, Lenane, MC, Swedo, SE, et al. A double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting). Arch Gen Psychiatry 1991; 48: 821–827Google Scholar

Lépine, J-P, Caillard, V, Bisserbe, J-C, et al. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depression. Am J Psychiatry 2004; 161: 836–842Google Scholar

Lepkifiker, E, Sverdlik, A, Iancu, I, et al. Renal insufficiency in long-term lithium treatment. J Clin Psychiatry 2004; 65: 850–856Google Scholar

Lepola, U, Bergtholdt, B, St Lambert, J, et al. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004; 65: 222–229Google Scholar

Lepola, U, Heftling, N, Zhang, D, et al. Adjunctive brexpiprazole for elderly patients with major depressive disorder: an open-label, long-term safety and tolerability study. Int J Geriatr Psychiatry 2018; 33: 1403–1410Google Scholar

Lerer, B, Segman, RH, Fangerau, H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105–119Google Scholar

Lerner, V, Miodownik, C, Kaptsan, A, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158: 1511–1514Google Scholar

Lerner, V, Miodownik, C, Kaptsan, A, et al. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2002; 63: 54–58Google Scholar

Leucht, S, Arbter, D, Engel, RR, et al. How effective are second generation antipsychotic drugs? A meta-analysis of placebo controlled trials. Mol Psychiatry 2009; 4: 429–447Google Scholar

Leucht, S, Busch, R, Kissling, W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007; 68: 352–360Google Scholar

Leucht, S, Chaimani, A, Leucht, C, et al. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: meta-regression of predictors of placebo response. Schizophr Res 2018; 201: 315–323Google Scholar

Leucht, S, Cipriani, A, Spinelli, L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013a; 382: 951–962Google Scholar

Leucht, S, Crippa, A, Siafis, S, et al. Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry 2020; 177: 342–353Google Scholar

Leucht, S, Helfer, B, Dold, M, et al. Lithium for schizophrenia. Cochrane Database Syst Rev 2015; (10): CD003834Google Scholar

Leucht, S, Helfer, B, Dold, M, Kissling, W, McGrath, J. Carbamazepine for schizophrenia. Cochrane Database Syst Rev 2014; (5): CD001258Google Scholar

Leucht, S, Heres, S, Davis, JM. Increasing placebo response rates in antipsychotic drug trials: let’s stop the vicious cycle. Am J Psychiatry 2013b; 170: 1232–1234Google Scholar

Leucht, S, Leucht, C, Huhn, M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry 2017; 174: 927–942Google Scholar

Leucht, S, Samara, M, Heres, S, et al. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr Bull 2014; 40: 314–326Google Scholar

Leucht, S, Samara, M, Heres, S, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull 2015; 41: 1367–1402Google Scholar

Leucht, S, Tardy, M, Komossa, K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2012; (5): CD008016Google Scholar

Leuchter, AF, McCracken, JT, Hunter, AM, et al. Monoamine oxidase A and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder. J Clin Psychopharmacol 2009; 29: 372–377Google Scholar

Levin, FR, Evans, SM, Kleber, HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend 1998; 52: 15–25Google Scholar

Levin, FR, Mariani, JJ, Brooks, DJ, et al. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 2011; 116: 142–150Google Scholar

Levin, FR, Mariani, J, Brooks, DJ, et al. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 2013; 108: 1084–1094Google Scholar

Levine, S, Saltzman, A. Pyridoxin (vitamin B6) neurotoxicity: enhancement by protein-deficient diet. J Appl Toxicol 2004; 24: 497–500Google Scholar

Li, N, Wu, X, Li, L. Chronic administration of clozapine alleviates reversal-learning impairment in isolation-reared rats. Behav Pharmacol 2007; 18: 135–145Google Scholar

Li, X, Moore, S, Olson, C. Urine drug tests: how to make the most of them. Curr Psychiatry 2019; 18: 11–20Google Scholar

Li, R, Wu, R, Chen, J, et al. A randomized, placebo-controlled pilot study of quetiapine-XR monotherapy or adjunctive therapy to antidepressant in acute major depressive disorder with current generalized anxiety disorder. Psychopharmacol Bull 2016; 46: 8–23Google Scholar

Li, X, Zhu, L, Su, Y, et al. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: a meta-analysis. PLoS One 2017; 12: e0185865Google Scholar

Li, X, Zhu, L, Zhou, C, et al. Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: a meta-analysis. PLoS One 2018; 13: e0194501Google Scholar

Lieberman, JA, Davis, RE, Correll, CU, et al. ITI-007 for the treatment of schizophrenia: a 4-week randomized, double-blind, controlled trial. Biol Psychiatry 2016; 79: 952–961Google Scholar

Lieberman, JA, Stroup, JS, McEvoy, JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223Google Scholar

Lieberman, JA, Tollefson, G, Tohen, M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396–1404Google Scholar

Liebowtizt, MR. Social Phobia. Mod Probl Pharmacopsychiatry 1987; 22: 141–173Google Scholar

Liebowitz, MR, Gelenberg, AJ, Munjack, D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Am J Psychiatry 2005; 62: 190–198Google Scholar

Liebowitz, MR, Careri, J, Blatt, K, et al. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. Depress Anxiety 2017; 34: 1164–1172Google Scholar

Liebowitz, MR, Schneier, FR, Campeas, R, et al. Phenelzine vs. atenolol in social phobia: a controlled comparison. Arch Gen Psychiatry 1992; 49: 290–300Google Scholar

Lim, SW, Ko, EM, Shin, DW, et al. Clinical symptoms associated with suicidality in patients with panic disorder. Compr Psychiatry 2015; 48: 137–144Google Scholar

Lin, CH, Lin, CH, Chang, YC, et al. Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Biol Psychiatry 2018; 84: 422–432Google Scholar

Lin, CY, Liang, SY, Chang, YC, et al. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: a randomised, double-blind, placebo-controlled trial. World J Biol Psychiatry 2017; 18: 357–386Google Scholar

Linde, M, Muelleners, WM, Chronicle, EP, et al. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013; (6): CD010608Google Scholar

Lindenmayer, J-P, Nasrallah, H, Pucci, M, et al. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res 2013; 137: 241–252Google Scholar

Lindley, SE, Carlson, EB, Hill, K. A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder. J Clin Psychopharmacol 2007; 27: 677–681Google Scholar

Linehan, MM, McDavid, JD, Brown, MZ, et al. Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69: 999–1005Google Scholar

Ling, J, Kritikos, M, Tiplady, B. Cognitive effects of creatine ethyl ester supplementation. Behav Pharmacol 2009; 20: 673–679Google Scholar

Links, P, Steiner, M, Boiago, I, et al. Lithium therapy for borderline patients: preliminary findings. J Pers Disord 1990; 4: 173–181Google Scholar

Lipkovich, I, Mallinckrodt, CH, Faries, DE. The challenges of evaluating dose response in flexible-dose trials using marginal structural models. Pharm Stat 2012; 11: 485–493Google Scholar

Lipper, S, Davidson, JR, Grady, TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; 27: 849–854Google Scholar

Litt, MD, Babor, TK, DelBoca, FK, et al. Types of alcoholics, II: application of an empirically derived typology to treatment matching. Arch Gen Psychiatry 1992; 49: 609–614Google Scholar

Litten, RZ, Castle, IJ, Falk, D, et al. The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies. Alcohol Clin Exp Res 2013; 37: 2128–2137Google Scholar

Liu, J, Wan, GB, Huang, MS, et al. Probiotic therapy for treating behavioral and gastrointestinal symptoms in autism spectrum disorder: a systematic review of clinical trials. Curr Med Sci 2019a; 39: 173–184Google Scholar

Liu, RT, Walsh, RFL, Sheehan, A. Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials. Neurosci Biobehav Rev 2019b; 102: 13–23Google Scholar

Liu, XH, Xiw, XH, Wang, KY, et al. Efficacy and acceptability of atypical antipsychotics for the treatment of post-traumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Psychiatr Res 2014; 219: 543–549Google Scholar

Liu, Y, Zhou, X, Zhu, D, et al. Is pindolol augmentation effective in depressed patients resistant to selective serotonin reuptake inhibitors? A systematic review and meta-analysis. Hum Psychopharmacol 2015; 30: 132–142Google Scholar

Lloret-Linares, C, Bellivier, F, Heron, K, et al. Treating mood disorders in patients with a history of intestinal surgery: a systematic review. Int Clin Psychopharmacol 2015; 30: 119–128Google Scholar

Lo, M-T, Hinds, DA, Tung, JY, et al. Genome-wide analyses for personality traits identify six genomic loci and show correlations with psychiatric disorders. Nat Genet 2017; 49: 152–156Google Scholar

Locher, C, Koechlin, H, Zion, SR, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. JAMA Psychiatry 2017; 74: 1011–1020Google Scholar

Locher, C, Kossowsky, J, Gaab, J, et al. Moderation of antidepressant and placebo outcomes by baseline severity in late-life depression: a systematic review and meta-analysis. J Affect Disord 2015; 181: 50–60Google Scholar

Loebel, A, Cucchiaro, J, Sarma, K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res 2013; 145: 101–109Google Scholar

Loebel, A, Cucchiaro, J, Silva, R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014a; 171: 160–168Google Scholar

Loebel, A, Cucchiaro, J, Silva, R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014b; 171: 169–177Google Scholar

Loebel, A, Cucchiaro, I, Silva, R, et al. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. Eur Psychiatry 2015; 30: 26–31Google Scholar

Loebel, A, Silva, R, Goldman, R, et al. Lurasidone dose escalation in early nonresponding patients with schizophrenia: a randomized, placebo-controlled study. J Clin Psychiatry 2016; 77: 1672–1680Google Scholar

Loew, TH, Nickel, MK, Muehlbacher, M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2006; 26: 61–66Google Scholar

Lohoff, FW, Etemad, B, Mandos, LA, et al. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol 2010; 30: 185–189Google Scholar

Lombardo, I, Sachs, G, Kolluri, S, et al. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? J Clin Psychopharmacol 2012; 32: 470–478Google Scholar

Loonen, AJM, Stahl, SM. The mechanism of drug-induced akathisia. CNS Spectrums 2011; 16: 7–10Google Scholar

Lopez, LV, Kane, JM. Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature. Schizophr Res 2013; 147: 368–374Google Scholar

Lopez, LM, Kaptein, AA, Helmerhorst, FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012; (2): CD006586Google Scholar

Lu, ML, Lane, HY, Chen, KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry 2000; 61: 594–599Google Scholar

Lu, ML, Lane, HY, Lin, SK, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbance. J Clin Psychiatry 2004; 65: 766–771Google Scholar

Lynch, JH, Mulvaney, SW, Kim, EH, et al. Effect of stellate ganglion block on specific symptom clusters for treatment of post-traumatic stress disorder. Mil Med 2016; 181: 1135–1141Google Scholar

Lyoo, IK, Soon, S, Kim, TS, et al. A randomized, double-blind placebo controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am J Psychiatry 2012; 169: 937–945Google Scholar

Macaluso, M, Preskorn, SH. Knowledge of the pharmacology of antidepressants and antipsychotics yields results comparable with pharmacogenetic testing. J Psychiatr Pract 2018; 24: 416–419Google Scholar

Mace, S, Taylor, D. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2009; 23: 773–780Google Scholar

MacKinnon, DF, Zandi, PP, Cooper, J, et al. Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry 2002; 159: 30–35Google Scholar

MacQueen, GM, Young, LT, Marriott, M, et al. Previous mood state predicts response and switch rates in patients with bipolar depression. Acta Psychiatr Scand 2002; 105: 414–418Google Scholar

Maddux, RE, Riso, LP, Klein, DN, et al. Select comorbid personality disorders and the treatment of chronic depression with nefazodone, targeted psychotherapy, or their combination. J Affect Disord 2009; 117: 174–179Google Scholar

Mahabir, M, Ashbaugh, AR, Saumier, D, et al. Propranolol’s impact on cognitive performance in post-traumatic stress disorder. J Affect Disord 2016; 192: 98–103Google Scholar

Mahmoud, RA, Pandina, GJ, Turkoz, I, et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 2007; 147: 593–602Google Scholar

Maisel, NC, Blodgett, JC, Wilbourne, PL, et al. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013; 108: 275–293Google Scholar

Malhotra, AK, Pinals, DA, Adler, CM, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141–150Google Scholar

Maller, JJ, Broadhouse, K, Rush, AJ, et al. Increased hippocampal tail volume predicts depression status and remission to anti-depressant medications in major depression. Mol Psychiatry 2018; 23: 1737–1744Google Scholar

Mallikaarjun, S, Kane, JM, Brincmont, P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res 2013; 150: 281–288Google Scholar

Mallinckrodt, CH, Zhang, L, Prucka, WR, et al. Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 2010; 43: 53–72Google Scholar

Malone, RP, Delaney, MA, Luebbert, F, et al. Double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Arch Gen Psychiatry 2000; 57: 649–654Google Scholar

Mammen, G, Rueda, S, Roerecke, M, et al. Association of cannabis with long-term clinical symptoms in anxiety and mood disorders: a systematic review of prospective studies. J Clin Psychiatry 2018; 79: 17r11839Google Scholar

Mancino, MJ, McGaugh, J, Chopra, MP, et al. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. J Clin Psychopharmacol 2014; 34: 234–239Google Scholar

Maneeton, N, Maneeton, B, Woottiluk, P, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2016; 10: 259–276Google Scholar

Mann, JJ, Aarons, SF, Wilner, PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989; 46: 45–50Google Scholar

Mannucci, C, Calapai, F, Cardia, L, et al. Clinical pharmacology of Citrus aurantium and Citrus sinensis for the treatment of anxiety. Evid Based Complement Alternat Med 2018; 2018: 3624094Google Scholar

Mannuzza, S, Klein, RG, Truong, NL, et al. Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 2008; 165: 604–609Google Scholar

Manos, GH. Possible serotonin syndrome associated with buspirone added to fluoxetine. Ann Pharmacother 2000; 34: 871–874Google Scholar

Manteghi, AA, Hebrani, P, Mortezania, M, et al. Baclofen add-on to citalopram in treatment of posttraumatic stress disorder. J Clin Psychopharmacol 2014; 34: 240–243Google Scholar

Manu, P, Lapitskaya, Y, Shaikh, A, et al. Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. Am J Ther 2018; 25: e218–e223Google Scholar

Manwani, SG, Pardo, TB, Albanese, MJ, et al. Substance use disorder and other predictors of antidepressant-induced mania: a retrospective chart review. J Clin Psychiatry 2006; 67: 1341–1345Google Scholar

Mao, JJ, Xie, SX, Keefe, JR, et al. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: a randomized clinical trial. J Clin Phytomedicine 2016; 23: 1735–1742Google Scholar

Marazziti, D, Baroni, S, Faravelli, L, et al. Plasma clomipramine levels in adult patients with obsessive-compulsive disorder. Int Clin Psychopharmacol 2012a; 27: 55–60Google Scholar

Marazziti, D, Baroni, S, Giannaccini, G, et al. Plasma fluvoxamine levels and OCD symptoms/response in adult patients. Hum Psychopharmacol 2012b; 27: 397–402Google Scholar

Marcus, R, Khan, A, Rollin, L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011; 13: 133–144Google Scholar

Marcus, RN, McQuade, RD, Carso, WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28: 156–165Google Scholar

Marcus, SC, Zummo, J, Pettit, AR, et al. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015; 21: 754–768Google Scholar

Marder, SR, Davis, JM, Chouinard, G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58: 538–546Google Scholar

Marder, SR, Kramer, M, Ford, L, et al. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007; 62: 1363–1370Google Scholar

Margolin, A, Kosten, TR, Avants, SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995; 40: 125–131Google Scholar

Markovitz, PJ. Pharmacotherapy of impulsivity, aggression and related disorders. In: Hollander, E, Stein, D (Eds) Impulsivity and Aggression. New York: John Wiley and Sons; 1995, 263–287Google Scholar

Markowitz, PJ. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: a preliminary study. J Clin Psychopharmacol 1992; 12: 27–31Google Scholar

Markowitz, JC, Petkova, E, Biyanova, T, et al. Exploring personality diagnosis stability following acute psychotherapy for chronic posttraumatic stress disorder. Depress Anxiety 2015; 32: 919–926Google Scholar

Markovitz, PJ, Calabrese, JR, Schulz, SC, et al. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148: 1064–1067Google Scholar

Marks, IM, Mathews, AM. Brief standard self-rating for phobic patients. Behav Res Ther 1979; 17: 263–267Google Scholar

Marriott, S, Tyrer, P. Benzodiazepine dependence. Drug Safety 2012; 9: 93–103Google Scholar

Marshall, M, Lewis, S, Lockwood, A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 2005; 62: 975–983Google Scholar

Marshall, RD, Lewis-Fernandez, R, Blanco, C, et al. A controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety 2007; 24: 77–84Google Scholar

Martinon-Torres, G, Fioravanti, M, Grimley, EJ. Trazodone for agitation in dementia. Cochrane Database Syst Rev 2004; (4): CD004990Google Scholar

Marx, CE, Bradford, DW, Hamer, RM, et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 2011; 191: 78–90Google Scholar

Masand, P, Murry, GB, Pickett, P. Psychostimulants in post-stroke depression. J Neuropsychiatr Clin Neurosci 1991; 3: 23–27Google Scholar

Masdrakis, VG, Papadimitriou, GN, Olis, P. Lamotrigine administration in panic disorder with agoraphobia. Clin Neuropharmacol 2010; 33: 126–128Google Scholar

Masi, G, Milone, A, Manfredi, A, et al. Effectiveness of lithium in children and adolescents with conduct disorder: a retrospective naturalistic study. CNS Drugs 2009; 23: 59–69Google Scholar

Maslow, AH. A theory of human motivation. Psychol Rev 1943; 50: 370–396Google Scholar

Mason, M, Cates, CJ, Smith, I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev 2015; (7): CD011090Google Scholar

Mason, BJ, Kocsis, JH, Ritvo, EC, et al. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. J Am Med Assoc 1996; 275: 761–767Google Scholar

Mason, BJ, Quello, S, Goodell, V, et al. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med 2014; 174: 70–77Google Scholar

Mathew, SJ, Murrough, JW, aan het Rot, M, et al. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2010; 13: 71–82Google Scholar

Matsuda, KT, Cho, MC, Lin, KM, et al. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacol Bull 1996; 32: 253–257Google Scholar

Matsunaga, S, Kishi, T, Iwata, N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS One 2015; 10: e0123289Google Scholar

Mattei, C, Rapagnani, MP, Stahl, SM. Ziprasidone hydrochloride: what role in the management of schizophrenia? J Cent Nerv Syst Dis 2011; 3: 1–16Google Scholar

Matthews, JD, Siefert, CJ, Blais, MA, et al. A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy. J ECT 2013; 29: 170–178Google Scholar

Maust, DT, Lin, LA, Blow, FC. Benzodiazepine use and misuse among adults in the United States. Psych Serv 2019; 70: 98–106Google Scholar

Mavissakalian, MR, Perel, JM. Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 1995; 152: 673–682Google Scholar

Mavissakalian, MR, Perel, JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol 2002; 22: 294–299Google Scholar

Mavissakalian, M, Perel, J, Bowler, K, et al. Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 1987; 144: 785–787Google Scholar

Mayberg, HS, Silva, JA, Brannan, SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728–737Google Scholar

Mayo-Smith, MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. J Am Med Assoc 1997; 278: 144–151Google Scholar

Mayoral-van Son, J, de la Foz, VO, Martinez-Garcia, O, et al. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry 2016; 77: 492–500Google Scholar

Mazure, CM, Nelson, JC, Jatlow, PI, et al. The relationship between blood perphenazine levels, early resolution of psychotic symptoms, and side effects. J Clin Psychiatry 1990; 51: 330–334Google Scholar

McClure, MM, Barch, DM, Romero, MJ, et al. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry 2007; 61: 1157–1160Google Scholar

McClure, MM, Graff, F, Triebwasser, J, et al. Guanfacine augmentation of a combined intervention of computerized cognitive remediation therapy and social skills training for schizotypal personality disorder. Am J Psychiatry 2019; 176: 307–314Google Scholar

McClure, MM, Koenigsberg, HW, Reynolds, D, et al. The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. J Clin Psychopharmacol 2009; 29: 396–398Google Scholar

McDermott, CL, Gray, SL. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression. Ann Pharmacother 2012; 46: 599–605Google Scholar

McDougle, CJ, Naylor, ST, Cohen, DJ, et al. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996; 53: 1001–1008Google Scholar

McDowell, D, Nunes, EV, Seracini, AM, et al. Desipramine treatment of cocaine-dependent patients with depression: a placebo-controlled trial. Drug Alcohol Depend 2005; 80: 209–221Google Scholar

McElroy, SL, Altshuler, LL, Suppes, T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158: 420–426Google Scholar

McElroy, SL, Bowden, CL, Collins, MA, et al. Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder. J Affect Disord 2008; 107: 127–133Google Scholar

McElroy, SL, Martens, BE, Creech, RS, et al. Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania. J Clin Psychiatry 2010a; 71: 557–565Google Scholar

McElroy, SL, Martens, BE, Mori, N, et al. Adjunctive lisdexamfetamine in bipolar depression: a preliminary randomized, placebo-controlled trial. Int Clin Psychopharmacol 2015; 30: 6–13Google Scholar

McElroy, SL, Weisler, RH, Chang, W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010b; 71: 163–174Google Scholar

McGirr, A, Vöhringer, PA, Ghaemi, SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 2016; 3: 1138–1146Google Scholar

McGlashan, TH, Zipursky, RB, Perkins, D, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790–799Google Scholar

McGorry, PD, Yung, AR, Phillips, LJ. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59: 921–928Google Scholar

McGrath, PJ, Nunes, EV, Stewart, JW, et al. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry 1996; 53: 232–240Google Scholar

McGrath, PJ, Stewart, JW, Fava, M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry 2006a; 163: 1531–1541Google Scholar

McGrath, PJ, Stewart, JW, Quitkin, FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment for major depression. Am J Psychiatry 2006b; 163: 1542–1548Google Scholar

McGuire, P, Robson, P, Cubala, WJ, et al. Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 2018; 175: 225–231Google Scholar

McIntyre, A, Gendron, A, McIntyre, A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 2007; 24: 487–494Google Scholar

McIntyre, RS, Alsuwaidan, M, Soczynska, JK, et al. The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder. Hum Psychopharmacol 2013; 28: 421–427Google Scholar

McIntyre, RS, Cucchiaro, J, Pikalov, A, et al. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry 2015; 76: 398–405Google Scholar

McIntyre, RS, Harrison, J, Loft, H, et al. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol 2016; 19: pyw055Google Scholar

McIntyre, RS, Subramaniapillai, M, Lee, Y, et al. Efficacy of adjunctive infliximab vs placebo in the treatment of adults with bipolar I/II depression: a randomized clinical trial. JAMA Psychiatry 2019; 76: 783–790Google Scholar

McMahon, FJ, Buervenich, S, Charney, D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78: 804–814Google Scholar

McNeil, MJ, Kamal, AH, Kutner, JS, et al. The burden of polypharmacy in patients near the end of life. J Pain Symptom Manage 2016; 51: 178–183Google Scholar

Mech, AW, Farah, A. Correlation of clinical response with homocysteine reduction during therapy with reduced B vitamins in patients with MDD who are positive for MTHFR C677T or A1298C polymorphism: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2016; 77: 668–671Google Scholar

Mehyrpooya, M, Yasrebifar, F, Haghighi, M, et al. Evaluating the effect of Coenzyme Q10 augmentation on treatment of bipolar depression: a double-blind controlled clinical trial. J Clin Psychopharmacol 2018; 38: 460–466Google Scholar

Meister, R, Jansen, A, Härter, M, et al. Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder: a meta-regression analysis. J Affect Disord 2017; 215: 288–298Google Scholar

Mejer, MH, Caspi, A, Ambler, A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci 2012; 109: E2657–2664Google Scholar

Mellman, TA, Bustamante, V, David, V, et al. Hypnotic medication in the aftermath of trauma. J Clin Psychiatry 2002; 63: 1183–1184Google Scholar

Meltzer, HY, Bobo, WV, Roy, A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2008; 69: 274–285Google Scholar

Meltzer, HY, Cucchiaro, J, Silva, R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011; 168: 957–967Google Scholar

Meltzer, HY, Matsubara, S, Lee, JC, et al. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pKi values. J Pharmacol Exper Ther 1989; 251: 238–246Google Scholar

Mendels, J, Krajewski, TF, Huffer, V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 1986; 47: 170–174Google Scholar

Menza, MA, Dobkin, RD, Marin, H. An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder. J Clin Psychopharmacol 2007; 27: 207–210Google Scholar

Mercer, D, Douglass, AB, Links, PS. Meta-analysis of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Pers Disord 2009; 23: 156–174Google Scholar

Merikangas, KR, Akiskal, HS, Angst, J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007; 64: 543–552Google Scholar

Meyer, JM. A rational approach to employing high plasma levels of antipsychotics for violence associated with schizophrenia: case vignettes. CNS Spectr 2014; 19: 432–438Google Scholar

Meyer, JM. Monitoring and improving antipsychotic adherence in outpatient forensic division programs. CNS Spectr 2019; 23: 1–9Google Scholar

Meyer, JM, Proctor, G, Cummings, MA, et al. Ciprofloxacin and clozapine: a potentially fatal but underappreciated interaction. Case Rep Psychiatry 2016; 2016: 5606098Google Scholar

Meyer, TJ, Mill, ML, Metzger, RL, et al. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 1990; 28: 487–495Google Scholar

Michelson, D, Bancroft, J, Targum, S, et al. Female sexual dysfunction associated with antidepressant administration: a randomized, placebo-controlled study of pharmacologic intervention. Am J Psychiatry 2000; 157: 239–243Google Scholar

Michelson, D, Kociban, K, Tamura, R, et al. Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Pract 2002; 36: 147–152Google Scholar

Miller, S, McTeague, LM, Gyurak, A, et al. Cognition-childhood maltreatment interactions in the prediction of antidepressant outcomes in major depressive disorder patients: results from the iSPOT-D trial. Depress Anxiety 2015; 32: 594–604Google Scholar

Miller, WR, Leckman, AL, Delany, HD, et al. Long-term follow-up of behavioral self-control training. J Stud Alcohol 1992; 53: 249–261Google Scholar

Millon, T, Davis, RO. Disorders of Personality: DSM-IV and Beyond, 2nd edn. Hoboken, New Jersey: John Wiley and Sons; 1996Google Scholar

Mini, LJ, Wang-Weigand, S, Zhang, J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007; 5: 177–184Google Scholar

Minozzi, S, Saulle, R, Rösner, S. Baclofen for alcohol use disorder. Cochran Database Syst Rev 2018; (11): CD012557Google Scholar

Minozzi, S, Amato, L, Vecchi, S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011; (4): CD001333Google Scholar

Mintz, M, Hollenberg, E. Revisiting lithium: utility for behavioral stabilization in adolescents and adults with autism spectrum disorder. Psychopharmacol Bull 2019; 49: 28–40Google Scholar

Miotto, K, McCann, M, Basch, J, et al. Naltrexone and dysphoria: fact or myth? Am J Addict 2002; 11: 151–160Google Scholar

Mitchell, AJ, Delaffon, V, Vancampfort, D, et al. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med 2012; 42: 125–147Google Scholar

Mithoefer, MC, Mithofer, AT, Feduccia, A, et al. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 2018; 5: 486–497Google Scholar

Mitsikostas, DD, Mantonakis, L, Chalarakis, L. Nocebo in clinical trials for depression: a meta-analysis. Psychiatry Res 2014; 215: 82–86Google Scholar

Miura, I, Zhang, JP, Hagi, K, et al. Variants in the DRD2 locus and antipsychotic-related prolactin levels: a meta-analysis. Psychoneuroendocrinology 2016; 72: 1–10Google Scholar

Miyaoka, T, Furuya, M, Yasuda, H, et al. Yi-gan san for the treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 150–154Google Scholar

Modaressi, A, Chaibakhsh, S, Koulaeinejad, N, et al. A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res 2019; 282: 112602Google Scholar

Mohamed, S, Johnson, GR, Chen, P, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA Psychiatry 2017; 318: 132–145Google Scholar

Mohammadi, MR, Kazemi, MR, Zia, E, et al. Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double-blind trial. Hum Psychopharmacol 2010; 25: 560–565Google Scholar

Mohammadzadeh, S, Ahangari, TK, Yousefi, F, et al. The effect of memantine in adult patients with attention deficit hyperactivity disorder. Hum Psychopharmacol 2019; 34: e2687Google Scholar

Mohn, C, Rund, BR. Neurocognitive profile in major depressive disorders: relationship to symptom level and subjective memory complaints. BMC Psychiatry 2016; 16:108Google Scholar

Mojtabai, R, Olfson, M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010; 67: 26–36Google Scholar

Molero, Y, Larsson, H, D’Onofrio, BM, et al. Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden. Br Med J 2019; 365: l2147Google Scholar

Monnelly, EP, Ciraulo, DA, Knapp, C, et al. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003; 23: 193–196Google Scholar

Montes, JM, Saiz-Ruiz, J, Laher, G, et al. Lamotrigine for the treatment of bipolar spectrum disorder: chart review. J Affect Disord 2005; 86: 69–73Google Scholar

Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389Google Scholar

Montgomery, SA, Altamura, AC, Katila, H, et al. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels. Int Clin Psychopharmacol 2014; 29: 93–105Google Scholar

Montgomery, SA, McIntyre, A, Osterheider, M, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993; 3: 143–152Google Scholar

Montgomery, SA, Tobias, K, Zornberg, GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771–782Google Scholar

Morgan, CJ, Monaghan, L, Curran, HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 2004; 99: 1450–1461Google Scholar

Morrissette, DA, Stahl, SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr 2014; 19: 439–448Google Scholar

Mosca, D, Zhang, M, Prieto, R, et al. Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline. J Clin Psychopharmacol 2017; 37: 182–192Google Scholar

Moukhtarian, TR, Cooper, RE, Vassos, E, et al. Effects of stimulants and atomoxetine on emotional lability in adults: a systematic review and meta-analysis. Eur Psychiatry 2017; 44: 198–207Google Scholar

Mrkobrada, M, Hackam, DDG. Selective serotonin reuptake inhibitors and surgery: to hold or not to hold, that is the question: comment on “Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery.” JAMA Intern Med 2013; 173: 1082–1083Google Scholar

Muehlbacher, M, Nickel, MK, Nickel, C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 580–583Google Scholar

Mula, M, Pini, S, Cassano, GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27: 263–272Google Scholar

Müller, U, Rowe, JB, Rittman, T, et al. Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropsychopharmacol 2013; 64: 490–495Google Scholar

Murphy, CC, Fullington, HM, Alvarez, CA, et al. Polypharmacy and patterns of prescription medication use among cancer survivors. Cancer 2018; 124: 2850–2857Google Scholar

Murrough, JW, Perez, AM, Pillemer, S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74: 250–256Google Scholar

Mushiroda, T, Takahashi, Y, Onuma, T, et al. Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population. JAMA Neurology 2018; 75: 842–849Google Scholar

Musil, R, Zill, P, Seemüller, F, et al. Genetics of emergent suicidality during antidepressive treatment: data from a naturalistic study on a large sample of inpatients with a major depressive episode. Eur Neuropsychopharmacol 2013; 23: 663–674Google Scholar

Myer, BM, Boland, JR, Faraone, SV. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry 2018; 23: 1929–1936Google Scholar

Myrick, H, Anton, RF, Li, X, et al. Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry 2008; 65: 466–475Google Scholar

Myrick, H, Anton, R, Voronin, K, et al. A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res 2007; 31: 221–227Google Scholar

Myrick, H, Malcolm, R, Randall, PK, et al. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 2009; 33: 1582–1588Google Scholar

Naderi, S, Faghih, H, Aqamolaei, A, et al. Amantadine as adjuvant therapy in the treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. Psychiatry Clin Neurosci 2019; 83: 169–174Google Scholar

Nair, NP. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia: the Risperidone Study Group. J Clin Psychopharmacol 1998; 18: 103–110Google Scholar

Nair, NP, Amin, M, Holm, P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord 1995; 33: 1–9Google Scholar

Nakamura, A, Mihara, K, Nagai, G, et al. Prediction of an optimal dose of lamotrigine for augmentation therapy in treatment-resistant depressive disorder from plasma lamotrigine concentration at week 2. Ther Drug Monit 2016; 38: 379–382Google Scholar

Nardi, AE, Lopes, FL, Valenca, AM, et al. Double-blind comparison of 30 and 60 mg tranylcypromine daily in patients with panic disorder comorbid with social anxiety disorder. Psychiatr Res 2010; 175: 260–265Google Scholar

Nasrallah, HA, Silva, R, Phillips, D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. J Psychiatry Res 2013; 47: 670–677Google Scholar

Nasreddine, ZS, Phillips, NA, Bédirian, V, et al. The Montreal Cognitive Assessment (MoCA): a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695–699Google Scholar

Naugle, RI, Kawczak, K. Limitations of the mini-mental state examination. Cleve Clin J Med 1989; 56: 277–281Google Scholar

Naylor, JC, Kilts, JD, Bradford, JW, et al. A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military veterans resistant to antidepressant treatment. Int Clin Psychopharmacol 2015; 30: 167–174Google Scholar

Nelson, JC, Byck, R. Rapid response to lithium in phenelzine non-responders. Br J Psychiatry 1982; 141: 85–86Google Scholar

Nelson, JC, Papakostas, GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166: 980–991Google Scholar

Nelson, JC, Delucchi, K, Schneider, LS. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Geriatr Psychiatry 2008; 16: 558–567Google Scholar

Nelson, JC, Delucchi, KL, Schneider, LS. Moderators of outcome in late-life depression: a patient-level meta-analysis. Am J Psychiatry 2013; 170: 651–659Google Scholar

Nelson, CLM, Amsbaugh, HM, Reilly, JL, et al. Beneficial and adverse effects of antipsychotic medication on cognitive flexibility are related to COMT genotype in first episode psychosis. Schizophr Res 2018; 202: 212–216Google Scholar

Nelson, JC, Baumann, P, Delucchi, K, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. J Affect Disord 2014; 168: 269–275Google Scholar

Nelson, JC, Mazure, CM, Jatlow, PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004; 55: 296–300Google Scholar

Newport, DJ, Carpenter, LL, McDonald, WM, et al. Ketamine and other NMDA receptor antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015; 172: 950–966Google Scholar

Neylan, TC, Lenoci, M, Samuelson, KW, et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006; 163: 2186–2188Google Scholar

Ng, CH, Chong, S, Lambert, T, et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int Clin Psychopharmacol 2005; 20: 163–168Google Scholar

Ng, QX, Koh, SSH, Chan, HW, et al. Clinical use of curcumin in depression: a meta-analysis. J Am Med Dir Assoc 2017; 18: 503–508Google Scholar

Ng, QX, Soh, AY, Venkatanarayanan, N, et al. A systematic review of the effect of probiotic supplementation on schizophrenia symptoms. Neuropsychobiology 2019; 78: 106Google Scholar

Nickel, MK, Muehlbacher, M, Nickel, C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163: 833–838Google Scholar

Nickel, MK, Nickel, C, Kaplan, P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005; 57: 495–499Google Scholar

Nickel, MK, Nickel, C, Miterlehner, FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2004; 65: 1515–1519Google Scholar

Nielsen, J, Jensen, SO, Friis, RB, et al. Comparative effectiveness of risperidone long-acting injectable vs first-generation antipsychotic long-acting injectables in schizophrenia: results from a nationwide, retrospective inception cohort study. Schizophr Bull 2015; 41: 627–636Google Scholar

Nielsen, S, Larance, B, Degenhardt, L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016; (5): CD01111Google Scholar

Nierenberg, AA, Keck, PE Jr. Management of monoamine oxidase inhibitor-associated insomnia with trazodone. J Clin Psychopharmacol 1989; 9: 42–45Google Scholar

Nierenberg, AA, Fava, M, Trivedi, MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163: 1519–1530Google Scholar

Nierenberg, AA, Friedman, ES, Bowden, CL, et al. Lithium treatment moderate-dose use study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry 2013; 170: 102–110Google Scholar

Nierenberg, AA, Østergaard, SD, Iovieno, N, et al. Predictors of placebo response in bipolar depression. Int Clin Psychopharmacol 2015; 30: 59–66Google Scholar

Niitsu, T, Fabbri, C, Bentini, F, et al. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45: 183–194Google Scholar

Nikiforuk, A, Popik, P. Amisulpride promotes cognitive flexibility in rats: the role of 5-HT7 receptors. Behav Brain Res 2013; 248: 136–140Google Scholar

Ninan, PT, McElroy, SL, Kane, CP, et al. Placebo-controlled study of fluvoxamine in the treatment of patients with compulsive buying. J Clin Psychopharmacol 2000a; 20: 362–366Google Scholar

Ninan, PT, Rothbaum, PO, Marsteller, FA, et al. A placebo-controlled trial of cognitive-behavioral therapy and clomipramine in trichotillomania. J Clin Psychiatry 2000b; 61: 47–50Google Scholar

Nordahl, HM, Vogel, PA, Morken, G, et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychother Psychosom 2016; 85: 346–356Google Scholar

Nordentoft, M, Thorup, A, Petersen, L, et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS Trial: a randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006; 83: 29–40Google Scholar

Noyes, R Jr., Moroz, G, Davidson, JR, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997; 17: 247–254Google Scholar

Nuijten, M, Blanken, P, van den Brink, W, et al. Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in the Netherlands. Drug Alcohol Depend 2014; 138: 177–184Google Scholar

Nunez, NA, Singh, B, Romo-Nava, F, et al. Efficacy and tolerability of adjunctive modafinil/ armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord 2020; 22: 109–120Google Scholar

O’Connell, CP, Goldstein-Piekarski, AN, Nemeroff, CB, et al. Antidepressant outcomes predicted by genetic variation in corticotropin-releasing hormone binding protein. Am J Psychiatry 2018; 175: 251–261Google Scholar

O’Connor, CM, Kuchibhatla, JW, Silva, SG, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010; 56: 962–969Google Scholar

O’Donnell, CP, Allott, KA, Murphy, BP, et al. Adjunctive taurine in first-episode psychosis: a phase 2, double-blind, randomized, placebo-controlled study. J Clin Psychiatry 2016; 77: e1610–e1617Google Scholar

Office of Management and Budget (OMB) Recommendations from the interagency committee for the review of the race and ethnic standards to the Office of Management and Budget concerning changes to the standards for the classification of federal data on race and ethnicity. Federal Register 1997; 62: 36874–36946Google Scholar

Ogasa, M, Kimura, T, Nakamura, M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacol (Berl) 2013; 225: 519–530Google Scholar

Ogawa, Y, Takeshima, N, Hayasaka, Y, et al. Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev 2019; 6: CD001026Google Scholar

Olbrich, S, Tränkner, A, Surova, G, et al. CNS- and ANS-arousal predict response to antidepressant medication: findings from the randomized ISPOT-D study. J Psychiatr Res 2016; 73: 108–115Google Scholar

Olesen, OV, Licht, RW, Thomsen, E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998; 20: 380–384Google Scholar

Oliveira, P, Ribeiro, J, Donato, H, et al. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry 2017; 16: 17Google Scholar

Oliveto, AH, Feingold, A, Schottenfeld, R, et al. Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. Arch Gen Psychiatry 1999; 56: 812–820Google Scholar

Oliveto, A, Poling, J, Mancino, MJ, et al. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. Addiction 2012; 107: 131–141Google Scholar

Olsson, EM, von Schéele, B, Panossian, AG. A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med 2009; 75: 105–112Google Scholar

Oneta, C, Simanowski, U, Martinez, M, et al. First pass metabolism of ethanol is strikingly influenced by the speed of gastric emptying. Gut 1998; 43: 612–619Google Scholar

Orlova, Y, Rizzoli, P, Loder, E. Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective serotonin norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurol 2018; 75: 566–572Google Scholar

Ortiz-Orendain, J, Castiello-de Obeso, S, Colunga-Lozano, LE, et al. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev 2017; (6): CD009005Google Scholar

Oslin, DW, Berretini, W, Kranzler, HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacol 2003; 28: 1546–1552Google Scholar

Ostacher, M, Ng-Mak, D, Patel, P, et al. Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: a systematic review and network meta-analysis. World J Biol Psychiatry 2018; 19: 586–601Google Scholar

Ostinelli, EG, Jajawi, S, Spyridi, S, et al. Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation). Cochrane Database Syst Rev 2018; (1): CD008074Google Scholar

Ota, M, Wakabayashi, C, Sato, N, et al. Effect of L-theanine on glutamatergic function in patients with schizophrenia. Acta Neuropsychiatrica 2015; 27: 291–296Google Scholar

Otasowie, J, Castells, X, Ehimare, UP, et al. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2014; (9): CD006997Google Scholar

Otto, MW, Tuby, KS, Gould, RA, et al. An effect-size analysis of the relative efficacy and tolerability of selective serotonin reuptake inhibitors for panic disorder. Am J Psychiatry 2001; 158: 1989–1992Google Scholar

Ozmenler, NK, Karlidere, T, Bozkurt, A, et al. Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors. Hum Psychopharmacol 2008; 23: 321–326Google Scholar

Pae, CU, Kim, JJ, Lee, CU, et al. Rapid versus conventional initiation of quetiapine in the treatment of schizophrenia: a randomized, parallel-group trial. J Clin Psychiatry 2007; 68: 399–405Google Scholar

Pae, CU, Lim, HK, Peindl, K, et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol 2008; 23: 1–8Google Scholar

Palac, DM, Cornish, RD, McDonald, WJ, et al. Cognitive function in hypertensives treated with atenolol or propranolol. J Gen Intern Med 1990; 5: 310–318Google Scholar

Palhano-Fontes, F, Barreto, D, Onias, H, et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 2019; 49: 655–663Google Scholar

Pallanti, S, Quercioli, L, Koran, LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002; 63: 796–801Google Scholar

Pallanti, S, Quercioli, L, Paiva, R, et al. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 1999; 14: 101–106Google Scholar

Palmer, SC, Natale, P, Ruospo, M, et al. Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. Cochrane Database Syst Rev 2016; (5): CD004541Google Scholar

Palpacuer, C, Duprez, R, Huneau, A, et al. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction 2018; 113: 220–237Google Scholar

Palpacuer, C, Laviolle, B, Boussageon, R, et al. Risks and benefits of nalmefene in the treatment of adult alcohol dependence: a systematic literature review and meta-analysis of published and unpublished double-blind randomized controlled trials. PLoS Med 2015; 12: e1001924Google Scholar

Pande, AC, Crockatt, JG, Janney, CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000a; 2: 249–255Google Scholar

Pande, AC, Davidson, JR, Jefferson, JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341–348Google Scholar

Pande, AC, Feltner, DE, Jefferson, JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24: 141–149Google Scholar

Pande, AC, Pollack, MH, Crockatt, J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000b; 20: 467–471Google Scholar

Pandina, GJ, Canuso, CM, Turkoz, I, et al. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial. Psychopharmacol Bull 2007; 40: 41–57Google Scholar

Pani, PP, Trogu, E, Pacini, M, et al. Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev 2014; (2): CD008544Google Scholar

Papakostas, GI, Cooper-Kazaz, R, Appelhof, BC, et al. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol 2009; 24: 19–25Google Scholar

Papakostas, GI, Fava, M. Does the probability of receiving a placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19: 34–40Google Scholar

Papakostas, GI, Perlis, RH, Scalia, MJ, et al. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol 2006; 26: 56–60Google Scholar

Papakostas, GI, Shelton, RC, Zajecka, JM, et al. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012a; 169: 1267–1274Google Scholar

Papakostas, GI, Shelton, RC, Zajecka, JM, et al. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry 2014; 75: 855–863Google Scholar

Papakostas, GI, Stahl, SM, Kishen, A, et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry 2008; 69: 1287–1292Google Scholar

Papakostas, GI, Thase, ME, Fava, M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007; 62: 1217–1227Google Scholar

Papakostas, GI, Vitolo, OV, Ishak, WW, et al. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry 2012b; 73: 1541–1547Google Scholar

Papp, LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry 2006; 67: 1573–1576Google Scholar

Park, JY, Kim, KH. A randomized, double-blind, placebo-controlled trial of Schisandra chinensis for menopausal symptoms. Climacteric 2016; 19: 574–580Google Scholar

Park, SH, Wackemah, RC, Stimmel, GL. Serotonin syndrome: is it a reason to avoid the use of tramadol with antidepressants? J Pharm Pract 2014; 27: 71–78Google Scholar

Park, C, Pan, Z, Brietzke, E, et al. Predicting antidepressant response using early changes in cognition: a systematic review. Behav Brain Res 2018; 353: 154–160Google Scholar

Parker, G, Brotchie, H, Parker, K. Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone? Am J Psychiatry 2005; 162: 796–798Google Scholar

Parkes, L, Tiego, J, Aquino, K, et al. Transdiagnostic variations in impulsivity and compulsivity in obsessive-compulsive disorder and gambling disorder correlate with effective connectivity in cortical-striatal-thalamic-cortical circuits. Neuroimage 2019; 202: 116070Google Scholar

Parsons, B, Quitkin, FM, McGrath, PJ, et al. Phenelzine, imipramine and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989; 25: 524–534Google Scholar

Pasco, JA, Jacka, FN, Williams, LJ, et al. Dietary selenium and major depression: a nested case-control study. Complement Ther Med 2012; 20: 119–123Google Scholar

Pascual, JC, Soler, J, Puigdemont, D, et al. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 2008; 69: 603–608Google Scholar

Patel, K, Allen, S, Haque, MN, et al. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol 2016; 6: 99–144Google Scholar

Patil, ST, Zhang, L, Millen, BA, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007; 13: 1102–1107Google Scholar

Patkar, A, Gilmer, W, Pae, C-U, et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS One 2012; 7: e34757Google Scholar

Patorno, E, Huybrechts, KF, Bateman, BT, et al. Lithium use in pregnancy and the risk of cardiac malformations. N Engl J Med 2017; 376: 2245–2254Google Scholar

Pavlik, VM, Doody, RS, Rountree, SD, et al. Vitamin E use is associated with improved survival in an Alzheimer’s disease cohort. Dement Geriatr Cogn Disord 2009; 28: 536–540Google Scholar

Pavlova, B, Perlis, RH, Alda, M, et al. Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry 2015; 2: 710–717Google Scholar

Pavlovic, ZM. Lamotrigine for the treatment of impulsive aggression and affective symptoms in a patient with borderline personality disorder comorbid with body dysmorphic disorder. J Psychiatry Clin Neurosci 2008; 20: 121–122Google Scholar

Payne, JL, MacKinnon, DF, Mondimore, FM, et al. Familial aggregation of postpartum mood symptoms in bipolar disorder pedigrees. Bipolar Disord 2008; 10: 38–44Google Scholar

Pazzaglia, PJ, Post, RM, Ketter, TA, et al. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res 1993; 49: 257–272Google Scholar

Peduzzi, P, Concato, J, Kemper, E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373–1379Google Scholar

Peet, M. The treatment of anxiety with beta-blocking drugs. Postgrad Med J 1988; 64(Suppl 2): 45–49Google Scholar

Pelissolo, A. Efficacy and tolerability of escitalopram in anxiety disorders: a review. Encephale 2008; 34: 400–408Google Scholar

Peng, Q, Gizer, IR, Libiger, O, et al. Association and ancestry analysis of sequence variants in ADH and ALDH using alcohol-related phenotypes in a Native American community sample. Am J Med Genet B Neuropsychiatr Genet 2014; 165B: 673–683Google Scholar

Penn, DL, Keefe, RS, Davis, SM, et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr Res 2009; 115: 17–23Google Scholar

Pennybaker, SJ, Niciu, MJ, Luckenbaugh, DA, et al. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. J Affect Disord 2017; 208: 560–566Google Scholar

Pérez-Mañá, C, Castells, X, Torrens, M, et al. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev 2013; (9): CD009695Google Scholar

Peritogiannis, V. Sensation/novelty-seeking in psychotic disorders: a review of the literature. World J Psychiatry 2015; 5: 79–87Google Scholar

Perlis, RH, Fraquas, R, Fava, M, et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry 2005; 66: 159–166Google Scholar

Perlis, RH, Laje, G, Smoller, JW, et al. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacol 2009; 34: 1819–1828Google Scholar

Perlis, RH, Ostacher, M, Miklowitz, DJ, et al. Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. J Clin Psychiatry 2010; 71: 194–200Google Scholar

Perlis, RH, Sachs, GS, Lafer, B, et al. Effect of abrupt change from standard to low serum levels of lithium: a reanalysis of double-blind lithium maintenance data. Am J Psychiatry 2002; 159: 1155–1159Google Scholar

Perrella, C, Carrus, D, Costa, E, et al. Quetiapine for the treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 158–163Google Scholar

Perroud, N, Aitchison, KJ, Uher, R, et al. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. Neuropsychopharmacology 2009; 34: 2517–2528Google Scholar

Perry, PJ, Zeilman, C, Arndt, S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14: 230–240Google Scholar

Perry, PJ, Alexander, B, Prince, RA, et al. The utility of a single-point dosing protocol for predicting steady-state lithium levels. Br J Psychiatry 1986; 148: 401–405Google Scholar

Perry, PJ, Lund, BC, Sanger, T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial. J Clin Psychopharmacol 2001; 21: 14–20Google Scholar

Perugi, G, Toni, C, Frare, F, et al. Effectiveness of adjunctive gabapentin in resistant bipolar disorder: is it due to anxious-alcohol abuse comorbidity? J Clin Psychopharmacol 2002; 22: 584–591Google Scholar

Peselow, ED, Dunner, DL, Fieve, RR, et al. Lithium prophylaxis of depression in unipolar, bipolar II, and cyclothymic patients. Am J Psychiatry 1982; 139: 747–752Google Scholar

Peters, W, Freeman, MP, Kim, S, et al. Treatment of premenstrual breakthrough of depression with adjunctive oral contraceptive pills compared with placebo. J Clin Psychopharmacol 2017; 37: 609–614Google Scholar

Petersen, T, Papakostas, GI, Posternak, MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005; 25: 335–341Google Scholar

Petrakis, IL, Ralevski, E, Desai, N, et al. Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence. Neuropsychopharmacol 2012; 37: 996–1004Google Scholar

Petrakis, IL, Ralevski, E, Nich, C, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol 2007; 27: 160–165Google Scholar

Pettinati, HM, Kampman, KM, Lynch, KG, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 2008; 33: 651–657Google Scholar

Pettinati, HM, Oslin, SW, Kampman, KM, et al. A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. Am J Psychiatry 2010; 167: 668–675Google Scholar

Petty, F, Davis, LL, Nugent, AL, et al. Valproate for chronic, combat-induced posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22: 100–101Google Scholar

Peuskens, J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 166: 712–726Google Scholar

Peuskens, J, Link, CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265–273Google Scholar

Philipsen, A, Richter, H, Schmahl, C, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry 2004a; 65: 1414–1419Google Scholar

Philipsen, A, Schmahl, C, Lieb, K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry 2004b; 37: 196–199Google Scholar

Phillips, KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry 2005; 162: 377–379Google Scholar

Phillips, KA, McElroy, SL. Personality disorders and traits in patients with body dysmorphic disorder. Compr Psychiatry 2000; 41: 229–236Google Scholar

Pierre, JM, Wishing, DA, Pierre, WC, et al. High dose quetiapine in treatment refractory schizophrenia. Schizophr Res 2005; 73: 373–375Google Scholar

Pilkinton, P, Berry, C, Norrholm, S, et al. An open label pilot study of adjunctive asenapine for the treatment of posttraumatic stress disorder. Psychopharmacol Bull 2016; 46: 8–17Google Scholar

Pillinger, T, McCutcheon, RA, Vano, L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020; 7: 64–77Google Scholar

Pinquart, M, Duberstein, PR. Treatment of anxiety disorders in older adults: a meta-analytic comparison of behavioral and pharmacological interventions. Am J Geriatr Psychiatry 2007; 15: 639–651Google Scholar

Pitman, RK, Sanders, KM, Zusman, RM, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002; 51: 189–192Google Scholar

Pittler, MH, Ernst, E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003; (1): CD003383Google Scholar

Pizzagalli, DA. Frontocingulate dysfunction in depression: toward biomarkers of treatment response. Neuropsychopharmacology 2011; 36: 183–206Google Scholar

Pohl, RB, Feltner, DE, Fieve, RR, et al. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151–158Google Scholar

Poling, J, Oliveto, A, Petry, N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006; 63: 219–228Google Scholar

Pollack, MH, Allqulander, C, Bandelow, B, et al. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 2003; 8(8 Suppl 1): 17–30Google Scholar

Pollack, MH, Lepola, U, Koponen, H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24: 1–14Google Scholar

Pollack, MH, Rappaport, MH, Fayyad, R, et al. Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. J Psychiatr Res 2002; 36: 229–236Google Scholar

Pollack, MH, Simon, NM, Zalta, AK, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006; 59: 211–215Google Scholar

Pollack, MH, Tiller, J, Xie, F, et al. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008; 28: 308–316Google Scholar

Pollok, J, van Agteren, JE, Carson-Chahhoud, KV. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2018; (12): CD012346Google Scholar

Popiel, A, Zawadski, B, Praglowska, E, et al. Prolonged exposure, paroxetine and the combination in the treatment of PTSD following a motor vehicle accident: a randomized clinical trial – The “TRAKT” study. J Behav Ther Exp Psychiatry 2015; 48: 17–26Google Scholar

Popova, V, Daly, J, Trivedi, M, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019; 176: 428–438Google Scholar

Porcelli, S, Drago, A, Fabbri, C, et al. Pharmacogenetics of antidepressant response. J Psychiatr Neurosci 2011; 36: 87–113Google Scholar

Porcelli, S, Fabbri, C, Serretti, A. Meta-analysis of serotonin transporter gene promoter polymorphism (5HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22: 239–258Google Scholar

Porsteinsson, AP, Drye, LT, Pollock, BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. J Am Med Assoc 2014; 311: 682–691Google Scholar

Portella, MJ, de Diego-Adeliño, J, Ballesteros, J, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in non-resistant depression. J Clin Psychiatry 2011; 72: 962–969Google Scholar

Posner, J, Kass, E, Hulvershorn, L. Using stimulants to treat ADHD-related emotional lability. Curr Psychiatry Rep 2014; 16: 478Google Scholar

Post, RM, Ketter, TA, Pazzaglia, PJ, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res Suppl 1996; 11: 153–180Google Scholar

Potkin, SG, Bunny, JY, Costa, J, et al. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry 1999; 156: 145–147Google Scholar

Potkin, SG, Keck, PE Jr., Segal, S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005; 25: 201–310Google Scholar

Potuzak, M, Ravichandran, C, Lewandowski, KE, et al. Categorical versus dimensional classifications of psychotic disorders. Compr Psychiatry 2012; 53: 1118–1129Google Scholar

Poulson, MB, Damgaard, B, Zerahn, B, et al. Modafinil may alleviate poststroke fatigue: a randomized, placebo-controlled, double-blinded trial. Stroke 2015; 46: 3470–3477Google Scholar

Prakash, J, Kotwal, A, Prabhu, H. Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized trial. J ECT 2006; 22: 163–168Google Scholar

Pratte, MA, Nanavati, KB, Young, V, et al. An alternative treatment for anxiety: a systematic review of human trial results reported for the Ayurvedic herb ashwagandha (Withania somnifera). J Altern Complement Med 2014; 20: 901–908Google Scholar

Preisig, M, Fenton, BT, Stevens, DE, et al. Familial relationship between mood disorders and alcoholism. Compr Psychiatry 2001; 42: 87–95Google Scholar

Premachandra, BN, Kabir, MA, Williams, IK. Low T3 syndrome in psychiatric depression. J Endocrinol Invest 2006; 29: 568–572Google Scholar

Preskorn, SH, Alderman, J, Chung, M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14: 90–98Google Scholar

Primavera, D, Bandecchi, C, Lepori, T, et al. Does duration of untreated psychosis predict very long term outcome of schizophrenic disorders? Results of a retrospective study. Ann Gen Psychiatry 2012; 11: 21Google Scholar

Pringsheim, T, Marras, C. Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev. 2009; (2): CD006996Google Scholar

Pringsheim, T, Holler-Managan, Y, Okun, MS, et al. Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology 2019; 92: 907–915Google Scholar

Privitera, M, Welty, T, Gidal, B, et al. How do clinicians adjust lamotrigine doses and use lamotrigine blood levels? A Q-PULSE survey. Epilepsy Curr 2014; 14: 218–223Google Scholar

Prosser, JM, Yard, S, Steele, A, et al. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. BMC Psychiatry 2009; 9: 25Google Scholar

Prudic, J, Haskett, RF, McCall, WV, et al. Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT 2013; 29: 3–12.Google Scholar

Pundiak, TM, Case, BG, Peselow, ED, et al. Discontinuation of maintenance selective serotonin reuptake inhibitor monotherapy after 5 years of stable response: a naturalistic study. J Clin Psychiatry 2008; 69: 1811–1817Google Scholar

Purdon, SE. The Screen for Cognitive Impairment in Psychiatry (SCIP): Administration Manual and Normative Data. Edmonton, Alberta: PNL Inc; 2005Google Scholar

Qi, W, Gevonden, M, Shalev, A. Efficacy and tolerability of high-dose escitalopram in posttraumatic stress disorder. J Clin Psychopharmacol 2017; 37: 89–93Google Scholar

Quante, A, Zeugmann, S. Tranylcypromine and bupropion combination therapy in treatment-resistant major depression: a report of 2 cases. J Clin Psychopharmacol 2012; 32: 572–574Google Scholar

Quitkin, FM, Rabkin, JG, Ross, D, et al. Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984; 41: 782–786Google Scholar

Quitkin, FM, Stewart, JW, McGrath, PJ, et al. Columbia atypical depression: a subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993; 21: 30–34Google Scholar

Rabinowitz, J, Baruch, Y, Barak, Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2008; 23: 49–53Google Scholar

Rabkin, JG, McElhiney, MC, Rabkin, R, et al. Modafinil treatment for HIV+ patients: a pilot study. J Clin Psychiatry 2004; 65: 1688–1695Google Scholar

Rabkin, JG, McElhiney, MC, Rabkin, R, et al. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry 2006; 163: 59–66Google Scholar

Raby, WN, Rubin, EA, Garawi, F, et al. A randomized, double-blind, placebo-controlled trial of venlafaxine for the treatment of depressed cocaine-dependent patients. Am J Addict 2014; 23: 68–75Google Scholar

Rae Olmsted, KL, Batoszk, M, Mulvaney, S, et al. Effect of stellate ganglion block treatment in posttraumatic stress disorder symptoms: a randomized clinical trial. JAMA Psychiatry 2020; 77: 130–138Google Scholar

Rahman, T, Ash, DM, Lauriello, J, et al. Misleading guidance from pharmacogenomic testing. Am J Psychiatry 2017; 174: 922–924Google Scholar

Raison, CL, Rutherford, RE, Wollwine, BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70: 31–41Google Scholar

Rajagopal, R, Sundaresan, L, Rajkumar, AP, et al. Genetic association between the DRD4 promoter polymorphism and clozapine-induced sialorrhea. Psychiatr Genet 2014; 24: 273–276Google Scholar

Rajizadeh, A, Mozaffari-Khosravi, H, Yassini-Ardakani, M, et al. Effect of magnesium supplementation on depression status in depressed patients with magnesium deficiency: a randomized, double-blind, placebo-controlled trial. Nutrition 2017; 35: 56–60Google Scholar

Rapaport, MH, Gharabawi, GM, Canuso, CM, et al. Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 2006; 31: 2505–2513Google Scholar

Rapaport, MH, Lydiard, RB, Pitts, CD, et al. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. J Clin Psychiatry 2009; 70: 46–57Google Scholar

Rapaport, MH, Schneider, LS, Dunner, DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 2003; 64: 1065–1074Google Scholar

Raskin, J, Wiltse, CG, Siegal, A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 164: 900–909Google Scholar

Raskind, MA, Peskind, ER, Chow, B, et al. Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med 2018; 378: 507–517Google Scholar

Ratey, JJ, Sorgi, P, O’Driscoll, GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 1992; 53: 41–46Google Scholar

Rauch, SAM, Kim, HM, Powell, C, et al. Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among veterans with posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 2019; 76: 117–126Google Scholar

Ravishankar, V, Chowdappa, SV, Beneqal, V, et al. The efficacy of atomoxetine in treating adult attention deficit hyperactivity disorder (ADHD): a meta-analysis of controlled trials. Asian J Psychiatry 2016; 24: 53–58Google Scholar

Ray, WA, Chung, CP, Murray, KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225–235Google Scholar

Reas, DL, Grilo, CM. Review and meta-analysis of pharmacotherapy for binge-eating disorder. Obesity 2008; 16: 2024–2038Google Scholar

Redden, L, DelBello, M, Wagner, KD, et al. Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol 2009; 19: 83–89Google Scholar

Reed, RC, Dutta, S. Does it really matter when a blood sample for valproic acid concentration is taken following once-daily administration of divalproex-ER? Ther Drug Monit 2006; 28: 413–418Google Scholar

Reeves, H, Batra, S, May, RS, et al. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 2008; 69: 1228–1236Google Scholar

Regier, DA, Narrow, WE, Clarke, DE, et al. DSM-5 field trials in the United States and Canada, part II: test-retest reliability of selected categorical diagnoses. Am J Psychiatry 2013; 170: 59–70Google Scholar

Reich, DB, Zanarini, MC, Bieri, KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol 2009; 24: 270–275Google Scholar

Reilly, TM, Jopling, WH, Beard, AW. Successful treatment with pimozide of delusional parasitosis. Br J Dermatol 1978; 98: 457–459Google Scholar

Reilly-Harrington, NA, Sylvia, LG, Leon, AC, et al. The medication recommendation tracking form: a novel tool for tracking changes in prescribed medication, clinical decision making, and use in comparative effectiveness research. J Psychiatr Res 2013; 47: 1686–1693Google Scholar

Reilly-Harrington, NA, Sylvia, LG, Rabideau, DJ, et al. Tracking medication changes to assess outcomes in comparative effectiveness research: a bipolar CHOICE study. J Affect Disord 2016; 205: 159–164Google Scholar

Reimherr, FW, Williams, ED, Strong, RE, et al. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry 2007; 68: 93–101Google Scholar

Reinares, M, Rosa, AR, Franco, C, et al. A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol 2013; 16: 485–496Google Scholar

Reis, M, Lundmark, J, Bengtsson, F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992–1997. Ther Drug Monit 2003; 25: 183–191Google Scholar

Reis, M, Chermá, MD, Carlsson, B, et al. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit 2007; 29: 758–766Google Scholar

Reis, M, Lundmark, J, Bjӧrk, H, et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 2002; 24: 545–553Google Scholar

Reist, C, Nakamura, K, Sagart, E, et al. Impulsive aggressive behavior: open-label treatment with citalopram. J Clin Psychiatry 2003; 64: 81–85Google Scholar

Remington, G, Agid, D, Fousslas, G, et al. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacol (Berl) 2013; 225: 505–518Google Scholar

Reoux, JP, Saxon, AJ, Malte, CA, et al. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res 2001; 25: 1324–1329Google Scholar

Rettenbacher, WA, Hofer, A, Kemmler, G, et al. Neutropenia induced by second generation antipsychotics: a prospective investigation. Pharmacopsychiatry 2010; 43: 41–44Google Scholar

Reynolds, GP, Hill, MJ, Kirk, SL. The 5-HT2C receptor and antipsychotic-induced weight gain – mechanisms and genetics. J Psychopharmacol 2006; 20(4 Suppl): 15–18Google Scholar

Reynolds, GP, Zhang, Z, Zhang, X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003; 160: 677–679Google Scholar

Reynolds, CF 3rd, Butlers, MA, Lopez, O, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry 2011; 68: 51–60Google Scholar

Rickels, K, Lipman, R, Raab, E. Previous medication, duration of illness and placebo response. J Nerv Ment Dis 1966; 142: 548–554Google Scholar

Rickels, K, DeMartinis, N, Gárcia-España, F, et al. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry 2000; 157: 1973–1979Google Scholar

Rickels, K, Pollack, MH, Feltner, DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022–1030Google Scholar

Rief, W, Nestoriuc, Y, Weiss, S, et al. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009; 118: 1–8Google Scholar

Rifkin, A, Karajgi, B, Dicker, R, et al. Lithium treatment of conduct disorders in adolescents. Am J Psychiatry 1997; 154: 554–555Google Scholar

Rink, L, Braun, C, Bschor, T, et al. Dose increase versus unchanged continuation of antidepressants after initial antidepressant treatment failure in patients with major depressive disorder: a systematic review and meta-analysis of randomized, double-blind trials. J Clin Psychiatry 2018; 79: 17r11693Google Scholar

Rinne, T, van den Brink, W, Wouters, L, et al. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002; 159: 2048–2054Google Scholar

Risse, S, Whitters, A, Burke, A, et al. Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. J Clin Psychiatry 1990; 51: 206–209Google Scholar

Ritsner, MS, Bawakny, H, Kreinin, A. Pregnenolone treatment reduces severity of negative symptoms in recent-onset schizophrenia: an 8-week, double-blind, randomized add-on two-center trial. Psychiatry Clin Neurosci 2014; 68: 432–440Google Scholar

Ritsner, MS, Gibel, A, Shleifer, T, et al. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry 2010; 71: 1351–1362Google Scholar

Ritsner, MS, Miodownik, C, Ratner, Y, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry 2011; 72: 34–42Google Scholar

Rivzi, SJ, Sproule, BA, Gallaugher, L, et al. Correlates of benzodiazepine use in major depressive disorder: the effect of anhedonia. J Affect Disord 2015; 187: 101–105Google Scholar

Robert, S, Hamner, MB, Ulmer, HG, et al. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry 2006; 67: 1522–1526Google Scholar

Roberts, AC. The importance of serotonin for orbitofrontal function. Biol Psychiatry 2011; 69: 1185–1191Google Scholar

Robertson, E, Grace, S, Wallington, T, et al. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry 2004; 26: 289–295Google Scholar

Robinson, M, Oakes, TM, Raskin, J, et al. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry 2014; 22: 34–45Google Scholar

Robinson, RG, Jorge, RE, Moser, DJ, et al. Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. J Am Med Assoc 2008; 299: 2391–2400Google Scholar

Rocca, P, Marchiaro, L, Cocuzza, E, et al. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002; 63: 241–244Google Scholar

Rock, EM, Bolognini, D, Limebeer, CL, et al. Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2012; 165: 2620–2634Google Scholar

Rodriguez, CI, Bender, J Jr., Morrison, S, et al. Does extended release methylphenidate help adults with hoarding disorder? A case series. J Clin Psychopharmacol 2013; 33: 444–447Google Scholar

Roh, D, Chang, JG, Kim, CH, et al. Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison. Aust N Z J Psychiatry 2014; 48: 52–60Google Scholar

Rohde, C, Polcwiartek, C, Asztalos, M, et al. Effectiveness of prescription-based CNS stimulants on hospitalization in patients with schizophrenia: a nation-wide register study. Schizophr Bull 2018; 44: 93–100Google Scholar

Rojas-Fernandez, CH. Can 5-HT3 antagonists really contribute to serotonin toxicity? A call for clarity and pharmacological law and order. Drugs Real World Outcomes 2014; 1: 3–5Google Scholar

Rojtabai, R, Olfson, M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010; 67: 26–36Google Scholar

Romanelli, RJ, Wu, FM, Gamba, R, et al. Behavioral therapy and serotonin reuptake inhibitor pharmacotherapy in the treatment of obsessive-compulsive disorder: a systematic review and meta-analysis of head-to-head randomized controlled trials. Depress Anxiety 2014; 31: 641–652Google Scholar

Roose, SP, Glassman, AH, Attia, E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151: 1735–1739Google Scholar

Roose, SP, Sackeim, HA, Krishnan, RR, et al. Old-Old Depression Study Group: antidepressant pharmacotherapy in the treatment of depression in the very old. A randomized, placebo-controlled trial. Am J Psychiatry 2004; 161: 2050–2059Google Scholar

Rosenbaum, JF, Fava, M, Hoog, SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77–87Google Scholar

Rosenberg, HC, Chiu, TH. Time course for the development of benzodiazepine tolerance and physical dependence. Neurosci Biobehav Rev 1985; 9: 123–131Google Scholar

Rosenberg, NK, Mellergård, M, Rosenberg, R, et al. Characteristics of panic disorder patients responding to placebo. Acta Psychiatr Scand 1991; 365: 33–38Google Scholar

Rosenblat, JD, McIntyre, RS. Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials. J Affect Disord 2018; 227: 219–225Google Scholar

Rosenblat, JD, Carvalho, AF, Li, M, et al. Oral ketamine for depression: a systematic review. J Clin Psychiatry 2019; 80: 18r12475Google Scholar

Rosenheck, R, Dunn, L, Peszke, M, et al. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia: Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Am J Psychiatry 1999; 156: 88–93Google Scholar

Rosenthal, M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; 64: 1245–1249Google Scholar

Ross, DC, Fischhoff, J, Davenport, B. Treatment of ADHD when tolerance to methylphenidate develops. Psychiatr Serv 2002; 53: 102Google Scholar

Roth, LS. Posttraumatic stress disorder and benzodiazepines: a myth agreed upon. Fed Pract 2010; 27: 12–21Google Scholar

Roth, T, Seiden, D, Sainati, S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006; 7: 312–318Google Scholar

Rothbaum, BO, Killeen, TK, Davidson, JR, et al. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry 2008; 69: 520–525Google Scholar

Rothschild, AJ, Duval, SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry 2003; 64: 390–396Google Scholar

Rozzini, L, Chilovi, BV, Conti, M, et al. Efficacy of SSRIs on cognition of Alzheimer’s disease patients treated with cholinesterase inhibitors. Int Psychogeriatr 2010; 22: 114–119Google Scholar

Rucker, JH, Jelen, LA, Flynn, S, et al. Psychedelics in the treatment of unipolar mood disorders: a systematic review. J Psychopharmacol 2016; 30: 1220–1229Google Scholar

Ruedrich, SL, Swales, TP, Rossvanes, C, et al. Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities. J Intellect Disabil Res 2008; 52: 132–140Google Scholar

Ruhé, HG, Huyser, J, Swinkels, JA, et al. Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review. Br J Psychiatry 2006a; 189: 309–316Google Scholar

Ruhé, HG, Huyser, J, Swinkels, JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 2006b; 67: 1836–1855Google Scholar

Ruiz, P, Varner, RV, Small, DR, et al. Ethnic differences in the neuroleptic treatment of schizophrenia. Psychiatr Q 1999; 70: 163–172Google Scholar

Rush, AJ, Carmody, TJ, Haight, BR, et al. Does pretreatment insomnia or anxiety predict acute response to bupropion SR? Ann Clin Psychiatry 2005; 17: 1–9Google Scholar

Rush, AJ, Kraemer, HC, Sackeim, HA, et al. Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology 2006a; 31: 1841–1853Google Scholar

Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006b; 163: 1905–1917Google Scholar

Russo, EB, Burnett, A, Hall, B, et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30: 1037–1043Google Scholar

Rutherford, BR, Pott, E, Tandler, JM, et al. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry 2014; 71: 1409–1421Google Scholar

Rutherford, BR, Wall, MM, Brown, PJ, et al. Patient expectancy as a mediator of placebo effects in antidepressant clinical trials. Am J Psychiatry 2017; 174: 135–142Google Scholar

Rynn, M, Khalid-Kahn, S, Garcia-Espana, JF, et al. Early response and 8-week treatment outcome in GAD. Depress Anxiety 2006; 23: 461–465Google Scholar

Ryszewska-Pokraśniewicz, B, Mach, A, Skalski, M, et al. Effects of magnesium supplementation on unipolar depression: a placebo-controlled study and review of the importance of dosing and magnesium status in the therapeutic response. Nutrients 2018; 10(8): E1014Google Scholar

Saad, K, Abdel-Rahman, AA, Elserogy, YM, et al. Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children. Nutr Neurosci 2016; 19: 346–351Google Scholar

Saavedra-Velez, C, Yusim, A, Anbarasan, D, et al. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry 2009; 70: 104–112Google Scholar

Sachs, GS, Chengappa, KN, Suppes, T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004; 6: 213–223Google Scholar

Sachs, GS, Greenberg, WM, Starace, A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord 2015; 174: 296–302Google Scholar

Sachs, GS, Grossman, F, Ghaemi, SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159: 1146–1154Google Scholar

Sachs, GS, Ice, KS, Chappell, PB, et al. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011; 72: 1413–1422Google Scholar

Sachs, GS, Peters, AT, Sylvia, L, et al. Polypharmacy and bipolar disorder: what’s personality got to do with it? Int J Neuropsychopharmacol 2014; 17: 1053–1061Google Scholar

Sachs, GS, Vanderburg, DG, Karayal, ON, et al. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2012; 73: 1412–1419Google Scholar

Sack, M, Spieler, D, Wizelman, L, et al. Intranasal oxytocin reduces provoked symptoms in female patients with posttraumatic stress disorder despite exerting sympathomimetic and positive chronotropic effects in a randomized controlled trial. BMC Med 2017; 15: 40Google Scholar

Sackeim, HA, Haskett, RF, Mulsant, BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. J Am Med Assoc 2001; 285: 1299–1307Google Scholar

Sackett, DL, Rosenberg, WMC, Gray, JA, et al. Evidence-based medicine: what it is and what it isn’t. Br Med J 1996; 312: 71–72Google Scholar

Sackner-Bernstein, J, Niebler, G, Earl, CQ, et al. Cardiovascular profile of modafinil: effects on blood pressure and heart rate. Chest 2004; 126: 729SGoogle Scholar

Saharian, A, Ehsaei, Z, Mowla, A. Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in manic phase of bipolar disorder: a randomized, double-blind, placebo-controlled clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2018; 84: 267–271Google Scholar

Sahlholm, K, Zeberg, H, Nilsson, J, et al. The fast-off hypothesis revisited: a functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor. Eur Neuropsychopharmacol 2016; 26: 467–476Google Scholar

Sakuma, K, Matsunaga, S, Nomura, I, et al. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis. Psychopharmacol (Berl) 2018; 235: 2303–2314Google Scholar

Salehi, B, Imani, R, Mohammadi, MR, et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 76–80Google Scholar

Salloum, IM, Cornelius, JR, Daley, DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62: 37–45Google Scholar

Salzman, C, Wolfson, AN, Schatzberg, A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1994; 15: 23–29Google Scholar

Sämann, PG, Höhn, D, Chechko, N, et al. Prediction of antidepressant treatment response from gray matter volume across diagnostic categories. Eur Neuropsychopharmacol 2013; 23: 1503–1515Google Scholar

Samara, MT, Goldberg, Y, Levine, SZ, et al. Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. Lancet Psychiatry 2017; 4: 859–867Google Scholar

Samara, MT, Leucht, C, Leeflang, MM, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry 2015; 172: 617–629Google Scholar

Samples, H, Williams, AR, Olfson, M, et al. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat 2018; 95: 9–16Google Scholar

Sandin, S, Lichtstein, P, Kuja-Halkola, R, et al. The familial risk of autism. J Am Med Assoc 2014; 311: 1770–1777Google Scholar

Sandmann, J, Lӧrch, B, Bandelow, B, et al. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 1998; 31: 117–121Google Scholar

Sanfilipo, M, Wolkin, A, Angrist, B, et al. Amphetamine and negative symptoms of schizophrenia. Psychopharmacol (Berl) 1996; 123: 211–214Google Scholar

Sani, G, Gualtieri, I, Paolino, M, et al. Drug treatment of trichotillomania (hair-pulling disorder), excoriation (skin-picking) disorder, and nail-biting (onychophagia). Curr Neuropharmacol 2019; 17: 775–786Google Scholar

Sansone, RA, Wiederman, MW, Sansone, LA. The Self-Harm Inventory (SHI): development of a scale for identifying self destructive behaviors and borderline personality disorder. J Clin Psychol 1998; 54: 973–83Google Scholar

Santos, B, González-Fraile, E, Zabala, A, et al. Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia. J Psychopharmacol 2018; 32: 1155–1166Google Scholar

Sarpal, DK, Argyelan, M, Robinson, DG, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry 2016; 173: 69–77Google Scholar

Sarris, J. Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. Phytother Res 2018; 32: 1147–1162Google Scholar

Sarris, J, Murphy, J, Mischoulon, D, et al. Adjunctive nutraceutical for depression: a systematic review and meta-analyses. Am J Psychiatry 2016; 173: 575–587Google Scholar

Sarris, J, Price, LH, Carpenter, LL, et al. Is S-adenosyl methionine (SAMe) for depression only effective in males? A re-analysis of data from a randomized clinical trial. Pharmacopsychiatry 2015; 48: 141–144Google Scholar

Sartori, HE. Lithium orotate in the treatment of alcoholism and related conditions. Alcohol 1986; 3: 97–100Google Scholar

Sasson, Y, Iancu, I, Fux, M, et al. A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 1999; 9: 191–196Google Scholar

Saxena, S, Sumner, J. Venlafaxine extended-release treatment of hoarding disorder. Int Clin Psychopharmacol 2014; 29: 266–273Google Scholar

Saxena, S, Brody, AL, Maidment, KM, et al. Paroxetine treatment of compulsive hoarding. J Psychiatr Res 2007; 41: 481–487Google Scholar

Scarvalone, PA, Cloitre, M, Spielman, LA, et al. Distress reduction during the structured clinical interview for DSM-III-R. Psychiatr Res 1996; 59: 245–249Google Scholar

Schaefer, M, Sarkar, S, Theophil, I, et al. Acute and long-term memantine add-on treatment to risperidone improves cognitive dysfunction in patients with acute and chronic schizophrenia. Pharmacopsychiatry 2020; 53: 21–29Google Scholar

Schaffler, K, Wolf, OT, Burkart, M. No benefit adding Eleutherococcus senticosus to stress management training in stress-related fatigue/weakness, impaired work or concentration, a randomized controlled study. Pharmacopsychiatry 2013; 46: 181–190Google Scholar

Schatzberg, A, Roose, S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 2006; 14: 361–370Google Scholar

Schatzberg, AF, DeBattista, C, Lazzeroni, LC, et al. ABCB1 genetic effects on antidepressant outcomes: a report from the iSPOT-D trial. Am J Psychiatry 2015; 172: 751–759Google Scholar

Schatzberg, AF, Haddad, P, Kaplan, EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. Discontinuation Consensus Panel. J Clin Psychiatry 1997; 58 (Suppl 7): 23–27Google Scholar

Schmahl, C, Kleindienst, N, Limberger, M, et al. Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. Int Clin Psychopharmacol 2012; 27: 61–68Google Scholar

Schmidt, PJ, Daly, RC, Bloch, M. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005; 62: 154–162Google Scholar

Schmitt, R, Gazelle, FK, Lima, MS, et al. The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Braz J Psychiatry 2005; 27: 18–24Google Scholar

Schneider, LS, Dagerman, K, Insel, SP. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14: 191–210Google Scholar

Schneider, LS, Nelson, JC, Clary, CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160: 1277–1285Google Scholar

Schneier, FR, Campeas, R, Carcamo, J, et al. Combined mirtazapine and SSRI treatment of PTSD: a placebo-controlled trial. Depress Anxiety 2015; 32: 570–579Google Scholar

Scholey, A, Ossoukhova, A, Owen, L, et al. Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study. Psychopharmacol (Berl) 2010; 212: 345–356Google Scholar

Schottenfeld, RS, Chawarski, MC, Pakes, JR, et al. Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 2005; 162: 340–349Google Scholar

Schulz, SC, Zanarini, MC, Bateman, A, et al. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry 2008; 193: 485–492Google Scholar

Schutters, SIJ, Van Megan, HJGM, Van Veen, JF, et al. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2010; 25: 302–304Google Scholar

Schweizer, E, Rickels, K, Hassman, H, et al. Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry 1998; 59: 175–183Google Scholar

Schwenk, ES, Viscusi, ER, Buvanendram, A, et al. Consensus guidelines on the use of intravenous ketamine infusions for acute pain management from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med 2018; 43: 456–466Google Scholar

Scoriels, L, Jones, PB, Sahakian, PJ. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropsychopharmacol 2013; 64: 168–184Google Scholar

Scuderi, C, De Filippis, D, Iuvone, T, et al. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother Res 2009; 23: 597–602Google Scholar

Seedat, S, Stein, MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004; 65: 244–248Google Scholar

Seeman, P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 2011; 17: 118–132Google Scholar

Seitz, DP, Adunuri, N, Gill, SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; (2): CD008191Google Scholar

Selle, V, Schalkwijk, S, Vásquez, GH, et al. Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014; 47: 43–52Google Scholar

Selles, RR, McGuire, JF, Small, BJ, et al. A systematic review and meta-analysis of psychiatric treatments for excoriation (skin-picking) disorder. Gen Hosp Psychiatry 2016; 41: 29–37Google Scholar

Senderovich, A, Jeyapragasan, G. Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true? Curr Med Res Opin 2018; 34: 677–682Google Scholar

Sephery, AA, Potvin, S, Elie, R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 2007; 68: 604–610Google Scholar

Serafini, G, Adavastro, G, Canepa, G, et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci 2018; 19: E2410Google Scholar

Serban, G, Siegel, S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984; 141: 1455–1458Google Scholar

Servan, A, Brunelin, J, Poulet, E. The effects of oxytocin on social cognition in borderline personality disorder. Encephale 2018; 44: 46–51Google Scholar

Shahani, L. Venlafaxine augmentation with lithium leading to serotonin syndrome. J Neuropsychiatry Clin Neurosci 2012; 24: E47Google Scholar

Shakibaei, F, Radmanesh, M, Salari, E, et al. Ginkgo biloba in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a randomized, placebo-controlled, trial. Compl Ther Clin Pract 2015; 21: 61–67Google Scholar

Shalev, AY, Ankri, Y, Israeli-Shalev, Y, et al. Prevention of posttraumatic stress disorder by early treatment: results from the Jerusalem Trauma Outreach and Prevention Study. Arch Gen Psychiatry 2012; 69: 166–176Google Scholar

Shams, M, Hiemke, C, Härtter, S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther Drug Monit 2004; 26: 78–84Google Scholar

Shapiro, HI, Davis, KA. Hypercalcemia and “primary” hyperparathyroidism during lithium therapy. Am J Psychiatry 2015; 172: 12–15Google Scholar

Shaw, P, Stringaris, A, Nigg, J, et al. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry 2014; 171: 276–293Google Scholar

Shear, MK, Reynolds, CF 3rd, Simon, NM, et al. Optimizing treatment of complicated grief: a randomized clinical trial. JAMA Psychiatry 2016; 73: 685–694Google Scholar

Sheard, MH, Marini, JL, Bridges, CI, et al. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133: 1409–1413Google Scholar

Sheehan, DV, Sheehan, KH, Raj, BA. The speed of onset of alprazolam-XR compared to alprazolam-CT in panic disorder. Psychopharmacol Bull 2007; 40: 63–81Google Scholar

Sheehan, DV, Burnham, DB, Iyengar, MK, et al. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 2005; 66: 34–40Google Scholar

Sheehan, DV, Harnett-Sheehan, K, Hidalgo, RB, et al. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. J Affect Disord 2013; 145: 83–94Google Scholar

Sheehan, DV, McElroy, SL, Harnett-Sheehan, K, et al. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord 2009; 115: 376–385Google Scholar

Sheehan, DV, Raj, AB, Harnett-Sheehan, K, et al. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88: 1–11Google Scholar

Sheehan, DV, Raj, AB, Sheehan, KH, et al. The relative efficacy of buspirone, imipramine and placebo in panic disorder: a preliminary report. Pharmacol Biochem Behav 1988; 29: 815–817Google Scholar

Sheehan, DV, Raj, AB, Sheehan, KH, et al. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990; 10: 3–11Google Scholar

Shelton, RC, Tollefson, GD, Tohen, M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131–134Google Scholar

Shelton, RC, Williamson, DJ, Corya, SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005; 66: 1289–1297Google Scholar

Shergis, JL, Zhang, AL, Zhou, W, et al. Panax ginseng in randomised controlled trials: a systematic review. Phytother Res 2013; 27: 949–965Google Scholar

Shi, Q, Pavey, ES, Carter, RE. Bonferroni-based correction factor for multiple, correlated endpoints. Pharm Stat 2012; 11: 300–309Google Scholar

Shim, J-C, Shin, JG, Kelly, DL, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007; 164: 1404–1410Google Scholar

Shin, B-C, Lee, MS, Yang, EJ, et al. Maca (L. myenii) for improving sexual function: a systematic review. BMC Complement Altern Med 2010; 10: 44Google Scholar

Shiner, B, Westgate, CL, Gui, J, et al. A retrospective comparative effectiveness study of medications for posttraumatic stress disorder in routine practice. J Clin Psychiatry 2018; 79: 18m12145Google Scholar

Shioda, K, Nisijima, K, Yoshino, T, et al. Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett 2010; 482: 216–219Google Scholar

Shiroma, PR, Drews, MS, Geske, JR, et al. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatry 2014; 22: 1140–1148Google Scholar

Shlipak, MG, Matsushita, K, Ärnlӧv, J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013; 369: 932–943Google Scholar

Shulman, KI, Walker, SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry 1999; 60: 191–193Google Scholar

Shulman, KI, Walker, SE, MacKenzie, S, et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989; 9: 397–402Google Scholar

Shuman, M, Chukwu, A, Van Veldhuizen, N, et al. Relationship between mirtazapine dose and incidence of adrenergic side effects: an exploratory analysis. Mental Health Clin 2019; 9: 41–47Google Scholar

Schumer, MC, Bartley, CA, Bloch, MH. Systematic review of pharmacological and behavioral treatments for skin picking disorder. J Clin Psychopharmacol 2016; 36(2): 147–152Google Scholar

Siassi, I. Lithium treatment of impulsive behavior in children. J Clin Psychiatry 1982; 43: 482–484Google Scholar

Sidor, MM, McQueen, GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis, J Clin Psychiatry 2011; 72: 156–167Google Scholar

Sievewright, H, Tyrer, P, Johnson, T. Change in personality status in neurotic disorders. Lancet 2002; 359: 2253–2254Google Scholar

Silberstein, SD, Peres, MF, Hopkins, MM, et al. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache 2002; 42: 515–518Google Scholar

Silverman, BL, Martin, W, Memisoglu, A, et al. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr Res 2018; 195: 245–251Google Scholar

Simeon, D, Stein, DJ, Gross, S, et al. A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry 1997; 58: 341–347Google Scholar

Simeon, JF, Ferguson, HB, Knott, V, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 1992; 31: 29–33Google Scholar

Simhandl, C, Denk, E, Thau, K. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord 1993; 28: 221–231Google Scholar

Simon, NM, Connor, KM, Lang, AJ, et al. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J Clin Psychiatry 2008; 69: 400–405Google Scholar

Simon, NM, Hoge, EA, Fischmann, D, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 2006a; 67: 381–385Google Scholar

Simon, NM, Worthington, JJ, Doyle, AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004; 65: 1219–1222Google Scholar

Simon, NM, Zalta, AK, Worthington, JJ 3rd, et al. Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anxiety 2006b; 23: 373–376Google Scholar

Simpson, EB, Yen, S, Costello, E, et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2005; 65: 379–385Google Scholar

Sinclair, DJ, Zhao, S, Qi, F, et al. Electroconvulsive therapy for treatment-resistant schizophrenia. Cochrane Database Syst Rev 2019; (3): CD011847Google Scholar

Singer, S, Tkachenko, E, Sharon, P, et al. Psychiatric adverse events in patients taking isotretinoin as reported in a Food and Drug Administration database from 1997–2017. JAMA Dermatol 2019; 155: 1162–1166Google Scholar

Singh, SP, Singh, V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011; 25: 859–885Google Scholar

Singh, M, Keer, D, Klimas, J, et al. Topiramate for cocaine dependence: a systematic review and meta-analysis of randomized controlled trials. Addiction 2016; 111: 1337–1346Google Scholar

Singh, NP, Despars, JA, Stansbury, DW, et al. Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety. Chest 1993; 103: 800–804Google Scholar

Singh, SP, Singh, V, Kar, N, et al. Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 2010; 197: 174–179Google Scholar

Siris, SG, Adan, F, Cohen, M, et al. Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. Am J Psychiatry 1988; 145: 1532–1537Google Scholar

Siskind, D, McCartney, L, Goldschlager, R, et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385–392Google Scholar

Siskind, DJ, Lee, M, Ravindran, A, et al. Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. Aust N Z J Psychiatry 2018; 52: 751–767Google Scholar

Skapinakis, P, Caldwell, DM, Hollingworth, W, et al. Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 2016; 3: 730–739CrossRef Google Scholar PubMed

Skelley, JW, Deas, CM, Curren, Z, Ennis, J. Use of cannabidiol in anxiety and anxiety-related disorders. J Am Pharm Assoc (2003) 2020; 60: 253–261Google Scholar

Skinner, MD, Lahmek, P, Pham, H, et al. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One 2014; 9: e87366Google Scholar

Skoglund, C, Chen, Q, Franck, J, et al. Attention-deficit/hyperactivity disorder and risk for substance use disorders in relatives. Biol Psychiatry 2015; 77: 880–886Google Scholar

Slee, A, Nazareth, I, Bondaronek, P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019; 393: 768–777Google Scholar

Small, JG, Hirsch, SR, Arvinitis, LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549–557Google Scholar

Smith, GC, Pell, JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. Br Med J 2003; 237: 1459–1461Google Scholar

Smith, DF, Schou, M. Kidney function and lithium concentrations in rats given an injection of lithium orotate or lithium carbonate. J Pharm Pharmacol 1979; 31: 161–163Google Scholar

Snyderman, SH, Rynn, MA, Rickels, K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol 2005; 25: 497–499Google Scholar

Soares-Weiser, K, Rathbone, J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2006; (1): CD000459Google Scholar

Soares-Weiser, K, Maayan, N, Bergman, H. Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018; (1): CD000209Google Scholar

Sobanski, T, Bagli, M, Laux, G, et al. Serotonin syndrome after lithium add-on medication to paroxetine. Pharmacopsychiatry 1997; 30: 106–107Google Scholar

Sobotka, JL, Alexander, B, Cook, BL. A review of carbamazepine’s hematologic reactions and monitoring recommendations. DICP 1990; 24: 1214–1219Google Scholar

Soler, J, Pascual, JC, Campins, J, et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005; 162: 1221–1224Google Scholar

Solmi, M, Fornaro, M, Toyoshima, K, et al. Systematic review and exploratory meta-analysis of the efficacy, safety, and biological effects of psychostimulants and atomoxetine in patients with schizophrenia or schizoaffective disorder. CNS Spectrums 2019; 24: 479–495CrossRef Google Scholar PubMed

Solmi, M, Pigato, G, Kane, JM, et al. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2018; 12: 1215–1238Google Scholar

Solmi, M, Veronese, N, Thapa, N, et al. Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr 2017; 22: 415–426Google Scholar

Soloff, PH, Cornelius, J, George, A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50: 377–385Google Scholar

Soloff, PH, George, A, Nathan, RS, et al. Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986; 43: 691–697Google Scholar

Soloff, PH, George, A, Nathan, S, et al. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmcol 1989; 9: 238–246Google Scholar

Solomon, DA, Leon, AC, Coryell, WH, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. Arch Gen Psychiatry 2010; 67: 339–347Google Scholar

Solomon, M, Ozonoff, S, Carter, C, et al. Formal thought disorder and the autism spectrum: relationship with symptoms, executive control, and anxiety. J Autism Dev Disord 2008; 38: 1474–1484Google Scholar

Sommer, IE, de Witte, L, Begemann, M, et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 2012; 73: 414–419Google Scholar

Sonne, S, Rubey, R, Brady, K, et al. Naltrexone treatment of self-injurious thoughts and behaviors. J Nerv Ment Dis. 1996;184:192–195Google Scholar

Sood, S. Neutropenia with multiple antipsychotics including dose dependent neutropenia with lurasidone. Clin Psychopharmacol Neurosci 2017; 15: 413–415Google Scholar

Soomro, GM, Altman, D, Rajagopal, S, et al. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2008; (1): CD001765Google Scholar

Southwick, SM, Pietrzak, RH, Charney, DS, et al. Resilience: the role of accurate appraisal, thresholds, and socioenvironmental factors. Behav Brain Sci 2015; 38: e122CrossRef Google Scholar PubMed

Soutif-Veillon, A, Ferland, G, Rolland, Y, et al. Increased dietary vitamin K intake is associated with less severe subjective memory complaint among older adults. Maturitas 2016; 93: 131–136CrossRef Google Scholar PubMed

Soyka, M. Othello syndrome: jealousy and jealous delusions as symptoms of psychiatric disorders. Fortschr Neurol Psychiatr 1995; 63: 487–494Google Scholar

Soyka, M. Neurobiology of aggression and violence. Schizophr Bull 2011; 37: 913–920CrossRef Google Scholar PubMed

Sparshatt, A, Taylor, D, Patel, MX, Kapur, S. A systematic review of aripiprazole: dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 2010; 71: 1447–1456Google Scholar

Sparshatt, A, Taylor, D, Patel, MX, Kapur, S. Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry 2011; 72: 1108–1123Google Scholar

Sperling, H, Eisenhardt, A, Virchow, S, et al. Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study. J Urol 2003; 169: 1048–1051Google Scholar

Spielberger, CD, Gorsuch, RL, Lushene, PR, et al. Manual for the State-Trait Anxiety Inventory. Palo Alto, California: Consulting Psychologists Press; 1983Google Scholar

Spina, E, De Domenico, P, Ruello, C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994; 9: 281–285Google Scholar

Sprouse, AA, van Breemen, RB. Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug Metab Dispos 2016; 44: 162–171Google Scholar

Sramek, JJ, Pi, EH. Ethnicity and antidepressant response. Mt Sinai J Med 1996; 63: 320–325Google Scholar

Sramek, JJ, Murphy, MF, Cutler, NR. Sex differences in the psychopharmacological treatment of depression. Dialogues Clin Neurosci 2016; 18: 447–457Google Scholar

Stahl, SM. Drugs for psychosis and mood: unique actions at D3, D2 and D1 dopamine receptor subtypes. CNS Spectr 2017; 22: 375–384Google Scholar

Stahl, SM. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? CNS Spectr 2018; 23: 239–243Google Scholar

Stahl, SM, Morrissette, DA, Faedda, G, et al. Guidelines for the recognition and management of mixed depression. CNS Spectr 2017; 22: 203–219CrossRef Google Scholar PubMed

Stamm, TJ, Becker, D, Sondergeld, LM, et al. Prediction of antidepressant response to venlafaxine by a combination of early response to assessment and therapeutic drug monitoring. Pharmacopsychiatry 2014a; 47: 174–179Google Scholar

Stamm, TJ, Lewitzka, U, Sauer, C, et al. Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014b; 75: 162–168Google Scholar

Stanley, B, Sher, L, Wilson, S, et al. Non-suicidal self-injurious behavior, endogenous opioids and monoamine neurotransmitters. J Affect Disord 2010; 124: 134–140CrossRef Google Scholar PubMed

Starzer, MSK, Nordentoft, M, Hjorthøj, C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry 2018; 175: 343–350Google Scholar

Steen, NE, Aas, M, Simonsen, C, et al. Serum level of venlafaxine is associated with better memory in psychotic disorders. Schizophr Res 2015; 160: 386–392Google Scholar

Steen, NE, Aas, M, Simonsen, C, et al. Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders. World J Biol Psychiatry 2017; 18: 471–482Google Scholar

Stein, DJ. Pharmacotherapy of adjustment disorder: a review. World J Biol Psychiatry 2018; 19(Suppl 1): S46–S52Google Scholar

Stein, DJ, Spadaccini, E, Hollander, E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995; 10: 11–18Google Scholar

Stein, MB, Kline, NA, Matloff, JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002b; 159: 1777–1779Google Scholar

Stein, DJ, Baldwin, DS, Dolberg, OT, et al. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006; 67: 1741–1746Google Scholar

Stein, DJ, Hollander, E, Anthony, DT, et al. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. J Clin Psychiatry 1992; 53: 267–271Google Scholar

Stein, DJ, Simeon, D, Frenkel, M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995a; 56: 506–510Google Scholar PubMed

Stein, DJ, Versiani, M, Hair, T, et al. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002a; 59: 1111–1118Google Scholar

Stein, MB, Chartier, MJ, Hazen, AL, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996; 16: 218–222Google Scholar

Stein, MB, Liebowitz, MR, Lydiard, RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. J Am Med Assoc 1998; 280: 708–713Google Scholar

Stein, MB, Ravindran, LN, Simon, NM, et al. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry 2010; 71: 627–631Google Scholar

Stein, MB, Sareen, J, Hami, S, et al. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158: 1725–1727Google Scholar

Sterne, JA, Gavaghan, D, Egger, M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119–1129Google Scholar

Stevinson, C, Ernst, E. Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Med 2000; 1: 91–99Google Scholar

Stewart, JW, Deliyannides, DA, McGrath, PJ. How treatable is refractory depression? J Affect Disord 2014; 167: 148–152Google Scholar

Stewart, JW, Quitkin, FM, McGrath, PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998; 55: 334–343Google Scholar

Stock, CJ, Carpenter, L, Ying, J, et al. Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment. Ann Pharmacother 2013; 47: 961–969Google Scholar

Stoffers, J, Völlm, BA, Rücker, G, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 2010; (6): CD005653Google Scholar

Stoll, AL, Sachs, GS, Cohen, BM, et al. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry 1996; 40: 382–388Google Scholar

Stone, JM, Roux, S, Taylor, D, et al. First-generation versus second-generation long-acting injectable antipsychotic drugs and time to relapse. Ther Adv Psychopharmacol 2018; 8: 333–336Google Scholar

Storch, EA, Larson, MJ, Shapira, NA, et al. Clinical predictors of early fluoxetine treatment response in obsessive-compulsive disorder. Depress Anxiety 2006; 23: 429–433Google Scholar

Storebø, OJ, Ramstad, E, Krogh, HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev 2015; (11): CD009885Google Scholar

Stough, C, Lloyd, J, Clarke, J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacol (Berl) 2001; 156: 481–484Google Scholar

Strain, EC, Stitzer, ML, Liebson, IA, et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151: 1025–1030Google Scholar

Streichenwein, SM, Thornby, JA. A long-term, double-blind, placebo-controlled, crossover trial of the efficacy of fluoxetine for trichotillomania. Am J Psychiatry 1995; 152: 1192–1196Google Scholar

Stübner, S, Grohman, R, Engel, R, et al. Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 2004; 37 (Suppl 1): S70–S78Google Scholar

Sugarman, MA, Kirsch, I, Huppert, JD. Obsessive-compulsive disorder has a reduced placebo (and antidepressant) response compared to other anxiety disorders: a meta-analysis. J Affect Disord 2017; 218: 217–226Google Scholar

Suliman, S, Seedat, S, Pingo, J, et al. Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial. BMC Psychiatry 2015; 15: 24Google Scholar

Sullivan, PF, Daly, MJ, O’Donovan, M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet 2012; 13: 537–551Google Scholar

Sullivan, JT, Sykora, K, Schneiderman, J, et al. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353–1357Google Scholar

Sultana, A, McMonagle, T. Pimozide for schizophrenia or related psychoses. Cochrane Database Syst Rev 2000; (2): CD001949Google Scholar

Sun, Y, Liang, Y, Jiao, Y, et al. Comparative efficacy and acceptability of antidepressant treatment in poststroke depression: a multiple-treatments meta-analysis. BMJ Open 2017; 7: e016499Google Scholar

Sundquist, J, Sundquist, K, Ji, J. Autism and attention deficit/hyperactivity disorder among individuals with a family history of alcohol use disorders. Elife 2014; 3: e02917Google Scholar

Suppes, T, Hirschfeld, RM, Vieta, E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies. World J Biol Psychiatry 2008; 9: 198–211Google Scholar

Suppes, T, McElroy, SL, Sheehan, DV, et al. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder. J Clin Psychiatry 2014; 75: 77–84Google Scholar

Suppes, T, Silva, R, Cucchiaro, J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2016; 173: 400–407Google Scholar

Sutherland, SM, Davidson, JR. Pharmacotherapy for posttraumatic stress disorder. Psychiatr Clin N Amer 1994; 17: 409–423Google Scholar

Swann, AC, Anderson, JC, Dougherty, DM, et al. Measurement of inter-episode impulsivity in bipolar disorder. Psychiatry Res 2001; 101: 195–197Google Scholar

Swann, AC, Bowden, CL, Calabrese, JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156: 1264–1266CrossRef Google Scholar PubMed

Swedo, SE, Leonard, HL, Rapoport, JL, et al. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med 1989; 321: 497–501Google Scholar

Sweet, RA, Pollock, BG, Mulsant, BH, et al. Pharmacological profile of perphenazine’s metabolites. J Clin Psychopharmacol 2000; 20: 181–187Google Scholar

Szegedi, A, Durgam, S, Mackle, M, et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 2018; 175: 71–79Google Scholar

Szegedi, A, Jansen, WT, van Willigenburg, AP, et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009; 70: 344–353Google Scholar

Szegedi, A, Wetzel, H, Leal, M, et al. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety and tolerability data. J Clin Psychiatry 1996; 57: 257–264Google Scholar PubMed

Szegedi, A, Zhao, J, van Willigenburg, A, et al. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 2011; 11: 101Google Scholar

Szeszko, PR, Bilder, RM, Dunlop, JA, et al. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. Biol Psychiatry 1999; 45: 680–686Google Scholar

Szuba, MP, Hornig-Rohan, M, Amsterdam, JD. Rapid conversion from one monoamine oxidase inhibitor to another. J Clin Psychiatry 1997; 58: 307–310Google Scholar

Tait, DS, Marston, HM, Shahid, M, et al. Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacol (Berl) 2009; 202: 295–306Google Scholar

Takano, A, Ono, S, Yamana, H, et al. Factors associated with long-term prescription of benzodiazepine: a retrospective cohort study using a health insurance database in Japan. BMJ Open 2019; 9: e029641Google Scholar

Takeshima, N, Ogawa, Y, Hayasaka, Y, et al. Continuation and discontinuation of benzodiazepine prescriptions: a cohort study based on a large claims database in Japan. Psychiatr Res 2016; 237: 201–207Google Scholar

Tang, TZ, DeRubeis, RJ, Hollon, SD, et al. Personality change during depression treatment: a placebo-controlled trial. Arch Gen Psychiatry 2009; 66: 1322–1330Google Scholar

Tanzer, T, Shah, S, Benson, C, et al. Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis. Psychopharmacol Berl 2020; 237: 11–19Google Scholar

Tardy, M, Dold, M, Engel, RR, et al. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2014c; (7): CD009396Google Scholar

Tardy, M, Huhn, M, Engel, RR, et al. Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane database Syst Rev 2014a; 7: CD009369Google Scholar

Tardy, M, Huhn, M, Engel, RR, et al. Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2014b; 3: CD009230Google Scholar

Targownik, LE, Bolton, JM, Metge, CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009; 104: 1475–1482Google Scholar

Tarleton, EK, Littenberg, B, MacLean, CD, et al. Role of magnesium supplementation in the treatment of depression: a randomized clinical trial. PLoS One 2017; 12: e0180067Google Scholar

Taylor, D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination: interactions and therapeutic uses. Br J Psychiatry 1995; 167: 575–580Google Scholar

Taylor, D, Paton, C, Kapur, S (Eds). The Maudsley Prescribing Guidelines in Psychiatry, 11th Edn. London: Wiley Blackwell; 2015Google Scholar

Taylor, CB, Youngblood, ME, Catellier, D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792–798Google Scholar

Taylor, CP, Traynelis, SF, Siffert, J, et al. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther 2016; 164: 170–182Google Scholar

Tedeschini, E, Levkovitz, Y, Iovieno, N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 2011; 72: 1660–1668Google Scholar

Teicher, MH, Glod, CA, Aaronson, ST, et al. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 1989; 25: 535–549Google Scholar

Terao, T, Ishida, A, Kimura, T, et al. Preventive effects of lamotrigine in bipolar II versus bipolar I disorder. J Clin Psychiatry 2017; 78: e1000–e1005Google Scholar

Thase, ME, Chen, D, Edwards, J, et al. Effect of vilazodone on anxiety symptoms in patients with major depressive disorder. Int Clin Psychopharmacol 2014; 29: 351–356Google Scholar

Thase, ME, Corya, SA, Ountokun, O, et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 2007; 68: 224–236Google Scholar

Thase, ME, Jonas, A, Khan, A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28: 13–20Google Scholar

Thase, ME, Parikh, SV, Rothschild, AJ, et al. Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial. J Clin Psychiatry 2019a; 80: 19m12910Google Scholar

Thase, ME, Youakim, JM, Skuban, A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry 2015a; 76: 1224–1231Google Scholar

Thase, ME, Youakim, JM, Skuban, A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 2015b; 76: 1232–1240Google Scholar

Thase, ME, Zhang, P, Weiss, C, et al. Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies. Expert Opin Pharmacother 2019b; 20: 1907–1916Google Scholar

Thomas, A, Baillie, GL, Phillips, AM, et al. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007; 150: 613–623Google Scholar

Thomas, SE, Randall, PK, Book, SW, et al. A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking? Alcohol Clin Exp Res 2008; 32: 77–84Google Scholar

Thone, J. Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole. J Neuropsychiatry Clin Neurosci 2007; 19: 481–482Google Scholar

Thorlund, K, Druyts, E, Wu, P, et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc 2015; 63: 1002–1009Google Scholar

Thys-Jacobs, S, Starkey, P, Bernstein, D, et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998; 179: 444–452Google Scholar

Tiihonen, J, Wahlbeck, K, Kiviniemi, V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009; 109: 10–14Google Scholar

Tiihonen, J, Ryynänen, OP, Kauhanen, J, et al. Citalopram in the treatment of alcoholism: a double-blind placebo-controlled study. Pharmacopsychiatry 1996; 29: 27–29Google Scholar

Timmer, CJ, Sitsen, JM, Delbressine, LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461–474Google Scholar

Tohen, M, Calabrese, JR, Sachs, GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247–256Google Scholar

Tohen, M, Chengappa, KNR, Suppes, T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62–69Google Scholar

Tohen, M, Chengappa, KNR, Suppes, T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337–345Google Scholar

Tohen, M, Frank, E, Bowden, CL, et al. The International Society for Bipolar Disorders (ISBD) task force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord 2009; 11: 453–473Google Scholar

Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003a; 60: 1218–1226Google Scholar

Tohen, M, Katagiri, H, Fujikoshi, S, et al. Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies. J Affect Disord 2013; 149: 196–201Google Scholar

Tohen, M, Vieta, E, Calabrese, J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003b; 60: 1079–1088Google Scholar

Tollefson, GD, Beasley, CM Jr., Tran, PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results from an international collaborative trial. Am J Psychiatry 1997; 154: 457–467Google Scholar

Tollefson, GD, Bosomworth, JC, Heiligenstein, JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression: the Fluoxetine Collaborative Study Group. Int Geropsychiatr 1995; 7: 89–104Google Scholar

Tollefson, GD, Greist, JH, Jefferson, JW, et al. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor? A comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol 1994a; 14: 385–391Google Scholar

Tollefson, GD, Rampey, AH, Potvin, JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994b; 51: 559–567Google Scholar

Tomita, T, Yasui-Furukori, N, Nakagami, T, et al. Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorder. Ther Drug Monit 2014; 36: 480–485Google Scholar

Tondo, L, Vázquez, G, Baldessarini, RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand 2010; 121: 404–414Google Scholar

Tondo, L, Burrai, C, Scamonatti, L, et al. Carbamazepine in panic disorder. Am J Psychiatry 1989; 146: 558–559Google Scholar

Toniolo, RA, Fernandes, FBF, Silva, M, et al. Cognitive effects of creatine monohydrate adjunctive therapy in patients with bipolar depression: results from a randomized, double-blind, placebo-controlled trial. J Affect Disord 2017; 224: 69–75Google Scholar

Toth, C. Substitution of gabapentin therapy with pregabalin therapy in neuropathic pain due to peripheral neuropathy. Pain Med 2010; 11: 456–465Google Scholar

Touma, KTB, Zoucha, AM, Scarff, JR. Liothyroine for depression: a review and guidance for safety monitoring. Innov Clin Neurosci 2017; 14: 24–29Google Scholar

Trichard, C, Paillère-Martinot, M-L, Attar-Levy, D, et al. Binding of antipsychotic drugs to cortical 5HT_2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155: 505–508Google Scholar

Tritt, K, Nickel, C, Lahman, C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19: 287–291Google Scholar

Trivedi, MH, Rush, AJ, Carmody, TJ, et al. Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients? J Clin Psychiatry 2001; 62: 776–781Google Scholar

Trivedi, MH, Thase, ME, Osuntokun, O, et al. An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry 2009; 70: 387–396Google Scholar

Truman, CJ, Goldberg, JF, Ghaemi, SN, et al. Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 2007; 68: 1472–1479Google Scholar

Tucker, P, Trautman, RP, Wyatt, DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68: 201–206Google Scholar

Tueth, MJ, Cheong, JA. Successful treatment with pimozide of Capgras syndrome in an elderly male. J Geriatr Psychiatry Neurol 1992; 5: 217–219Google Scholar

Turkmen, S, Backstrom, T, Wahlstrom, G, et al. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol 2011; 162: 311–327Google Scholar

Turkoz, I, Daly, E, Sigh, J, et al. Treatment response with esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression without evidence of early response: a pooled post hoc analysis of the TRANSFORM Studies.. J Clin Psychiatry, 2021; 82(4):20m13800Google Scholar

Turner, DC, Clark, L, Dowson, J, et al. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 2004a; 55: 1031–1040Google Scholar

Turner, DC, Clark, L, Pomarol-Clotet, E, et al. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004b; 29: 1363–1373Google Scholar

Turner, DC, Robbins, TW, Clark, L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003; 165: 260–269Google Scholar

Turner, H, Matthews, AM, Linardatos, E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252–260Google Scholar

Turner, SM, Beidel, DC, Dancu, C, et al. An empirically derived inventory to measure social fears and anxiety: the Social Phobia and Anxiety Inventory. Psychol Assess 1989; 1: 35–40Google Scholar

Uguz, F. Second-generation antipsychotics during the lactation period: a comparative systematic review on infant safety. J Clin Psychopharmacol 2016; 36: 244–252Google Scholar

Uhde, T, Stein, MB, Post, RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988; 145: 1104–1109Google Scholar

Uher, R, Perlis, RH, Henigsberg, N, et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 2012; 42: 967–980Google Scholar

Uher, R, Perroud, N, Ng, MYM, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry 2010; 167: 555–564Google Scholar

Uher, R, Tansey, KE, Dew, T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram or nortriptyline. Am J Psychiatry 2014; 171: 1278–1286Google Scholar

Ujike, H, Nomura, A, Morita, Y, et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008; 69: 1416–1422Google Scholar

Ulrich, S, Wurthmann, C, Brosz, M, et al: The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998; 34: 227–263Google Scholar

Umbricht, D, Alberati, D, Martin-Facklam, M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry 2014a; 71: 637–646Google Scholar

Umbricht, A, DeFulio, A, Winstanley, EL, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug Alcohol Depend 2014b; 140: 92–100Google Scholar

Ungvari, GS, Hollokoi, RI. Successful treatment of litigious paranoia with pimozide. Can J Psychiatry 1993; 38: 4–8Google Scholar

Unterecker, S, Deckert, J, Pfuhlman, B. No influence of body weight on serum levels of antidepressants. Ther Drug Monit 2011; 33: 730–744Google Scholar

Unterecker, S, Riederer, P, Proft, F, et al. Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm (Vienna) 2013; 120: 1237–1246Google Scholar

Usmani, ZA, Carson-Chahhoud, KV, Esterman, AJ, et al. A randomized placebo-controlled trial of paroxetine for the management of anxiety in chronic obstructive pulmonary disease (PAC Study). J Multidiscip Health 2018; 11: 287–293Google Scholar

Vahedi, H, Merat, S, Rashidioon, A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Alim Pharmacol Ther 2005; 22: 381–385Google Scholar

Vaishnavi, S, Alamy, S, Zhang, W, et al. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropharmacol Biol Psychiatry 2007; 31: 1464–1469Google Scholar

Vaiva, G, Ducrocq, F, Jezquel, K, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003; 54: 947–949Google Scholar

Vallée, M, Vitiello, S, Bellocchio, L, et al. Pregnenolone can protect the brain from cannabis intoxication. Science 2014; 343: 94–98Google Scholar

Valles-Colomer, M, Falony, G, Darzi, Y, et al. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol 2019; 4: 623–632Google Scholar

Van Ameringen, M, Lane, RM, Walker, JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 275–281Google Scholar

Van Ameringen, M, Mancini, C, Pipe, B, et al. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004; 64: 1674–1678Google Scholar

van Broekhoven, KEM, Karreman, A, Hartman, EE, et al. Obsessive-compulsive personality disorder symptoms as a risk factor for postpartum depressive symptoms. Arch Womens Ment Health 2019; 22: 475–483Google Scholar

VanderZwaag, C, McGee, M, McEvoy, JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153: 1579–1584Google Scholar

Van den Eynde, F, Senturk, V, Naudts, K, et al. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. J Clin Psychopharmacol 2008; 28: 147–155Google Scholar

Van der Loos, ML, Mulder, PG, Hartong, EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multi-center, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 223–231Google Scholar

van Dinteren, R, Arns, M, Kenemans, L, et al. Utility of event-related potentials in predicting antidepressant treatment response: an iSPOT-D report. Eur Neuropsychopharmacol 2015; 25: 1981–1990Google Scholar

Van Haelst, IM, van Klei, WA, Doodeman, HJ, et al. Antidepressant treatment with monoamine oxidase inhibitors and the occurrence of intraoperative hemodynamic events: a retrospective observational cohort study. J Clin Psychiatry 2012; 73: 1103–1109Google Scholar

van Kammen, DP, Boronow, JJ. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol 1988; 3: 111–121Google Scholar

Van Os, J. Is there a continuum of psychotic experiences in the general population? Epidemiol Psichiatr Soc 2003; 12: 242–252Google Scholar

van Vliet, IM, den Boer, JA, Westenberg, HG. Psychopharmacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 1994; 115: 128–134Google Scholar

van Vliet, IM, den Boer, JA, Westenberg, HG, et al. Clinical effects of buspirone in social phobia: a double-blind, placebo-controlled study. J Clin Psychiatry 1997; 58: 164–168Google Scholar

van Zuiden, M, Frijling, JL, Nawijn, L, et al. Intranasal oxytocin to prevent posttraumatic stress disorder symptoms: a randomized controlled trial in emergency department patients. Biol Psychiatry 2017; 81: 1030–1040Google Scholar

Varma, A, Moore, MB, Miller, CWT, et al. Topiramate as monotherapy or adjunctive treatment for posttraumatic stress disorder: a meta-analysis. J Trauma Stress 2018; 31: 125–133Google Scholar

Vasudev, K, Goswami, U, Kohli, K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacol (Berl) 2000; 150: 15–23Google Scholar

Veale, D, Miles, S, Smallcombe, N, Atypical antipsychotic augmentation in SSRI treatment-refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry 2014; 14: 317Google Scholar

Veefkind, AH, Haffmans, PMJ, Hoencamp, E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202–208Google Scholar

Veerman, SR, Schulte, PF, Deijen, JB, et al. Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study. Psychol Med 2017; 47: 363–375Google Scholar

Veerman, SR, Schulte, PF, Smith, JD, et al. Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study. Psychol Med 2016; 46: 1909–1921Google Scholar

Vellekkatt, F, Menon, V. Efficacy of vitamin D supplementation in major depression: a meta-analysis of randomized controlled trials. J Postgrad Med 2019; 65: 74–80Google Scholar

Verbeeck, W, Bekkering, GE, Van den Noortgate, W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2017; (10): CD009504Google Scholar

Verheul, R, Lehert, P, Geerlings, PJ, et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacol (Berl) 2005; 178: 167–173Google Scholar

Verhulst, FC, Van der Ende, J. The eight-year stability of problem behavior in an epidemiologic sample. Ped Res 1995; 38: 612–617Google Scholar

Vernon, JA, Grudnikoff, E, Seidman, AJ, et al. Antidepressants for cognitive impairment in schizophrenia: a systematic review and meta-analysis. Schizophr Res 2014; 159: 385–394Google Scholar

Veroniki, AA, Cogo, E, Rios, P, et al. Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes. BMC Med 2017; 15: 95Google Scholar

Versiani, M, Nardi, AE, Mundim, FD, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353–360Google Scholar

Victoroff, J, Coburn, K, Reeve, A, et al. Pharmacological management of persistent hostility and aggression in persons with schizophrenia spectrum disorders: a systematic review. J Neuropsychiatry Clin Neurosci 2014; 26: 283–312Google Scholar

Vieta, E, Calabrese, JR, Goikolea, JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007; 9: 413–425Google Scholar

Vieta, E, Cruz, N, García-Campayo, J, et al. A double-blind, randomized, placebo-controlled prophylaxis study of oxcarbazepine as adjunct treatment to lithium in the long-term treatment of bipolar I and II disorder. Int J Neuropsychopharmacol 2008a; 11: 445–452Google Scholar

Vieta, E, Nuamah, IF, Lim, P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010; 12: 230–243Google Scholar

Vieta, E, T’Joen, C, McQuade, RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry 2008b; 165: 1316–1325Google Scholar

Vigen, CL, Mack, WJ, Keefe, RS, et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168: 831–839Google Scholar

Viguera, AC, Nunacs, R, Cohen, LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000; 157: 179–184Google Scholar

Viguera, AC, Tondo, L, Koukopoulos, AE, et al. Episodes of mood disorders in 2,252 pregnancies and postpartum periods. Am J Psychiatry 2011; 168: 1179–1185Google Scholar

Viktorin, A, Rydén, E, Thase, ME, et al. The risk of treatment-emergent mania with methylphenidate in bipolar disorder. Am J Psychiatry 2017; 174: 341–348Google Scholar

Villarreal, G, Hamer, MB, Cañive, JM, et al. Efficacy of quetiapine monotherapy in posttraumatic stress disorder: a randomized, placebo-controlled trial. Am J Psychiatry 2016; 173: 1205–1212Google Scholar

Villeneuve, E, Lemelin, S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005; 66: 1298–1303Google Scholar

Vita, D, De Peri, L, Siracusano, A, et al. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials. Int Clin Psychopharmacol 2013; 28: 219–227Google Scholar

Voican, CS, Corruble, E, Naveau, S, et al. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014; 171: 404–415Google Scholar

Volavka, J, Citrome, L. Pathways to aggression in schizophrenia affect results of treatment. Schizophr Bull 2011; 37: 921–929Google Scholar

Volavka, J, Czobor, P, Citrome, L, et al. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr 2014; 19: 374–381Google Scholar

von Wolff, A, Hölzel, P, Westphal, A, et al. Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis. J Affect Disord 2013; 144: 7–15Google Scholar

Wagner, GJ, Rabkin, R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61: 436–440Google Scholar

Wagner, J, Wagner, ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev 2000; 4: 551–581Google Scholar

Wagner, KD, Kowatch, R, Emslie, GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163: 1179–1186Google Scholar

Waldschmitt, C, Vogel, F, Pfuhlmann, B, et al. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. Pharmacopsychiatry 2009; 42: 189–193Google Scholar

Walker, SE, Shulman, KI, Tailor, SA, et al. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol 1996; 16: 383–388Google Scholar

Walshaw, PD, Gyulai, L, Bauer, M, et al. Adjunctive thyroid hormone treatment in rapid cycling bipolar disorder: a double-blind placebo-controlled trial of levothyroxine (L-T₄) and triiodothyronine (T₃). Bipolar Disord 2018; 20: 594–603Google Scholar

Walther, A, Breidenstein, J, Miller, R. Association of testosterone treatment with alleviation of depression symptoms in men: a systematic review and meta-analysis. JAMA Psychiatry 2019; 76: 31–40Google Scholar

Wang, G-J, Volkow, N, Wigal, T, et al. Chronic treatment with methylphenidate increases dopamine transporter density in patients with attention deficit hyperactivity disorder. J Nucl Med 2009; 50(Suppl 2): 1283Google Scholar

Wang, MT, Tsai, CL, Lin, CW, et al. Association between antipsychotic agent and risk of acute respiratory failure in patients with chronic obstructive pulmonary disease. JAMA Psychiatry 2017b; 74: 252–260Google Scholar

Wang, PW, Hill, SJ, Childers, ME, et al. Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients. J Psychiatr Res 2011; 45: 1128–1132Google Scholar

Wang, SM, Han, C, Lee, SJ, et al. Modafinil for the treatment of attention-deficit/hyperactivity disorder: a meta-analysis. J Psychiatr Res 2017a; 84: 292–300Google Scholar

Warner, MD, Dorn, MR, Peabody, CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 2001; 34: 128–131Google Scholar

Watanabe, T, Ueda, M, Saeki, Y, et al. High plasma concentrations of paroxetine impede clinical response in patients with panic disorder. Ther Drug Monit 2007; 29: 40–44Google Scholar

Watts, BV, Schnurr, PR, Mayo, L, et al. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. J Clin Psychiatry 2013; 74: e541–e550Google Scholar

Waxmonsky, JG, Waschbusch, DA, Glatt, SJ, et al. Prediction of placebo response in 2 clinical trials of lisdexamfetamine dimesylate for the treatment of ADHD. J Clin Psychiatry 2011; 72: 1366–1375Google Scholar

Weathers, FW, Keane, TM, Davidson, JR. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety 2001; 13: 132–156Google Scholar

Weimer, K, Colloca, L, Enck, P, et al. Placebo effects in psychiatry: mediators and moderators. Lancet Psychiatry 2015; 2: 246–257Google Scholar

Weinstock, LM, Gaudino, BA, Epstein-Lubow, G, et al. Medication burden in bipolar disorder: a chart review of patients at psychiatric hospital admission. Psychiatry Res 2014; 216: 24–30Google Scholar

Weiser, M, Heresco-Levy, U, Davidson, M, et al. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia. J Clin Psychiatry 2012; 73: e728–e734Google Scholar

Weisler, R, Ginsberg, L, Dirks, B, et al. Treatment with lisdexamfetamine dimesylate improves self- and informant-rated executive function behaviors and clinician- and informant-rated ADHD symptoms in adults: data from a randomized, double-blind, placebo-controlled study. J Atten Disord 2017; 21: 1198–1207Google Scholar

Weisler, R, Joyce, M, McGill, L, et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 2009; 14: 299–313Google Scholar

Weisler, RH, Keck, P Jr., Swann, AC, et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005; 66: 323–330Google Scholar

Weiss, RD, O’Malley, SS, Hosking, JD, et al. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. J Stud Alcohol Drugs 2008; 69: 878–884Google Scholar

Weissman, H, Qureshi, IA. Systematic review: pharmacological treatment of tic disorders: efficacy of antipsychotic and alpha-2 adrenergic agonist agents. Neurosci Biobehav Rev 2013; 37: 1162–1171Google Scholar

Weissman, AM, Levy, BT, Hartz, AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 2004; 161: 1066–1078Google Scholar

Welge, J, Keck, PE Jr. Moderators of placebo response to antipsychotic treatment in patients with schizophrenia: a meta-regression. Psychopharmacol (Berl) 2003; 166: 1–10Google Scholar

Welten, CCM, Koeter, MJW, Wohlfarth, T, et al. Placebo response in antipsychotic trials of patients with acute mania. Results of an individual patient data meta-analysis. Eur Neuropsychopharmacol 2015; 25: 1018–1026Google Scholar

Wesson, DR, Ling, W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs 2003; 35: 253–259Google Scholar

Wheeler, SD. Donepezil treatment of topiramate-related cognitive dysfunction. Headache 2006; 46: 332–335Google Scholar

Whitaker, LR, Degulet, M, Morikawa, H. Social deprivation enhances VTA synaptic plasticity and drug-induced contextual learning. Neuron 2013; 77: 335–345Google Scholar

White, K, Simpson, G. Combined MAOI-tricyclic antidepressant treatment: a reevaluation. J Clin Psychopharmacol 1981; 1: 264–282Google Scholar

White, K, Razani, J, Simpson, G. Combined MAOI-tricyclic antidepressant treatment: a controlled trial. Psychopharmacol Bull 1982; 18: 180–181Google Scholar

Wigal, SB, Biederman, J, Swanson, JM, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with or without prior stimulant treatment for attention-deficit/hyperactivity disorder: pooled analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion J Clin Psychiatry 2006; 8: 352–360Google Scholar

Wijkstra, J, Lijmer, J, Burger, H, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2015; (7): CD004044Google Scholar

Wilens, T, McBurnett, K, Stein, M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005b; 44: 1015–1023Google Scholar

Wilens, TE, Faraone, SV, Biederman, J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003a; 111: 179–185Google Scholar

Wilens, TE, Haight, BR, Horrigan, JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005a; 57: 793–801Google Scholar

Wilens, TE, Prince, JB, Spencer, T, et al. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry 2003b; 54: 9–16Google Scholar

Wilens, TE, Spencer, TJ, Biederman, J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001; 158: 282–288Google Scholar

Williams, AM. Coadministration of intramuscular olanzapine and benzodiazepines in agitated patients with mental illness. Ment Health Clin 2018; 8: 208–213Google Scholar

Williams, J, Ziedonis, DM. Naltrexone-bupropion combination therapy for protracted abstinence dysphoria. Am J Addict 2003; 12: 270–272Google Scholar

Williams, LM, Debattista, C, Duchemin, AM, et al. Childhood trauma predicts antidepressant response in adults with major depression: data from the Randomized International Study to Predict Optimized Treatment for Depression. Mol Psychiatry 2016; 6: e799Google Scholar

Williams, NR, Heifets, BD, Blasey, C, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 2018; 175: 1205–1215Google Scholar

Wils, RS, Gotfredsen, DR, Hjorthøj, C, et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res 2017; 182: 42–48Google Scholar

Wilson, W. The brief social phobia scale. J Clin Psychiatry 1993; (52 Suppl): 48–51Google Scholar

Wingård, L, Taipale, H, Reutfors, J, et al. Initiation and long-term use of benzodiazepines and Z-drugs in bipolar disorder. Bipol Disord 2018; 20: 634–646Google Scholar

Winhusen, T, Somoza, E, Ciraulo, DA, et al. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug Alcohol Depend 2007; 91: 141–148Google Scholar

Wink, LK, Pedapati, EV, Horn, PS, et al. Multiple antipsychotic medication use in autism spectrum disorder. J Child Adolsc Psychopharmacol 2017; 27: 91–94Google Scholar

Winkler, A, Auer, C, Doering, BK, et al. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs 2014; 28: 799–816Google Scholar

Winstanley, EL, Bigelow, GE, Silverman, K, et al. A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients. J Subst Abuse Treat 2011; 40: 255–264Google Scholar

Winter, H, Irle, E. Hippocampal volume in adult burn patients with and without posttraumatic stress disorder. Am J Psychiatry 2004; 161: 2194–2200Google Scholar

Witcomb, GL, Bouman, WP, Claes, L, et al. Levels of depression in transgender people and its predictors: results of a large matched control study with transgender people accessing clinical services. J Affect Disord 2018; 235: 308–315Google Scholar

Wittenborn, JR, Weber, ESP, Brown, M. Niacin in the long-term treatment of schizophrenia. Arch Gen Psychiatry 1973; 28: 308–315Google Scholar

Woelk, H, Arnoldt, KH, Keiser, M, et al. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: a randomized, double-blind, placebo-controlled trial. J Psychiatry Res 2007; 41: 472–480Google Scholar

Wolf, EJ, Lunney, CA, Schnurr, PP. The influence of the dissociative subtype of posttraumatic stress disorder on treatment efficacy in female veterans and active duty service members. J Consult Clin Psychol 2016; 84: 95–100Google Scholar

Wolkowitz, OM, Reus, VI, Keebler, A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999; 156: 646–649Google Scholar

Wollweber, B, Keck, ME, Schmidt, U. Improvement of nonsuicidal self-injury following treatment with antipsychotics possessing strong D1 antagonistic activity: evidence from a report of three cases. Ther Adv Pharmacol 2015; 5: 208–213Google Scholar

Woodman, CL, Noyes, R Jr. Panic disorder: treatment with valproate. J Clin Psychiatry 1994; 55: 134–136Google Scholar

Woodruff-Pak, DS, Lander, C, Geerts, H. Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev Winter 2002; 8: 405Y426Google Scholar

Woon, FL, Sood, S, Hedges, DW. Hippocampal volume deficits associated with exposure to psychological trauma and post traumatic stress disorder in adults: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2010; 24: 1181–1188Google Scholar

Wu, YL, Ding, XX, Sun, YH, et al. Association between MTHFR C677T polymorphism and depression: an updated meta-analysis of 26 studies. Prog Neuropsychopharmacol Biol Psychiatry 2013; 46: 78–85Google Scholar

Wunderink, L, Nieboer, RM, Wiersma, D, et al. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70: 913–920Google Scholar

Xie, C, Tang, Y, Wang, Y, et al. Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis. PLoS One 2015; 10: e0127815Google Scholar

Yamatsu, A, Yamashita, Y, Manu, I, et al. The improvement of sleep by oral intake of GABA and Apocynum venetum leaf extract. J Nutr Sci Vitaminol (Tokyo) 2015; 61: 182–187Google Scholar

Yang, C, Hao, Z, Tian, J, et al. Does antipsychotic drug use increase the risk of long term mortality? A systematic review and meta-analysis of observational studies. Oncotarget 2018; 9: 15101–15110Google Scholar

Yang, CS, Zhang, LL, Zeng, LN, et al. Topiramate for Tourette’s syndrome in children: a meta-analysis. Pediatr Neurol 2013; 49: 344–350Google Scholar

Yargic, LI, Corapcioglu, A, Kocabesoglu, N, et al. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int J Clin Pract 2004; 8: 205–211Google Scholar

Yasui-Furukori, N, Saito, M, Nakagami, T, et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol 2010; 24: 987–994Google Scholar

Yasui-Furukori, N, Tsuchimine, S, Nakagami, T, et al. Association between plasma paroxetine concentration and changes in plasma brain-derived neurotrophic factor levels in patients with major depressive disorder. Psychopharmacology 2011; 26: 194–200Google Scholar

Yatham, LN, Beaulieu, S, Schaffer, A, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial. Mol Psychiatry 2016; 21: 1050–1056Google Scholar

Yatham, LN, Grossman, F, Augustyns, I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141–147Google Scholar

Yatham, LN, Mackala, S, Basivireddy, J, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. Lancet Psychiatry 2017; 4: 208–217Google Scholar

Yazici, O, Kora, K, Polat, A, et al. Controlled lithium discontinuation in bipolar patients with good response to long-term lithium prophylaxis. J Affect Disord 2004; 80: 269–271Google Scholar

Yeh, MS, Mari, JJ, Costa, MC, et al. A double-blind randomized controlled trial to study the efficacy of topiramate in a civilian sample of PTSD. CNS Neurosci Ther 2011; 17: 305–310Google Scholar

Yeh, RW, Valsdottir, LR, Yeh, M, et al. Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. Br Med J 2018; 363: k5094Google Scholar

Yehuda, R, Bierer, LM, Pratchett, LC, et al. Cortisol augmentation of a psychological treatment for warfighters with posttraumatic stress disorder: randomized trial showing improved treatment retention and outcome. Psychoneuroendocrinology 2015; 51: 589–597Google Scholar

Yeung, CK, Chan, HH. Cutaneous adverse effects of lithium: epidemiology and management. Am J Clin Dermatol 2004; 5: 3–8Google Scholar

Yildiz, A, Nikodem, M, Vieta, , et al. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med 2015; 45: 299–317Google Scholar

Yildiz, A, Vieta, E, Leucht, S, et al. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011a; 36: 375–389Google Scholar

Yildiz, A, Vieta, E, Tohen, M, et al. Factors modifying drug and placebo responses in randomized trials for bipolar mania. Neuropsychopharmacology 2011b; 14: 863–875Google Scholar

Yokoi, F, Gründner, G, Biziere, K, et al. Dopamine D ₂ and D ₃ receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [¹¹ C] raclopide. Neuropsychopharmacology 2002; 27: 248–259Google Scholar

Yolland, CO, Hanratty, Y, Neill, E, et al. Meta-analysis of randomised controlled trials with N-acetylcysteine in the treatment of schizophrenia. Aust N Z J Psychiatry 2020; 54: 453–466Google Scholar

Yonkers, KA, Pearlstein, TB, Gotman, N. A pilot study to compare fluoxetine, calcium, and placebo in the treatment of premenstrual syndrome. J Clin Psychopharmacol 2013; 33: 614–620Google Scholar

Yonkers, KA, Gotman, N, Smith, MV, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 2011; 22: 848–854Google Scholar

Yonkers, KA, Kornstein, SG, Gueorquieva, R, et al. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. JAMA Psychiatry 2015; 72: 1037–1044Google Scholar

Yu, H, Yan, H, Wang, L, et al. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. Lancet Psychiatry 2018; 5: 327–338Google Scholar

Yudofsky, S, Williams, D, Gorman, J. Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes. Am J Psychiatry 1981; 138: 218–220Google Scholar

Yun, LWH, Maravi, M, Koayashi, JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. J Acquired Immune Defic Syndr 2005; 38: 432–438Google Scholar

Yung, AR, Phillips, LJ, Nelson, B, et al. Randomized controlled trial of interventions for young people at ultra high risk for psychosis: a 6-month analysis. J Clin Psychiatry 2011; 72: 430–440Google Scholar

Yury, CA, Fisher, JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom 2007; 76: 213–218Google Scholar

Zajecka, JM. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996; 57(Suppl 2): 10–14Google Scholar

Zajecka, J, Tracy, KA, Mitchell, S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 1997; 58: 291–297Google Scholar

Zanarini, MC, Frankenburg, FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 2001; 62: 849–854Google Scholar

Zanarini, MC, Frankenburg, FR, Parchini, A. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65: 903–907Google Scholar

Zanarini, MC, Schulz, SC, Detke, HC, et al. A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2011; 72: 1353–1362Google Scholar

Zanarini, MC, Schulz, SC, Detke, HC, et al. Open-label treatment with olanzapine for patients with borderline personality disorder. J Clin Psychopharmacol 2012; 32: 398–402Google Scholar

Zanarini, MC, Vujanovic, AA, Parachini, EA, et al. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord 2003; 17: 233–242Google Scholar

Zanos, P, Moaddel, R, Morris, PJ, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016; 533: 481–486Google Scholar

Zarate, CA Jr., Tohen, M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004; 161: 169–171Google Scholar

Zareifopoulos, N, Dylja, I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis. Asia J Psychiatry 2017; 26: 115–122Google Scholar

Zaremba, D, Schulze Kalthoff, I, Förster, K, et al. The effects of processing speed on memory impairment in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2019; 92: 494–500Google Scholar

Zedler, BK, Mann, HL, Kim, MM, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction 2016; 111: 2115–2128Google Scholar

Zeier, Z, Carpenter, LL, Kalin, NH, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry 2018; 175: 873–886Google Scholar

Zeng, T, Long, Y-S, Min, F-L, et al. Association of HLA-B*1502 alleles with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis. Int J Dermatol 2015; 54: 488–493Google Scholar

Zetin, M, Garber, D, De Antonio, M, et al. Prediction of lithium dose: a mathematical alternative to the test-dose method. J Clin Psychiatry 1986; 47: 175–178Google Scholar

Zhang, J-P, Lencz, T, Malhotra, AK. D₂ receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 2010; 167: 763–772Google Scholar

Zhang, W, Connor, KM, Davidson, JR. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 2005; 19: 551–553Google Scholar

Zhang, JP, Lencz, T, Zhang, RX, et al. Pharmacogenetic associations of antipsychotic drug-related weight gain: a systematic review and meta-analysis. Schizophr Bull 2016; 42: 1418–1437Google Scholar

Zhang, XY, Tan, YL, Zhou, DF, et al. Association of clozapine-induced weight gain with polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol 2007a; 27: 246–251Google Scholar

Zhang, ZJ, Kang, WH, Li, Q, et al. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res 2006; 88: 102–110Google Scholar

Zhang, ZJ, Kang, WH, Li, Q, et al. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) for mood disorders: double-blind, placebo-controlled studies. J Psychiatry Res 2007b; 41: 828–836Google Scholar

Zhang, ZJ, Kang, WT, Tan, QR, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007c; 41: 360–369Google Scholar

Zheng, W, Cai, DB, Zhang, Q-E, et al. Adjunctive ondansetron for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. J Psychiatry Res 2019; 113: 27–33Google Scholar

Zheng, W, Cao, XL, Ungvari, GS, et al. Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: meta-analysis of randomized controlled trials. PLoS One 2016a; 11: e0156510Google Scholar

Zheng, W, Wang, S, Ungvari, GS, et al. Amantadine for antipsychotic-related weight gain: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol 2017a; 37: 341–346Google Scholar

Zheng, W, Xiang, Y-T, Xiang, Y-Q, et al. Efficacy and safety of adjunctive topiramate for schizophrenia: a meta-analysis of randomized controlled trials. Acta Psychiatr Scand 2016b; 134: 385–398Google Scholar

Zheng, W, Xiang, YT, Yang, XH, et al. Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a met-analysis of randomized controlled trials. J Clin Psychiatry 2017b; 78: e498–e505Google Scholar

Zhong, G, Wang, Y, Zhang, Y, et al. Association between benzodiazepine use and dementia: a meta-analysis. PLoS One 2015; 10: e0127836Google Scholar

Zhou, X, Ravindran, AV, Qin, B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 2015; 76: e487–e498Google Scholar

Zhu, J, Cai, H, Yuan, Y, et al. Variance of the global signal as a pretreatment predictor of antidepressant treatment response in drug-naïve major depressive disorder. Brain Imaging Behav 2018; 12: 1768–1774Google Scholar

Zhu, ZG, Sun, MX, Zhang, WL, et al. The efficacy and safety of coenzyme Q10 in Parkinson’s disease: a meta-analysis of randomized controlled trials. Neurol Sci 2017; 38: 215–224Google Scholar

Zilcha-Mano, S, Roose, SP, Barber, JP, et al. Therapeutic alliance in antidepressant treatment: cause or effect of symptomatic levels? Psychother Psychosom 2015; 84: 177–182Google Scholar

Zipursky, RB, Menezes, NM, Streiner, DL, et al. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res 2014; 152: 408–414Google Scholar

Zisook, S, Johnson, GR, Tal, I, et al. General predictors and moderators of depression remission: a VAST-D report. Am J Psychiatry 2019; 176: 348–357Google Scholar

Zisook, S, Lesser, IM, Lebowitz, B, et al. Effects of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the combining medications to enhance depression outcomes study. J Clin Psychiatry 2011; 72: 1322–1332Google Scholar

Zisook, S, Rush, AJ, Haight, BR, et al. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006; 59: 203–210Google Scholar

Zisook, S, Shuchter, SR, Pedrelli, P, et al. Bupropion sustained release for bereavement: results of an open trial. J Clin Psychiatry 2001; 62: 227–230Google Scholar

Zohar, J, Amital, D, Miodownik, C, et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22: 190–195Google Scholar

Zohar, J, Fostick, L, Juven-Wetzler, A, et al. Secondary prevention of chronic PTSD by early- and short-term administration of escitalopram: a prospective randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2018; 79: 16m10730Google Scholar

Zung, WWK. A rating instrument for anxiety disorders. Psychosomatics 1971; 12: 371–379Google Scholar

Zweifel, JE, O’Brien, WH. A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology 1997; 22: 189–212Google Scholar

Book contents

References

Summary

Access options

Subscription

Individual access

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive